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Abbreviations
2NF- 2 -nitrofluorene.
1 1 -CH3 -CPP-1 7-one- 15,16-dihydro-11-methyl-cyclopenta[a]phenanthren-17-one.
B[a]P- benzo[a]pyrene.
BA- benz[a]anthracene.
CDNB- 1 -chIoro-2 ,4-dinitrobenzene.
cpp- cyclopenta[a]phenanthrene(s).
cpp-17-one- 15,16-dihydrocyclopenta[a]phenanthren-17-one.
CYP450- Cytochrome P-450.
dA- deoxyadenosine.
DCNB- 3,4-dichloronitrobenzene.
DD- dihydrodiol dehydrogenase.
dG- deoxyguanosine.
DNA- deoxyribonucleic acid.
EDTA- ethylenediaminetetraacetic acid.
EH- epoxide hydrolase (c- cytosolic; m- microsomal).
GSH- glutathione.
GSTv glutathione-S-transferase.
HEPES- 4-(2-hydroxyethyl)-1 -piperazineethanesulphonic acid.
HPLC- high performance liquid chromatography.
MNNG- N-methyl-N'-nitro-N-nitrosoguanidine.
NADP- nicotinamide adenine dinucleotide phosphate.
NADPH- nicotinamide adenine dinucleotide phosphate (reduced form).
NB+- nutrient broth supplemented with ampicillin.
PAH- Polycyclic aromatic hydrocarbon(s).
PB- phenobarbitone.
PBS- phosphate-buffered saline.
S"9” post-mitochondrial supernatant.
S.cerevisiae- Saccharomyces cerevisiae.
S.typhimurium- Salmonella typhimurium.
T.O.- Theilers original mouse strain.
TCDD- 2,3,7,8 -tetrachlorodibenzo-p-dioxin.
TCDF- 2,3,7,8-tetrachlorodibenzofuran.
TEMED- N,N,N',N'-tetramethylethylenediamine.
Tris- tris( hydroxymethyl)aminomethane.
U.V.- ultraviolet.
UDP- uridine diphosphate.
XRE- xenobiotic responsive element.
M+ Molecular ion
M ++ x[Si(CH3)3] M+-H + x[Si(CH3)3]
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Abstract
The cyclopenta[a]phenanthren-17-ones, in common with many other PAH series, 
exhibit the phenomenon of bay-region methyl group activation. Substitution of a 
methyl group into the bay-region (C-11) of 15,16-dihydrocyclopenta[a]phenanthren- 
17-one confers carcinogenic activity on the molecule.
Investigations were carried out in order to elucidate any metabolic differences 
between cpp-17-one and its carcinogenic 11-methyl analogue. 15,16-dihydro-11- 
methylcyclopenta[a]phenanthren-17-one was shown to be metabolised more readily 
to the proximate genotoxic form of the cyclopenta[a]phenanthren-17-ones, the 3,4- 
dihydrodiol. Moreover the II-C H 3 analogue was demonstrated to more efficiently 
induce cytochrome P-4501A1 and microsomal epoxide hydrolase, the enzymes 
responsible for its activation to genotoxins.
Investigations into the precise nature of the effect of the methyl group revealed that 
steric considerations were rather more important than electronic effects, since an 11- 
trifluoromethyl derivative was activated to mutagens in an entirely analogous manner 
to the 11-methyl compound.
Prelim inary studies into the metabolism of 15-16-dihydro-11-methyl- 
cyclopenta[a]phenanthren-17-one by species other than the rat suggested that 
primates such as the cynomolgous monkey might be efficient A-ring metabolisers. 
Further studies established that the pseudo-diequatorial conformation of the 
proximate genotoxin, the 3,4-dihydrodiol, was vital in determining biological activity, 
since it was observed that the pseudo-diaxial 3,4-dihydrodiol of 15,16-dihydro-6- 
methylcyclopenta[a]phenanthren-17-one could not be activated to genotoxic 
intermediates.
VII
CHAPTER 1.
General Introduction.
1.1 Cancer
The multitude of disease states which are united under the pseudonym of 
cancer have become the most widely feared affliction In the developed world. The 
rise in the prevalence of the fear of cancer has led to its being described as the " 
modern plague", this false impression of the novelty of cancer is due in large 
measure to the success in eliminating the great infectious diseases .eg. leprosy , 
bubonic plague and, latterly, tuberculosis which at various times in the past have 
haunted the minds of the public. The processes we know as cancer have probably 
been in existence since the emergence of the first multicellular organism; it has been 
demonstrated for example that neoplastic lesions occurred in dinosaur bones (Pitot,
1978). Moreover an Egyptian surgical papyrus refers to a clinical tumour (Breasted, 
1930) and autopsies of mummified bodies have revealed the existence of bone 
tumours. Indeed in the 4th century B.C. Hippocrates coined the term "carcinoma", 
which he used to describe a tumour which spread and killed the patient (Bett, 1957). 
Cancer cells result from one or more derangements in the biochemistry of a "normal" 
cell resulting in the uncontrolled growth and division of that cell, culminating in a 
disruption of the functions of the surrounding tissue. This relatively autonomous 
growth of tissue is termed neoplasia.
One of the characteristics of carcinogenesis is the frequently long period 
between the initial application of the carcinogen - whether physical, chemical or 
biological- and neoplasia. This latent period led to the realisation that carcinogenesis 
could be divided into at least two stages; initiation .ie. the application of the 
carcinogen, and promotion, subsequent events resulting from environmental factors 
such as the application of promotors (Berenblum and Shubik, 1947; Fisher and 
Fisher, 1959; Roe et a i, 1972). Indeed it is now understood that carcinogenesis is a 
multistage process, only a few of which have been elucidated (fig 1.1).
Carcinogen
Normal cell
I n i t i â t
-► Initiated cell
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P r o g r e s s i o n
Métastasés
O
3
o
o
3
Visible tumour
Fig. 1.1: Schematic representation of the principal 
stages in the development of cancer.
1.2 Chemical Carcinogenesis
Chemicals have long been implicated in the aetiology of human cancer. In 
1761 the London physician Dr. John Hill wrote an article advising against the use of 
snuff which he associated with nasal cancer (Redmond, 1970); it is remarkable that 
many of the observations which Hill made are still true 230 years later ; " whether or 
not polypusses, which attend snuff-takers, are absolutely caused by that custom; or 
whether the principles of the disorder were there before, and snuff only irritated the 
parts, and hastened the mischief, I shall not pretend to determine .... it is evident that 
no man should venture upon snu ff, who is not certain that he is not so far liable to 
cancer: and no man can be certain of that ". Dr. Hill went on to say that the fact that 
not all users of snuff developed nasal cancer did not negate his hypothesis since "if
only five in a hundred ruin their constitutions by I t , who shall be able to say, when he 
enters on the custom, whether he shall be one of the ninety-five who escape, or of the 
five that perish". Some fourteen years later a London surgeon, Percival Pott 
published a paper concerning the incidence of scrotal cancer among chimney 
sweeps which he ascribed to their exposure to soot (Pott, 1775). It is now known that 
the active constituents of both tobacco and soot were in fact polycyclic aromatic 
hydrocarbons.
1.2.1 Polycyclic aromatic hydrocarbons
The polycyclic aromatic hydrocarbons (PAH) (Harvey, 1991) form, 
arguably, the most important class of chemical carcinogens known to man. PAH are 
omnipresent environmental pollutants arising mainly from the incomplete combustion 
of organ les (Dipple, 1983). However PAH have been found in both oil and shale 
deposits (Guerin, 1978) and must therefore have existed in the environment for 
thousands of years, predating the large scale combustion of fossil fuels. Thus arose 
the possibility of biosynthesis of PAH; bacteria have been found which are capable of 
synthesising benzo[a]pyrene (B[a]P) (Baum, 1978) and in addition PAH have been 
found in phytoplankton and algae in places remote from contamination. Moreover it 
has been noted that the levels of B[a]P increase during the germination of the seeds 
of wheat, oats, rye and lentils; substantial increases in the levels of PAH have also 
been noted during the yellowing of the leaves of beech, oak and tobacco (Badger, 
1962; Grasso and Hare, 1976; Shabad, 1980). Polycyclic aromatic hydrocarbons 
have been demonstrated to be produced during cooking, especially where high 
temperatures are involved .eg. the charbroiling of meat (Grasso and Hare, 1976) or 
the overheating of cooking oils. This generation of PAH during cooking has led to the 
advice that food should be cooked for longer at lower temperatures.
The major sources of PAH are however man-made, it is estimated that 
around 40% of B[a]P output in the U.S.A. is due to power generation with a further 
40% due to the burning of refuse with the final 20% being contributed by coke works 
(Dipple, 1983). Thus PAH pervade the air and the soil as well as our food/water 
sources.
1.2.2 Cyciopenta[a]phenanthrenes
The cyclopenta[a]phenanthrenes (cpp) (Coombs and Bhatt, 1987) are a 
unique class of PAH, in that they possess the same carbon skeleton as the natural 
steroids
Bay Region
K-Region
Fig. 1.2: 16,17-Dihydro-15-H-cyclopenta[a]phenanthrene
This superficial resemblance excited considerable interest and led to the 
investigation of the possibilities of (a) carcinogenicity of these compounds and (b) 
their endogenous production due to faulty steroid metabolism. This interest led to a 
burst of synthetic work; Butenandt was able to prepare Diels hydrocarbon and its 6- 
methyl derivatives from dehydroepiandrosterone (fig 1.3) (Butenandt and Suranyi, 
1942).
HO
Dehydroepiandrosterone Diels hydrocarbon
Fig 1.3: Conversion of dehydroepiandrosterone 
to Diels hydrocarbon.
All of the methyl isomers, of 16,17-dihydro-15-H-cpp, were prepared over the next 
decade. These compounds were tested in mice for their ability to induce tumours on 
dorsal application (Butenandt and Dannenberg, 1953). All of the compounds were 
inactive, except for those with methyl groups at positions 7 and 11.
Cyclopenta[a]phenanthrenes differ from steroids in that they are fully aromatic, the 
oestrogens are, however, partially aromatic and are known to be synthesised from 
the androgens, which have ketone groups at C-17. It was therefore decided to 
synthesise the 17=ketones of the cpp series. The synthesised ketones were tested for
carcinogenic potential by skin painting in the same way as their hydrocarbon 
analogues (Coombs et al., 1974). The 17-ketone (cpp-17-one) was found to be 
inactive but its 11-methyl analogue (1 l-CHs-cpp-l7-one) was a potent carcinogen 
(figs. 1.4 and 1.5).
cpp-17-one 
(inactive)
1 l-CHg-cpp-l 7-one 
(active)
Fig 1.4: 15,16-dihydro-cpp-17-one and its 
11-m ethyl analogue.
#
Fig 1.5: Carcinoma produced by application of ll-C H s -cp p -l7 -o n e  
on the dorsal skin of a T.O. mouse
Méthylation at C-7 enhances the carcinogenicity of cpp-17-one, although not to the 
same extent as 11-méthylation. It was observed that the 11 -methoxy and hydroxy 
compounds were active, but that increasing the size of the substituent, at the 11 
position, diminished activity (Coombs, 1988). It was later established that, although 
the methyl group at 11 conferred greater carcinogenicity on the molecules, the 
methyl group was not actually altered. In the same study the binding of the 
carcinogen to DNA was shown to be covalent and that this could be inhibited by the 
aryl hydroxylase inhibitor, benzoflavone (Coombs et al., 1976a). Thus it was 
apparent that these compounds were not carcinogenic per se and that they required 
biological activation to express their carcinogenic potential.
1.3 Metabolism of Polycyclic aromatic hydrocarbons
Glutathione
conjugates
Benzo[a]pyrene
Arene oxides QuinonesPhenols
Glucuronide+
Sulphate
conjugates
TriolsDiols
Glutathione
conjugates Catechols
Diol-epoxides
Tetraols
Fig 1.6: Schematic representation of the metabolic 
fate of benzo[a]pyrene.
Figure 1.6 outlines the possible metabolism of the carcinogen B[a]P (loannides, 
1989). The production of arene oxides, diol-epoxides and quinones have all been
associated with DNA damage. The arene oxides and diol-epoxides bind covalently 
to the DNA, whereas the quinones are believed to give rise to reactive oxygen 
species
DNA Damage
Fig 1.7: Possible mechanism of quinone 
mediated genotoxicity.
Mechanisms exist whereby these genotoxic metabolites can be detoxicated and 
excreted from the cell, ie. by conjugation (Levin etal., 1982). Whether or not a PAH is 
genotoxic will depend, therefore, on the balance between the detoxication and 
activation pathways.
Precarcinogen
(Inactive)
t
Inactive
Metabolites
t
Excretion
-=Detoxication
=Activation
Proximate
Carcinogen
Inactive
Metabolites
t
Excretion
Ultimate
carcinogen
DNA
Damage
t
Tumour
Fig 1.8: Activation/detoxication pathways of a 
PAH carcinogen.
Some compounds therefore possess a structure that renders them substrates of the 
detoxication pathways, whereas others are substrates of activation pathways .
The Millers advanced the theory that the PAH carcinogens were all capable 
of being metabolised to reactive electrophiles (Miller, 1970; Miller and Miller, 1971), 
which could then react with cellular nucleophiles, e.g. DNA. The metabolism of the 
PAH, including the cpp, involves the concerted actions of various enzyme systems 
including the cytochrome P-450 dependent mixed-function oxidases (CYP450), 
epoxide hydrolase (EH) and the glutathione-S-transferases (GST).
CYP450
CYP450
CYP450
Fig 1.9: Metabolism of B[a]P to its principal dihydrodiol 
metabolites by CYP450 and epoxide hydrolase.
The compounds are acted upon by the mixed function oxidases to produce a variety 
of epoxides (fig 1.9). These compounds matched the requirements of the Millers, in 
that they were strong electrophiles (Miller, 1970; Miller and Miller, 1971). It was 
originally felt that the most likely candidates from amongst these as the molecules
which bind to DNA, were the K-region epoxides (Coulson, 1953; Pullman and 
Pullman, 1955). However, all of these epoxides (fig.1.9) are substrates of the 
enzyme, EH. This enzyme opens the epoxide by adding the elements of water to 
form the dihydrodiol, the dihydrodiols are then substrates, once again, for the mixed 
function oxidases, forming the corresponding diol-epoxides(the K-region epoxides 
are not metabolised to diol-epoxides). The cpp are believed to be metabolised in an 
entirely analogous manner (fig 1.10).
Excretion
"GST
CYP450 p: EH
/
Phenols (Excretion)
Tumour ?
Tetraols
Conjugates
(Excretion)
DNA
Binding
HO
OH
GYP450
HO
OH
Fig 1.10: Putative scheme of the metabolic activation 
of the cyclopenta[a]phenanthrenes.
It was these bay-region diol-epoxides which were found to be the ultimate 
carcinogenic forms of the PAH (Sims et a/., 1974; Yagi et al., 1975; Beland and 
Harvey, 1976). These compounds are powerful alkylating agents and they were 
shown to react with the exocyclic amino group of the guanine residues of DNA (King 
eta!., 1976; Weinstein etal., 1976; Jeffrey etal., 1977) (fig 1.11).
10
ai"
HOHjÇ q  I L f '-
HO
deoxyguanosine
h -Q h
HO
OH
3,4 diol-1,2-epoxy- 
11 -methyi-cpp-17-one.
NH
NH
HOHO OH
Fig 1.11: The proposed binding of a cpp dioi-epoxide to the 
exocyclic amino group of deoxyguanosine.
The result of such a reaction is to bring about a base substitution in the DNA, during 
replication. Although the dG adducts are the major entities formed by the interaction 
of diol-epoxides with DNA, there is no a priori reason to assume that these are any 
more important in the aetiology of cancer than the minor adducts which are formed. It 
has been demonstrated, for example, that the tumourigen DMBA yields, relatively, 
high levels of deoxyadenosine (dA) adducts (Bigger et al., 1983; Cheng etal., 1988). 
Similarly benzo[c]phenanthrene shows a high level of binding to adenine residues in 
DNA (Agarwai et ai., 1987). if this binding to DNA were to occur in a region vital to 
cell growth/proliferation/regulation, then it is relatively easy to envisage how cancers 
might arise, in the metabolism of 11-methyi-cpp-17-one, it is possible to produce two 
enantiomeric pairs of bay-region diol-epoxides (fig 1.12).
11
OH
be I
>
ÔH
Optical
Isomers
HO^
OH
L  HO
OH
Anti-isomers. Syn-isomers
Fig 1.12: The possible diol-epoxides of ll-C H g-cpp-IT -one.
The carcinogenic potency of the molecules shown in figure 1.12 is almost certainly 
unequal. This inequality is found in many of the classes of PAH, in B[a]P only the (+) 
enantiomer of the ant/-?,8-diol-9,10-epoxide displays high tumourigenic activity 
(Buening etal., 1978; Slaga et al., 1979); similarly, an anf/-diol-epoxide of chrysene 
was shown to be ten times more mutagenic than the corresponding sy/7-isomer, 
which was in turn more potent than the other metabolites tested (Phillips etal., 1986). 
The reason(s) why some diol-epoxides are more important, in the aetiology of 
cancer, than the other eiectrophilic PAH metabolites, has not yet been established. It 
was postulated that they were distinguished by their exceptional chemical reactivity 
(Lehr etal., 1985) but this cannot, however, be the sole reason as K-region epoxides 
are very reactive and will readily bind to DNA (Jennette et al., 1977; Blobstein etal., 
1975). The K-region epoxides are not believed to be important in the causation of 
cancers. The K-region epoxides are, in fact, very susceptible to enzymic detoxication. 
It therefore seemed possible that part of the reason for the activity of the dioi- 
epoxides, lay in whether or not they were substrates for the enzyme systems 
responsible for detoxication.
1.3.1 Enzymic "Detoxication"
The diol-epoxides of the PAH may be detoxicated in a number of ways (fig
1.13).
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Fig 1.13: Some of the possible detoxication routes of 
a diol-epoxide.
Some diol-epoxides are subject to the EH activity associated with the endoplasmic 
reticulum. EH catalyses the addition of the elements of water to the epoxide (fig 1.14).
i-A i - O OH
HO
Hq
HO
OH OH
Fig 1.14: Epoxide hydrolase catalysed opening 
of an epoxide.
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Perhaps a more important group of enzymes in the metabolism of the diol-epoxides 
are the Glutathione-S-transferases (GST) (Glatt etal., 1983). The GSTs catalyse the 
opening of epoxides, by the addition of the nucleophile glutathione (fig 1.15).
>O + G-S-H
GS'.
OH
SG
Fig 1.15: Conjugation of glutathione to an epoxide 
catalysed by GST.
Following the conjugation of the glutathione to the epoxide, the conjugate is acted on 
by peptidases and an acetylase, yielding the mercapturic acid derivative, these 
compounds being more easily excreted. It has however been established that 
potentially toxic substances can be generated from mercapturic acid pathway 
metabolites (Bakke and Gustafsson, 1984). Other conjugation processes can occur 
in the metabolism of PAH involving conjugation of the compound to glucuronic acid 
or sulphate groups. Conjugations are designed to make lipophilic substances more 
hydrophilic and thus facilitate their excretion in the urine and bile. On the whole, this 
is also the case with the PAH metabolites. However, the sulphate conjugation of 7- 
hydroxymethyl-12-methylbenz[a]anthracene, gives rise to a species which covalently 
binds to DNA. Indeed, it has been suggested that the sulphate ester of 7,12-dimethyl 
BA is responsible for its carcinogenicity (Watabe, 1985). It has been reported that the 
rat aryl hepatic sulphotransferase IV can be inhibited by dihydrodiol derivatives of 
B[a]P and naphthalene (Rao and Duffel, 1982). Thus sulphation may not be a 
particularly efficacious means of detoxicating many PAH.
Dihydrodiol dehydrogenase (DD) has also been implicated in the detoxication of 
diol-epoxides (Glatt etal., 1982). It may be important in anticarcinogenesis from two
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standpoints; firstly, the enzyme shows specificity for dihydrodiols converting them to 
catechols and thus sequestering the precursors of the diol-epoxides (fig 1.16).
D.D.
H0 ‘HO
OH OH
NADP NADPH + H
Fig 1.16: Conversion of a dihydrodiol to a catechol 
catalysed by dihydrodiol dehydrogenase.
Secondly, the enzymes have been shown to act on the diol-epoxides forming tri- 
hydroxylated aromatics, and show greater activity towards diol-epoxides than EH 
(Glatt et al., 1982).Thus it is apparent that the diol-epoxides of a
particular CPP - and their biological fate, is dependent on several enzyme
systems including; (a) The CYP450-dependent mixed-function oxidases, (b) the 
epoxide hydrolases, (c) the glutathione-S-transferases and (d) the dihydrodiol 
dehydrogenases.
1.4 The principal enzyme systems involved in the metabolism of polycyclic^ 
aromatic hydrocarbons
1.4.1 The Cytochromes P-450
The cytochromes P-450 (CYP450) are a ubiquitous superfamily of 
haemoproteins involved in a vast range of oxidations (Guengerich, 1988). The 
enzymes are believed to exist as complexes with a flavoprotein reductase and the 
CYP450S are dependent on the association between the protein and an iron- 
porphyrin ring system for their activity. The porphyrin in all of the CYP450S is 
protoporphyrin IX, thus it is the protein moiety which confers substrate specificity on a
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particular enzyme. The active site of the enzymes has been postulated to contain a 
"porphyrin cleft " as illustrated in figure 1.17, where the fifth ligand of the iron atom is 
generally held to be a specific cysteine residue of the polypeptide chain (Champion 
etal., 1982; Hahn etal., 1982). Studies revealed that the greatest homology is seen 
in the cysteine residue nearest the carboxyl terminus and it has ,therefore, been 
postulated that this residue provides the sulphur ligand (Coon and Inouye, 1985).
Fig 1.17: Schematic representation of the porphyrin 
cleft of the cytochromes P-450.
The sixth co-ordinate position is thought to be occupied by a group which can be 
readily displaced by molecular oxygen, e.g. water; the hydroxyl groups of serine or 
threonine residues of the protein could , however, fulfil this role (Segawa etal., 1984; 
Kawajiri et al., 1984). While a great deal of the work on the CYP450s has involved 
their metabolism of xenobiotics, the principal endogenous function of the enzymes 
has proved much more difficult to ascertain. They are known however to be involved 
in the metabolism of the natural steroids (Coon and Inouye, 1985; loannides et al., 
1984; Hall, 1985). Although the details of the mechanism of the reactions of the CYP 
450s have not been elucidated, it is believed that the CYP450-dependent 
hydroxylations proceed as shown in figure 1.18. The flavoprotein reductase, which 
unusually contains both FAD and FMN, accepts two electrons from NADPH, the 
substrate,AH, binds to the CYP450 and the reductase then donates one electron, 
reducing the iron to the Fe2+ state. Molecular oxygen then binds to the sixth ligand
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position of the iron and the second electron is transferred from the reductase further 
reducing the oxygen molecule. The 0 - 0  bond is then believed to split giving water 
and an iron-oxene species and the substrate hydrogen is believed then to be 
abstracted to give an iron bound hydroxyl radical and a protein bound carbon radical 
(Groves eta/., 1978); the radicals recombine and the product dissociates from the 
enzyme.
P-450-AH
Fe3+.0,2NADPH
NADP
AH•P-450-AH
Fe3+
Fig 1.18: Reaction scheme for CYP450 dependent 
hydroxylation of xenobiotics.
As stated earlier, the term CYP450 denotes a superfamily of haemoproteins. The 
constitutive levels of the different GYP450s in the microsomal fraction of liver differs 
considerably. Only three of the cytochrome P-450 families are thought to be involved 
in the metabolism of xenobiotics and those which are, tend to have relatively low 
constitutive levels (Luster eta!., 1982; Pickett eta!., 1981). The cytochromes P-450 
are, however, inducible (table 1.1); this induction of the CYP450s can have a 
remarkable effect on the carcinogenicity of a compound. It is clear that since the 
families responsible for the metabolism of xenobiotics are at low constitutive levels, 
induction may enhance their metabolism to carcinogenic reactive intermediates. 
However induction need not necessarily lead to activation, it has been demonstrated 
that trans-sW\bene oxide induction can cause a shift in the site of B[a]P oxidation and 
a concomitant decrease in mutagenesis (Jerina and Daly, 1974) (fig.1.19).
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/  I \
MICROSOMAL OXYGENASES
+EH \
frans-STILBENE OXIDE-induced 
MICROSOMAL OXYGENASES.
CONJUGATES
Fig 1.19: The B[a]P oxidase shift caused by frans-stilbene oxide 
induction of microsomal CYP450.
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Table 1.1: Substrate characteristics and typical inducing agents of 
the principal xenobiotic metabolising Cytochromes P-450.
Fam ily /S ub
fa m ily
Substrate characteris tics inducing agents
CYP1 Essentially planar Benzo[a]pyrene
CYP2B Broad specificity Phenobarbitone
CYP2E Small molecular mass Ethanol
CYP3 Large molecular mass clotrimazole
The inducers act in a differential manner, indicating that the induction cannot simply 
involve a general increase in protein synthesis, indeed induction of one family can 
often result in a decrease in the levels of another (loannides, 1990). This may 
indicate that the mechanism of synthesis , of at least some, of the CYP450s is co- 
ordinately controlled. The CYP1A subfamily is generally recognised as the most 
important family in the activation of PAH carcinogens (loannides and Parke, 1987) 
since it is this subfamily which is believed to activate the PAH. The family comprises 
two proteins, A1 and A2. CYP1A acts on and is induced by rather planar molecules, 
hence the activity of the proteins towards the PAH. CYP1A can be induced by Aroclor 
1254, a mixture of polychlorinated biphenyls used as a pesticide. If the biphenyls are 
substituted at the meta or para positions they will induce CYP1A. If, on the other 
hand, they are substituted at the ortho-positions, then the compounds will not induce 
CYP1A due to loss of planarity. The response is however a graded one, if one of the 
positions are substituted then the plane of the rings will be slightly distorted and 
induction will be decreased but not abolished. If the compound is substituted at two 
ortho-positions on different rings then one of the rings will lie at 90 degrees to the 
original plane and there will be no induction. This may be explained by the CYP1A 
induction mechanism; it appears that the induction may involve at least one cytosolic 
receptor protein designated the Ah receptor (fig. 1.20)(Fujisawa-Sehara et al., 1987; 
Neuhold etal., 1989).
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Interaction 
with haem
Nuclear
Membrane.
mRNA for 
CYP1A
Binding to the XRE 
of the DNA
Enhanced Transcription
Cytoplasmic
Membrane.
R= Receptor 
XRE= xenobiotic responsive 
element.
Fig. 1.20: induction of CYP1A1 mediated by 
the Ah receptor.
Thus it is envisaged that the cytosolic receptor possesses a binding site into which 
only planar molecules can fit ,ie. it mimics the active site of GYP1A1. This 
inducer/receptor complex is translocated into the nucleus where it binds to an 
upstream regulatory sequence, designated the xenobiotic responsive element (XRE). 
This binding then facilitates an increase in the rate of transcription of the CYP1A 
gene (Daujat etal., 1991).
By analogy with the structure of the P-450cam of Pseudomonas species 
and by using the amino acid sequence of the CYP1A1, computer models of the 
structure of the protein and its active site have been constructed (Figs. 1.21a and 
1.21b) (Lewis and Moereels, 1992). The CYP1A proteins are believed to convert 
carcinogens to their ultimate carcinogenic forms as a consequence of their ability to 
oxidise the compounds at conformationally hindered positions. The activation of the 
PAH requires that the compound be oxidised at the bay-region (Jerina and Daly, 
1974). This ability to oxidise at hindered positions is believed to be due to the fact 
that the enzymes possess a planar active site (loannides and Parke, 1990). 
Moreover it appears that the products of these transformations are resistant to the 
actions of the detoxicating enzymes (Oesch and Guenthner, 1983; Glatt etal., 1983).
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Conversely the PB-lnduced CYP450s have a globular active site and therefore only 
oxygenate at unhindered sites eg. the K-region. Such K-region epoxides are, 
however, good substrates for the detoxicating enzymes and as such are unlikely to 
be involved in carcinogenesis(Glatt etal., 1983).
1.4.2 Epoxide Hydrolase
Epoxide hydrolase (EC 4.2.1.63)(EH) is responsible for converting the 
epoxides, produced by the action of the hepatic microsomal mono-oxygenases on 
xenobiotics, to vicinal diols (fig. 1.14). EH levels in rat liver are very low at birth and 
remain so until the animals reach puberty, when a large rise in activity occurs 
(Mukhtar et al., 1978). EH is believed to exist in two forms, a membrane bound or 
microsomal enzyme (mEH) and a cytosolic enzyme (cEH). Friedberg e ta l (1989) 
reported the isolation of four proteins using a polyclonal antibody raised to mEH but 
whether or not these proteins possessed EH activity was not investigated. It appears 
that the mEH may have a higher specific activity, towards many substrates, than the 
cytosolic enzyme (Bellucci etal., 1989). The interindividual variation in human EH 
levels is considerable since in a study of the levels of EH in patients with various liver 
diseases it was found that mEH varied 66-fold and cEH varied 539-fold (Mertes et 
al., 1985). In the same study the possible induction of EH in different groups of 
patients was investigated. Patients being treated for tuberculosis with rifampicin, 
ethambutol or isoniazid showed EH levels 1.7 times those of controls; moreover the 
authors reported finding no difference between the sexes or between non-smokers 
and smokers, or alcoholics and non-alcoholics. These results suggest that human 
EH may not be inducible, or, at least, is not influenced by sex, smoking or alcohol. 
The authors further reported no correlation between cEH and mEH-suggesting 
separate biological control. These findings differ from those obtained with rat EH 
since it has been reported that male rats have higher EH levels than females 
(Christou et al., 1989) and that rat EH can be induced (Oesch, 1988). This apparent 
difference between the EH enzymes of rats and other species, makes the 
extrapolation of data on the activation of PAH, to species other than that used in the 
experiment, very difficult. Although EH is the enzyme whose function is the hydrolysis
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of endogenously formed epoxides, a number of studies have found that EH is 
inefficient at inactivating a number of PAH metabolites eg. benz[a]anthracene-8,9- 
diol-10,11 -oxide (Oesch, 1984; Glatt et al., 1982).
1.4.3 The Giutathicne-S-Transferases
The glutathione-S-transferases (GST) (EC 2.5.1.18) are the enzymes 
responsible for catalysing the attack of the sulphur atom of glutathione (7- 
glutamylcysteinylglycine) on electrophilic groups in the substrate (Mannervik and 
Danielson, 1988)(fig 1.15). The enzymes occur in multiple forms in all of the 
organisms and tissues which have GST activity, and exist as either homo or 
heterodimers of eight subunits (Armstrong, 1991). Other than the fact that they 
catalyse the conjugation of xenobiotics, little is known of the function of the GST. As 
the endogenous substrates of the enzymes are unknown, it has been impossible to 
classify and name the GST by the usual substrate criteria, consequently various 
arbitrary systems were used in their classification, e.g. order of elution from a 
chromatography column or in order of increasing isoelectric point. A new system of 
classification was therefore devised, each distinct subunit protein being denoted by 
an arabic numeral 1 to 8. Each enzyme was then named using the formula: "species" 
glutathione transferase "subunit numbers" e.g. Rat glutathione transferase 1-1. The 
enzymes were also assigned to one of four main structural classes, alpha, mu, pi and 
theta (tables 1.2 and 1.3). This numbering system has not yet been applied to the 
human enzymes.
A number of GST have been purified and partially characterized 
(Armstrong, 1991). The GST are believed to inactivate epoxides by conjugating 
glutathione directly at the epoxide function, in a classic example of an acid catalysed 
opening of an epoxide (figs. 1.15 and 1.22). The mechanism shown in figure 1.22 
has been postulated as that of the GST acting on epoxides. The mechanism 
,however, gives no indication of the positions of the acidic and basic amino acid 
residues involved, or of the nature of the binding of the substrates to the enzyme 
(Mannervik and Danielson, 1988). Indeed it has since been demonstrated that 
histidine residues in the GST are not essential for catalysis (Wang etal., 1991 ; Wang 
et al., 1992; Widersten et al., 1992). Moreover it appears that the formation of the
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thiolate anion is facilitated by the formation of a hydrogen bond between GSH and 
the hydroxyl function of a highly conserved tyrosine residue (Stenberg et al., 1991; 
Liu etal., 1992). The binding of the co-substrate, Glutathione ,to class |i isoenzymes 
has been hypothesised to occur as shown in figure 1.23 (Adang etal., 1990).
Table 1.2: Characteristics of rat glutathione-S-transferases
Isozyme Class Apparent subunit 
Mr.(kD)
No of Amino 
acids
pi
1-1 a 25 221 10
1-2 a 25+28 ———— 9.9
2-2 a 28 220 9.8
3-3 m 26.5 217 8.9
3-4 m 26.5 ---------- 8
3-6 m 26.5+26 ---- 7.4
4-4 m 26.5 217 6.9
4-6 m 26.5+26 ---- 6.1
5-5 —— 26.5 ---- 7.3
6-6 m 26 ———— 5.8
7-7 P 24 209 7.0
8-8 a 24.5 - - — 6.0
Microsomal — 17 154 10.1
Table 1.3: Characteristics of human glutathione-S-transferases
Isozyme Class Apparent 
subunit Mr.(kD)
pi
B lB i a 25 8.9
B iB 2 a 25 8.75
B2B2 a 25 8.4
m m 26.5 6.6
y m 26.5 5.5
P P 23 4.8
Skin "9.9" a 27.5 9.9
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Fig. 1.22; Proposed mechanism of the conjugation of glutathione 
to an epoxide catalysed by a glutathione-S-transferase
(Mannervik and Danielson, 1988)
HN
,SH
N^H
= H-bonds.
Fig.1.23: Glutathione binding to ^i-class GST's.
It appears that GST may show greater activity towards some epoxides than EH does 
(Oesch, 1984). Glatt etal. (1983) have reported the efficient inactivation of both a
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diol-epoxide and a K-region epoxide by a GST. These reactions cannot merely be 
due to broad substrate specificity on the part of the GST since they display 
considerable specific activity and stereo-selectivity. Of the GST examined, the k- 
isozyme displayed the greatest specific activity for a diol-epoxide of B[a]P, and the 
lowest Km for glutathione {Robertson eta/., 1986). Furthermore the jc-isozyme has 
been found to preferentially act on the (+) enantiomer of the carcinogenic diol- 
epoxide of benzo[a]pyrene. It has been demonstrated that several bay-region diol- 
epoxides, are substrates of the GST (Hodgson et a/.,1986), the GST with greatest 
activity towards the diol-epoxides being GST-X, isolated from rat liver (Glatt et a/., 
1983; Friedberg et a!., 1983). A GST has been isolated from rat cardiac tissue and 
appears, by immunological, isoelectric point and substrate specificity criteria, to be 
identical to GST-X (Ishikawa et a!., 1986). Thus a GST with considerable ability to 
detoxicate diol-epoxides appears to be present in a number of rat tissues. It has 
recently been demonstrated that murine hepatic GST can be induced by various 
anti-cancer drugs, though all classes of enzyme are not induced to the same extent. 
The induction pattern appeared to vary between the sexes and the magnitude of 
induction was found to be greater in male animals (Benson etal., 1989).
1.4.4 Dihydrodiol Dehydrogenase
In the metabolism of xenobiotics, it is believed that dihydrodiol 
dehydrogenase (DD) may interfere with the production of diol-epoxides by 
sequestration of the precursors (Glatt etal., 1982), it is also thought to have a direct 
role in the inactivation of diol-epoxides. The enzyme has been observed to decrease 
the mutagenicity of BA-8,9-diol-10,11 -oxide, towards Salmonella typhlmurium  
TA100 (Glatt etal., 1982) indicating that DD was able to inactivate a diol-epoxide on 
which EH had, apparently, no effect; the nature of the products of this inactivation are 
however unknown. It has been speculated that the enzyme may convert the diol- 
epoxide to a ketol-epoxide, these species could then isomerize by a number of non- 
enzymic routes, to an aromatic triol (Glatt etal., 1982). DD shows considerable regio- 
and stereo-specificity for the frans-dihydrodiol metabolites of PAH and furthermore 
the enzyme will only oxidise non-K-region dihydrodiols. It has been proposed that
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this is due to the fact that EH efficiently metabolises K-region epoxides, and that DD 
also having this capability, would be a duplication of effort. DD has been found only 
to act on the (-) enantiomers of a range of 1,2-diol-epoxides, whereas it acts on both 
enantiomers of the 7,8-dihydrodiol of B[a]P (Smithgall et al., 1986). Thus it appears 
that DD has the ability to metabolise the major and minor dihydrodiol metabolites of 
B[a]P. There is no intrinsic reason why this ability should not apply equally to other 
PAH. As with the other enzymes mentioned, the major repository of DD activity is the 
liver; however, also in keeping with the other enzymes is the fact that, DD has been 
reported to occur in other tissues, e.g. lung, small intestine, testis, bladder and 
prostate (Ivins and Penning, 1987). It has been demonstrated that the specific activity 
of hepatic DD in female rats is two-fold higher than in males, and it appears that this 
difference is due to induction. The difference can be abolished by ovariectomy and 
then re-established by a single injection of oestrogen-3-sulphate. It, therefore, seems 
that oestrogen is a "natural" inducer of DD activity (Smithgall and Penning, 1985). 
DD is, perhaps, unique among the enzymes under discussion in that, at least one of 
its natural functions in rats seems to be established. It appears that, in rats but not in 
rabbits, DD and 3a-hydroxy-steroid-dehydrogenase are of the same enzyme family 
(Worner and Oesch, 1984). DD appears to be inhibited by a range of drugs used as 
anti-inflammatory agents (Smithgall and Penning, 1986), such inhibition could have 
serious implications bearing in mind the possible role of DD in the detoxication of 
PAH metabolites.
Thus it was considered pertinent to examine the metabolic activation of 
various cyclopenta[a]phenanthren-17-ones and to investigate the role of the more 
important enzyme systems {vide supra) in this activation, with a view to shedding 
some light on the structure/activity relationships observed in the cpp-17-ones.
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CHAPTER 2
General methods
29
2.1 M ate ria ls
HEPES and 2-nitrofluorene were purchased from the Aldrich chemical company , 
Gillingham , Dorset, UK.
Lab M No 1 agar was purchased from Amersham International, Amersham ,U.K. 
Phénobarbital sodium and Triton X-100 were supplied by BDH Ltd. , Poole , Dorset 
,U.K.
Hydroxylapatite was purchased from Bio-rad laboratories , Hemel Hempstead , 
Hertfordshire ,U.K.
Pico-Fluor 40 liquid scintillation cocktail was supplied by Canberra Packard , 
Pangbourne , Berkshire ,U.K.
All solvents and acids were the best available grade and were purchased from 
Fisons Scientific equipment, Loughborough ,U.K. or May and Baker Ltd , Dagenham 
, Essex ,U.K.
Benzo[a]pyrene-4,5-dihydrodiol and benzo[a]pyrene-4,5-epoxide were obtained from 
the Mid-West research institute , Kansas city , Missouri,U.S.A. 
Ethoxyresorufin.pentoxyresorufin and resorufin were purchased from Molecular 
probes , Eugene , Oregon ,U.S.A.
Acrylagel and bisacrylagel were purchased from National diagnostics , Manville , 
New Jersey,U.S.A.
Oxoid Nutrient broth No.2 was obtained from Unipath Ltd , Basingstoke , Hampshire 
,U.K.
TCDF was supplied by Promochem , St Albans , Hertfordshire ,U.K.
Aroclor 1254 was obtained from the Robens institute , Guildford , Surrey ,U.K. 
2-aminoanthracene , ammonium persulphate , ampicillin , benzo[a]pyrene , D-biotin , 
bovine serum albumin (fraction V ) , bromophenol blue , clofibric acid , crystal v io le t, 
dexamethasone-21-phosphate , dithiothreitol , EDTA , Folin-Ciocalteau phenol 
reagent, Glucose-6-phosphate , Glucose-6-phosphate dehydrogenase , L-histidine , 
isoniazid , lauric acid , 2-mercaptoethanoI , MNNG , NADP , NADPH , 4-nitrocatechol 
, p-nitrophenol , sodium dodecyl sulphate , TEMED , Tris and Trizma base (Sigma 
chemical company , Poole , Dorset, UK.).
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All other chemicals were of general purpose reagent grade and were purchased from 
various suppliers.
i4C-lauric acid (SOmCi.mmoH) was supplied by Amersham International, Amersham 
,U.K.
3H-TCDD was purchased from Chemsyn science laboratories , Lenexa , Kansas 
.U.S.A.
Polycarbonate centrifuge tubes (10ml) were purchased from Beckman Ltd , Berkeley , 
California ,U.S.A.
Minimal agar plates were supplied by Becton Dickinson , Oxford ,U.K.
Sterile polyethylene universal bottles and sterile polyethylene tubes (10ml) were 
supplied by Bibby sterilin Ltd , Staffordshire ,U.K.
All glass homogenisation tubes were supplied by Jencons scientific Ltd , Leighton 
Buzzard , Bedfordshire ,U.K.
Glass-backed silica T.L.C plates were purchased from E.Merck , Darmstadt 
.Germany.
Polyethylene centrifuge tubes (50ml) were obtained from MSE scientific instruments , 
Crawley, Sussex .U.K.
Nitrocellulose paper was purchased from Anderman and company . Kingston upon 
Thames. Surrey .U.K.
All animals were purchased from the University of Surrey animal breeding unit . 
Guildford .U.K.
Gel transfer (wet) system was purchased from Bio-rad laboratories . Hemel 
Hempstead . Hertfordshire .U.K.
Vertical slab-gel electrophoresis unit was obtained from Hoefer scientific instruments 
, San Francisco , California .U.S.A.
2.2 Induction of Rat Hepatic cytochrome P-450 and preparation of liver 8-9
Male Wistar albino rats (~ 200g body wt.) were treated with a single intraperitoneal
(ip) dose of Aroclor 1254 (500mg.kg-‘>) in corn oil. Control animals received the
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vehicle only. The animals were housed in cages with woodchip bedding and were 
permitted to feed and drink ad libitum. The cages were maintained at a temperature 
of 20°C with 50% relative humidity and a twelve hour light/dark cycle. Five days after 
dosing, the animals were sacrificed by cervical dislocation and the livers immediately
- excised, using sterilised instruments. All manipulations were carried out 
asceptically. The livers were then washed , twice , in 1.15%(w/v) KCI. After 
ascertaining the weight of the iivers they were scissor-minced in 1.15%(w/v) KCI (~ 
5ml) and homogenised in a glass homogeniser with Teflon pestle. The homogenates 
were diluted to 25%(w/v) with 1.15%(w/v) KCI, so that 1g liver = 4ml of diluted 
homogenate. The homogenate was then decanted into sterile centrifuge tubes and 
centrifuged at 9,000g and 4°C for twenty minutes in a Beckman J2-21 centrifuge. The 
supernatant fraction (S-9) was decanted and aliquoted into polyethylene tubes. The 
S-9 aliquots were then stored at -20°C until use. The induction of specific isoforms of 
cytochrome P-450 was achieved by the use of archetypal inducers (see Table 2.1).
Table 2.1: Induction of various rat hepatic cytochrome P-450 isoforms 
using archetypal inducing agents.
Isoform Inducer Dose Route Vehicle Dosing
regime
Sacrifice
1A benzo[a]pyrene 25mg.kg-i i.p. corn oil
single doses 
on 3 
successive 
days
24 hrs after 
final dose
2B1/2 Phenobarbital-
sodium
80mg.kg-i ip- water
single doses 
on 3 
successive 
days
24 hrs after 
final dose
2E1 Isoniazid
0.1% (w/v) 
in drinking 
water
oral water
10 days 
exposure
the
eleventh
day
3A1 Dexamethasone 
-21-phosphate
lOOmg.kg 1 Intragastric
gavage
water
single doses 
on 3 
successive 
days
24hrs after 
final dose
4A1 Sodium
clofibrate
80mg.kg-i i.p. 0.9%(w/v)
saline
single doses 
on 3 
successive 
days
24 hrs after 
final dose
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2.2.1 Preparation of Microsomes
Aliquots of S-9 were thawed over ice and decanted into 10ml polycarbonate 
centrifuge tubes, and centrifuged at 105,000g and 4°C for 1 hr in a Beckman L7 
ultracentrifuge. The supernatant fraction (cytosol) was decanted and the microsomal 
pellet washed three times with 1.15%(w/v) KCI. Further 1.15%(w/v) KCI was added to 
attain the original S-9 volume. The pellet was then gently dislodged from the walls of 
the tube and decanted into a homogeniser. Homogenisation was then carried out to 
resuspend the microsomes, thus producing a 25%(w/v) microsomal suspension.
2.3 Characterisation of microsomal suspensions
2.3.1 Protein Determination
Protein concentrations were ascertained using the method of Lowry (Lowry et al., 
1951).
2.3 .1 .1 . Reagents
Copper Solution
0.01% (w/v) CuS04*5 H20
0.02% (w/v) (K-02C(CH0H)2C02-Na)-4H20
0.02% (w/v) Na2C0 g
This solution was prepared freshly for each assay.
Folin-Ciocalteau Phenol reagent
Commercial reagent was diluted 1:1 with distilled water immediately before use.
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2.3.1.2 Assay Procedure
The microsomal suspension (25%(w/v)) was diluted 1:24 with 0.5N NaOH and an 
aliquot (0.5ml) was added to 0.5N NaOH (0.5ml), followed by copper solution (5ml). 
The mixture was allowed to stand for ten minutes and Folin-Ciocalteau phenol 
reagent (0.5ml) was added and the tubes immediately mixed. The absorbances of the 
solutions were measured at 720nm after thirty minutes. The protein concentrations 
were calculated by reference to a standard curve using bovine serum albumin in the 
range of 25-250|ig.
2.3 .2  Cytochrome P-450 activities
2.3.2.1 Total cytochrome P-450
Total cytochrome P-450 was assayed according to the method of Omura and Sato 
(1964).
25%(w/v) microsomal suspension (500pl) was diluted 1:5 with potassium phosphate 
buffer (0.1M;pH7.4). A few mg of sodium dithionite were added, mixed and the 
resulting solution was divided between two cuvettes. Carbon monoxide was bubbled 
through one of the cuvettes for around thirty seconds. A difference spectrum was then 
obtained between 390 and 500nm. Total cytochrome P-450 was calculated using the 
extinction coefficient E= 91mM-i cm-%
2.3 .2 .2  The 0-deethylation of Ethoxyresorufin
Ethoxyresorufin-O-deethylase activity is considered to be a marker for the CYP1A 
family (especially the 1A1 protein) and was used throughout this study for that 
purpose. The activity was measured by the method of Burke and Mayer (1974).
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Reagents
Tris-HCI buffer (100mM;pH 7.8 at 37°C) 
NADPH {50mM in 1% (w/v) NaHCOg) 
Ethoxyresorufin (0.53mM in DMSO) 
Resorufin (0.1 mM in DMSO)
Assay Procedure
Tris-HCI buffer (2ml) was placed in a fluorimeter cuvette with 25%(w/v) microsomal 
suspension (50|il) and ethoxyresorufin (3pl). The contents of the cuvette were mixed 
and a baseline was recorded in a Perkin-Elmer LS-5 luminescence 
spectrophotometer (Excit.A,= 510nm; Emis. X = 586nm; Excit. Slit Width = 10cm; Emis, 
slit width = 2.5cm). The reaction was initiated by the addition of NADPH (lOpI). The 
initial linear rate was recorded. Calibration was achieved using aliquots of resorufin 
(5pl) in the presence of buffer and microsomes.
An entirely analogous method was used to determine the methoxyresorufin-0- 
demethylase activity of microsomal samples which is believed to be a marker of CYP 
1A2 levels.
2.3 .2 .3  The 0-depentylation of pentoxyresorufin
Pentoxyresorufin-O-depentylase activity is considered to be a marker for the CYP2B 
subfamily and was therefore used to assess the levels of this activity in microsomal 
samples. The method employed was that of Lubet etal. (1985).
Reagents
Tris-HCI buffer (100mM;pH 7.8 at 37°C)
NADPH (50mM in 1% (w/v) NaHCOa)
Pentoxyresorufin (ImM in DMSO)
Resorufin (0.1 mM in DMSO)
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Assay Procedure
The following were placed in a fluorimeter cuvette 
Tris-HCi Buffer 2ml
25% microsomal suspension 50pl 
Pentoxyresorufin 3pl
The contents of the cuvette were mixed and a baseline was recorded in a Perkin- 
Eimer LS-5 luminescence spectrophotometer (Excit.l = 510nm; EmisA = 586nm; 
Excit.slit width = 10cm; Emis.slit width = 2.5cm). The reaction was initiated by the 
addition of NADPH (lOpI). The initial, linear rate was recorded. Calibration was 
effected using aliquots of resorufin (5pl) in the presence of buffer and microsomes.
2 .3 .2 .4  p-Nitrophenol oxidase activity
The oxidation of p-nitrophenol to 4-nitrocatechol is considered to be a probe for the 
CYP2E subfamily of cytochrome P-450. Consequently it was used as a measure of 
the activity of CYP2E in this work (Reinke and Moyer 1985).
Reagents
potassium phosphate buffer (200mM; pH6.8) 
p-nitrophenol (ImM in assay buffer)
NADPH (lOmM in 1% (w/v) NaHCOs) 
perchloric acid (0.6N)
4-nitrocatechol (0.5mM in assay buffer) 
ascorbate (ImM)
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Assay Procedure
Potassium phosphate buffer (0.65ml), p-nitrophenol (0.1ml), ascorbate (0.1ml) and 
25%(w/v) microsomal suspension (50pl) , were placed in tubes and incubated at 
37°C, in a shaking waterbath, for three minutes. The reaction was initiated by the 
addition of NADPH (0.1ml) and the incubation was continued for a further ten 
minutes. The reaction was terminated by the addition of ice-cold perchloric acid 
(0.5ml). The precipitated protein was sedimented by centrifugation at 1850g for ten 
minutes in a Beckman J-6B centrifuge. Aliquots of the resulting supernatants (1ml) 
were transferred to fresh tubes, to which ION NaOH (lOOpI) was added. The resulting 
solutions were mixed, and their absorbances at 536nm obtained in a Kontron 
instruments Uvikon 860 spectrophotometer. The activity of the microsomal 
suspensions was ascertained by reference to a standard curve, which utilised 4- 
nitrocatechol in the range of 10-50 nmoles per tube.
2.3.2 .5  Erythromycin-N-Demethyiase
The N-demethylation of erythromycin is considered to be a characteristic activity of 
the CYP3A sub-family of cytochrome P-450. It was therefore used to monitor CYP3A 
activity in the present studies. The method is that of Wrighton et al. (1985) and 
involves the measurement of the formaldehyde (Nash 1953) formed from the methyl 
group.
Reagents
potassium phosphate buffer (0.05M;pH 7.25)
MgCl2 (0.15M)
Erythromycin (0.01 M in assay buffer)
NADPH (0.016M in 1% (w/v) NaHCOa)
Nash reagent (4M ammonium acetate containing 4ml. L-i of acetylacetone) 
trichloroacetic acid (12.5% (w/v) )
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Assay Procedure
Potassium phosphate buffer (0.6ml), MgCl2 (0.1ml), erythromycin (0.1ml) and 
25%(w/v) microsomal suspension (0.1ml) were added to tubes and incubated at 
37°C for three minutes in a shaking waterbath. The reaction was initiated by the 
addition of NADPH (0.1ml), the incubation was continued for a further ten minutes. 
The reaction was terminated by the addition of ice-cold trichloroacetic acid (0.5ml). 
The precipitated protein was removed by centrifugation at 1850g for ten minutes in a 
Beckman J-6B centrifuge. Freshly prepared Nash reagent (1ml) was added to 
aliquots of the resulting supernatants (1ml). The solutions were mixed and allowed to 
stand for ten minutes. The absorbances of the solutions were then read at 412nm in a 
Kontron instruments Uvikon 860 spectrophotometer. The activity of the microsomal 
suspensions were calculated by reference to a standard curve using formaldehyde in 
the range of 15-90 nmoles per tube.
2.3 .2 .6  Lauric acid hydroxylase
The (Ù hydroxylation of lauric acid is known to be an activity of CYP4A1 and was 
therefore used as a measure of CYP4A activity in this work. The determination of the 
activity is as described by Parker and Orton (1980).
Reagents
Lauric acid (200mM in methanol) (A). 
i4C-Lauric acid (lOpCi. ml-i in methanol) 
Tris-HCI Buffer (500mM; pH7.4)
NADPH (40mM in 1% (w/v) NaHCOs)
HCI (3N)
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Assay Procedure
Lauric acid solution (A) was diluted 1:199 with Tris-HCi buffer to produce a ImM 
Lauric acid solution. For each millilitre of this ImM solution, i^c-lauric acid (50pl) was 
added to produce lauric acid solution (B). The following were added to each assay 
tube:-
Lauric acid solution (B) 210pl
25%(w/v) microsomal suspension 200pl
Tris-HCi buffer 1.5ml
After mixing, the tubes were incubated at 37°C for five minutes, in a shaking 
waterbath. The reaction was initiated by the addition of NADPH (40pl) and the 
incubation continued for a further ten minutes. The reaction was terminated by the 
addition of 3N HCI (0.2ml). The contents of the tubes were extracted with diethylether 
(10ml) on a rotating wheel for ten minutes. The tubes were allowed to stand for five 
minutes before the removal of aliquots (7.8ml) of the organic phase. These aliquots 
were placed in clean, dry tubes,and the ether evaporated to dryness under nitrogen. 
The residues were reconstituted by the addition of methanol (60pl), and an aliquot 
(25pl) of this solution was spotted onto glass-backed silica TLC plates. The plates 
were then run in a hexane:ether:acetic acid solvent system (70:28:1.5). Following the 
evaporation of the solvents from the surface of the plates, they were analysed using a 
Berthold LB2842 linear TLC analyser. Computerised integration of the radioactivity 
peaks facilitated measurement of the lauric acid hydroxylase activity of the
microsomal suspensions. This method suffers from a disadvantage in that it
measures both the co and the co-1 hydroxylations of lauric acid, however only the œ- 
hydroxylation is associated with CYP4A1.
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2.3 .2 .7  Epoxide hydrolase activity
The epoxide hydrolase activity of the microsomal suspensions was determined by 
following the hydrolysis of the 4,5-epoxide of benzo[a]pyrene to the corresponding 
dihydrodiol. The method is essentially that of Dansette etal, (1979).
Reagents
Tris-HCI buffer (0.015M; pH8.7 at 37°C) 
benzo[a]pyrene-4,5-epoxide (2mM in acetonitrile) 
benzo[a]pyrene-4,5-frans-dihydrodiol (2mM in acetonitrile)
Assay Procedure
Tris-HCI buffer (2ml), 25%(w/v) microsomal suspension (50pl) and benzo[a]pyrene- 
4,5-epoxide (lOpI) were placed in a fluorimeter cuvette. The fluorescence of the 
solution was measured in a Perkin-Elmer LS-5 luminescence spectrophotometer 
[Excit.À = 310nm; Emis X = 385nm; Excit.slit width = 2.5cm; Emis.slit width = 5cm]. 
Calibration was effected by the addition of aliquots of benzo[a]pyrene-4,5-dihydrodioi
(lOpI) to a cuvette containing assay buffer and microsomes.
2.4  In vitro Metabolism of cyclopenta[a]phenanthrenes
2.4.1 Preparation of incubation mixtures
The metabolism of cyclopenta[a]phenanthrenes (CPP) by rat hepatic microsomal 
suspensions was carried out using a method adapted from that of Coombs et al. 
(1980).
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Incubation mixtures
potassium phosphate buffer (0.1M;pH7.4) 
NADP (4mM)
G6P (5mM)
CPP (Img)
microsomes from 2g liver (in 2ml buffer) 
glucose-6-phosphate dehydrogenase (20 U) 
in a total volume of 10ml
Procedure
Incubations were performed in 250ml conical flasks, incubated at 37°C for thirty 
minutes, in a shaking waterbath. Metabolism was terminated by placing the flasks on 
ice.
2.4 .2  Analysis of the in vitro metabolites of the cyclopenta[a]phenanthrenes 
Procedure
Incubation mixtures were extracted six times with equal volumes of ice-cold ethyl 
acetate. The extracts were dried over MgS04*H20 for fifteen minutes, and evaporated 
to dryness under reduced pressure at 45°C. The residues were resuspended in 
HPLC-grade methanol (150pl) and aliquots (50-1 OOpI) were subjected to reverse- 
phase HPLC, on a Whatman partisil 10- CDS semi-preparative column (500mm x 
1.9mm i.d.), utilising a methanol/H20 gradient of 30-100% methanol, executed 
linearly over one hour (flow rate = 2ml.min-i). The CPP were detected using a Waters 
440 absorbance detector, set at 254nm.
The major U.V. absorbing peaks were collected and their U.V. spectra between 200 
and 400nm were obtained. Tentative identification of the metabolites was effected by 
comparison with the published U.V. spectra of CPP (Coombs and Bhatt, 1987).
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2.5  The Ames mutagenicity assay
The mutagenicity testing procedure used throughout this study was essentially that of 
Maron and Ames (1987).
2.5.1 The Bacteria
Two strains of Salmonella typhlmuriumvjere used in this study: TA100 which is 
considered to be more sensitive to base-pair substitutional mutagens such as PAH 
and TA98 which are more sensitive to frame-shift mutagens such as aromatic amines.
Solutions
Nutrient broth supplemented with ampiciliin (NB+);
Nutrient Broth No.2 (2.5% (w/v)}
Ampiciliin (72p,M)
Growth of the bacteria
Frozen permanent stock cultures were inoculated into 10ml of NB+ and incubated for 
12 hours at 37°C in a shaking waterbath.
2.5.1.1 Testing the bacterial genotype
Periodically, a set of standard tests was carried out on the bacterial tester strains to 
ensure that they retained their particular characteristics.
Solutions
Agar [0.6% (w/v) No.1 Agar; 0.5% (w/v) NaCI]
Low L-Histidine/Biotin [0.5mM histidine; 0.5mM biotin]
High L-Histidine/Biotin [0.1 M histidine; 0.5mM biotin] 
potassium phosphate buffer [0.2M; pH7.4]
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Histidine requirement
The bacterial strains possess a lesion in the His operon which renders them 
incapable of synthesising histidine and so they have an absolute requirement for an 
exogenous supply. Indeed this lesion, is the basis of the Ames test, the formation of 
colonies in the presence of low levels of histidine indicates that mutagenic events 
have occurred.
Test Procedure
High histidine/biotin (100pl) was spread onto the surface of minimal agar plates, 
when the solution had dried, the tester strains were streaked. Plates which had not 
been supplemented with high histidine/biotin were also streaked. The plates were 
incubated at 37°C for 24hr. Failure to grow in the absence of histidine demonstrated 
that the bacteria were still His".
Crystal Violet test
This test was used to detect the deep rough mutation in the bacterial genome. This 
mutation ensures that the lipopolysaccharide coat, normally present around the 
bacterium, would not be fully formed ,remaining porous, and thus allowing diffusion of 
large molecular weight compounds.
Reagents
Crystal violet (0.1% (w/v))
Test Procedure
Bacterial culture (lOOjil) was added to nutrient agar (2ml) supplemented with low 
histidine/biotin (10% (v/v)). Potassium phosphate buffer (0.2M; pH7.4) (0.5ml) was 
added and the resulting mixture was poured onto minimal agar plates. When the agar 
had solidified, a steriie filter disc was placed onto the centre of the plate and crystal 
violet solution (40pl) was pipetted onto the surface of the disc. The plates were
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incubated at 37°C for 24hr. A zone of inhibition, in the bacterial lawn, around the disc 
indicated the presence of the mutation.
Presence of the R-factor
The two strains of bacteria used in this study, TA 98 and TA 100, contain the R-factor 
plasmid pKMIOI. This plasmid increases the susceptibility of the bacteria to 
mutagens. Part of the plasmid DNA confers resistance to the antibiotic ampiciliin. 
Thus the bacteria were assessed for their resistance to ampiciliin.
Reagents
Ampiciliin (0.023M in 0.02N NaOH)
Test Procedure
An aliquot of bacterial culture (lOOpI) was added to nutrient agar (2ml) containing low 
histidine/biotin (10% (v/v)), mixed and poured onto minimal agar plates. When the top 
agar had solidified a sterile filter disc was placed onto the centre of the plate and 
ampiciliin (40pl) was pipetted onto the disc. The plates were incubated at 37°C for 
24hr. No zone of inhibition, in the bacterial lawn, around the disc, indicated the 
presence of the R-factor.
Viability test 
Test Procedure
Bacterial culture (100^1) was added to nutrient broth supplemented with ampiciliin 
(NB+)(10ml) and vortexed for two minutes. An aliquot of this suspension (lOOjxi) was 
transferred to fresh NB+(lOm l) and mixed, this procedure was repeated thus 
achieving a 106 dilution of the original culture. An aliquot of this final dilution (lOOpI) 
was added to nutrient agar (2ml) fortified with high histidine/biotin (5% (v/v)). The 
resulting mixture was poured onto minimal agar plates and incubated at 37°C for
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24hr. The colonies were then counted and the number of viable cells in the culture 
calculated.
2.5 .2  Ames test system
2.5.2.1 Preparation of activation systems
Many compounds are only mutagenic after metabolic activation. Thus it was usually 
necessary to include an activation system in order to achieve this mutagenic activity. 
The activation systems utilised either S-9 or microsomal suspension both at 
25%(w/v).
Reagents
KCI (0.33M)
MgCl2 (0.08M)
Cofactor solution (20mM NADP+; 25mM G6P) 
potassium phosphate buffer (0.2M; pH7.4)
Activation Systems 4%  10%
KCI 10%(v/v) 10%(v/v)
MgCl2 10%{v/v) 10%(v/v)
Cofactor solution 20%(v/v) 20%(v/v)
S-9 or microsomal suspension 4%(v/v) 10%(v/v)
potassium phosphate buffer 56%(v/v) 50%(v/v)
When microsomai suspension was used in the activation system it was 
supplemented with glucose-6-phosphate dehydrogenase (1 unit per plate).
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Test Procedure
The following were added to sterile 10ml polyethylene tubes:-
2ml molten nutrient agar containing low histidine/biotin (10% (v/v))
< 0.1ml test solution (in H2O or DMSO)
0.1ml 12hr bacterial culture
0.5ml potassium phosphate buffer or activation system
The contents of the tubes were then mixed and poured onto minimal agar plates. The 
plates were incubated at 37°C for 48hr and the number of revertant colonies was 
then manually counted. Positive controls were included in each test ( table 2.2) and 
similarly spontaneous reversion rates were determined.
Strain
Spontaneous
reversion
Positive control 
with activation
Positive control 
without activation
TA 100 Test compound 
vehicle
2AA (5pg/plate) MNNG (0.5 pg/plate)
TA 98 Test compound 
vehicle
2AA (5pg/plate) 2NF (2^ig/plate)
2AA = 2-aminoanthracene.
MNNG = N-methyl-N-nitro-N-nitrosoguanidine.
2NF = 2-nitrofiuorene
Table 2.2 : Positive control and spontaneous reversion
regimes for
Salmonella typhimurlum TA98 and 100 in the Ames 
mutagenicity assay.
A compound was deemed to show significant mutagenicity if it at least doubled the 
spontaneous reversion rate and showed a concentration dependent increase in 
mutagenic response.
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2.6 Binding to the Ah receptor
It is believed that the induction of CYP1A proceeds via a cytosolic receptor protein, 
designated as the Ah receptor, Fujisawa-Sehara et al. (1987) and Neuhold et al. 
(1989). The method used was that of Gasiewicz and Neal (1982).
Reagents
HEPES buffer (25mM HEPES; 1.5mM EDTA; ImM dithiothreitol; 10% (v/v) glycerol; 
pH7.4)
HEPES detergent buffer (HEPES buffer containing 0.5% (w/v) Tween 80)
Cytosoi
Freshly excised rat livers were homogenised with HEPES buffer (10ml) using a glass 
homogeniser with Teflon pestle. The homogenate was diluted so that 1g liver = 4ml 
homogenate (25%(w/v)) and subjected to centrifugation at 9,000g at 4°C for twenty 
minutes in a Beckman J2-21 centrifuge. The supernatants were decanted and 
subjected to further centrifugation at 105,000g at 4°C for sixty minutes. The resulting 
supernatants were aliquoted and stored at -80°C until use.Immediatly prior to use in 
the assay, the cytosol was diluted with HEPES buffer, to give a final protein 
concentration of 1.5 - 2.5mg. ml-i.
Hydroxyiapatite:
Hydroxylapatite (lOg) was washed five times with HEPES buffer (200ml) until the pH 
of the washings dropped to 7.4. The final wash was decanted and fresh HEPES 
buffer was added to a final volume of 75ml.
1 ,6-3H-2,3,7,8 tetrachloro-dibenzo-p-dioxin (TCDD) [60nM ; 40 Ci.mmoM] 
2,3,7,8-tetrachloro-dibenzofuran (TCDF) [40jiM]
N.B. Both of the above ligands were dissolved in 1,4-Dioxan
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Assay Procedure
Diluted cytosol (985jil) was placed in clean, dry tubes followed by ^H-TCDD (5pl). 
The compound under investigation was then added as a dioxan solution (lOpI) to 
give a final concentration of 5x10-9 - ixlO-^M. An estimate of total TCDD binding to 
the receptor was obtained by substituting dioxan for the test compound. The level of 
non-specific binding was ascertained by replacing the test compound with dioxan 
(5pl) and TCDF (5pl). The solutions were then mixed and incubated in a shaking 
waterbath at 20°C for two hours and aliquots (200p.l) of each incubate were 
transferred to 4.5ml polyethylene tubes. Hydroxylapatite slurry (250|il) was added to 
each tube and the resulting suspension, mixed. The tubes were then incubated, on 
ice, for forty minutes with gentle shaking every ten minutes. HEPES/detergent buffer 
(1ml) was then added to each tube and the tubes mixed. The suspensions were 
centrifuged at 1850g and 4°C for three minutes. The supernatants were removed, a 
further aliquot (1ml) of detergent buffer was added, and the suspensions mixed and 
centrifuged as before. Following removal of the supernatants, a similar wash was 
carried out. Absolute ethanol (1ml) was added to the hydroxylapatite pellets, which 
were then decanted into liquid scintillation vials. Pico-Fluor 40 scintillation cocktail 
(4ml) was then added to each vial and the vials counted for five minutes in a Wallac 
1410 liquid scintillation counter.
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2.7. Discontinuous sodium dodecyi sulphate (SDS) poiyacryiamide gel 
electrophoresis and Western blot analysis of hepatic microsomal 
proteins
Reagents:
Upper gel buffer
0.5M Tris 
0.4% (w/v) SDS 
pH 6.8
Lower gel buffer
1.5MTris 
0.4% (w/v) SDS 
pH 8.8
Electrode buffer
0.025M Tris 
0.192M Glycine 
0.1% (w/v) SDS 
pH 8.3
Transfer buffer
0.02M Tris 
0.15M Glycine 
13.33% (v/v) Methanol
Wash buffer
0.22% (v/v) Triton X I00 
1% (v/v) PBS 
1 % (w/v) BSA
PBS
0.8% (w/v) NaCI 
0.02% (w/v) KH2PO4 
0.29% (w/v) Na2HP04  
0.02% (w/v) KCI
Freshly prepared ammonium persulphate (lOOmg.mM).
2.7.1 Discontinuous SDS-PAGE
The method used to separate microsomal proteins was that of Laemmii (1970).
Sample preparation
Sample buffer was prepared as follows:
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Trizma base (1.51 g) was dissolved in distilled water (15ml) and the pH adjusted to 
6.8 with concentrated HCI. The following were then added:
10% (w/v) SDS (40 ml)
2-mercaptoethanol (10ml)
Glycerol (20ml)
Bromphenol blue dye (0.004g)
The final volume was then adjusted to 100ml with distilled water. The 25% 
microsomal suspensions were diluted with sample buffer to give a final protein 
concentration of 2mg.ml T
Gel preparation
Two clean, dry glass plates were clamped together in a Hoefer Scientific Instruments 
vertical slab gel setting unit. Lower gel was prepared as follows:
Acrylagel (8.11ml)
Bisacrylagel (3.38ml)
Buffer (6.25ml)
HgO (7.14ml)
Ammonium persulphate (125|il)
N,N,N',N-tetramethyl-
ethylenediamine (TEMED) (20pl)
This solution was poured between the plates, followed by a few millilitres of water. 
When the lower gel had set the water was decanted and the upper gel prepared as
follows:
Acrylagel (1.0ml)
Bisacrylagel (400|il)
Buffer (2.5ml)
HgO (6.0ml)
Ammonium persuiphate (lOOpI)
TEMED (20pl)
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The upper gel was then poured between the plates and a comb was inserted to form 
sample wells. When the upper gel had s e t, the comb was removed and the position 
of the wells marked. The plate cassette was then placed in a Hoeffer vertical slab gel 
electrophoresis chamber, the wells were filled with electrode buffer and the desired 
amount of sample protein was loaded into each well. The top reservoir was then 
clamped into place and filled with electrode buffer, as was the bottom reservoir. A 
current of 20mA was applied down the gel using a Pharmacia EPS 500/400 power 
supply. The current was maintained until the dye front was approximately 2cm from 
the base of the lower gel.
2.7.2. Western blot analysis
This technique involved the transfer of microsomal proteins from a gel onto the 
surface of nitrocellulose paper and subsequent immunostaining as previously 
reported (Towbin et al. 1979). The electrophoresis plate cassette was dismantled 
and the top and bottom of the gel were cut off. The top right-hand corner was also 
removed in order to orientate the gel. The cut gel was placed in transfer buffer for 30 
minutes (or overnight under refrigeration). Transfer was effected using a Bio-rad wet 
system transfer cassette. The following arrangement was used for transfer:
1 layer of Scotchbrite scouring pad
2 layers of Whatman No.1 filter paper 
The gel
1 layer of Nitrocellulose
2 layers of Whatman No.1 filter paper 
1 layer of Scotchbrite scouring pad
Air bubbles were removed from this "sandwich" by rolling in transfer buffer. The 
cassette was then closed and placed in a Bio-rad transfer tank so that the 
nitroceliulose was closest to the positive electrode. The tank was then filled with
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transfer buffer and a potential difference of 60V was applied across the gel for 1 hr. 
The cassette was then dismantled and the nitrocellulose placed in wash buffer for 2 
hr (or overnight under refrigeration). The nitrocellulose was then placed in a 1:10,000 
dilution of an anti-CYPIA polyclonal antibody raised against purified rat CYP1A1 and 
1A2 proteins (for characterisation see Rodrigues etal., 1987), in 50ml of wash buffer 
for 1 hr. The antibody solution was repiaced by wash buffer for 30 minutes. The 
nitrocellulose was then placed in a solution, containing a 1:2,500 dilution of a donkey 
anti-sheep IgG horseradish peroxidase conjugate in 50ml of wash buffer for 1 hr. The 
antibody solution was then replaced with fresh wash buffer for 30 minutes. The 
nitrocellulose was then transferred to a PBS solution for 10 minutes. The PBS was 
decanted off and replaced with a developing solution which comprised: 0.1% (w/v) 
diaminobenzidine and 0.04% (v/v) H2O2 in 0.1 M Tris-HCI buffer, pH 7.5. When the 
bands had developed the nitrocellulose was washed several times with ice-cold 
distilled water.
Statistical evaluation of the results of these procedures was effected by means of the 
Student's t-test with (na-1)+(nb-1) degrees of freedom.
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CHAPTER 3.
The metabolism and activation 
of 15,16-DihydrocycIopenta[a]phenanthren-17-one 
by Cytochrome P-450 proteins
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3.1 Introduction
15,16-Dihydrocyclopenta[a]phenanthren-17-one (cpp-17-one) ( Fig.3.1)
O
2
3
64
M6
Flg 3.1: 15,16-Dlhydrocyc!openta[a]phenanthren-17-one
is the parent 17-ketone of the cyciopenta[a]phenanthrene (cpp) series. It was first 
synthesised in the 1960s as part of a study investigating the biological properties of 
aromatised, steroid like, carbon skeletons (Nasipuri and Roy, 1961,, Coombs etal. 
1970).
Mutagenicity studies
The compound was tested for biological activity and was found to be 
mutagenic to Salmonella typhimurlum TA100, following metabolic activation using rat 
liver S-9 preparations induced with Aroclor 1254 (Coombs et a i, 1976).It was further 
tested in a mammalian cell culture system using V79 Chinese hamster cells (Bhatt et 
a/., 1983), noting mutations conferring 6-thioguanine resistance (Huberman and 
Sachs, 1974). Human Hep G2 cells were used to activate the compound in these tests. 
Again the compound proved to be moderately mutagenic. The ability of the compound 
to induce genetic activity in the yeast Saccharomyces cerevisiae, strains JD1 and D6,
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was also examined. Cpp-17-one failed to induce mitotic aneupioidy in D6 or the 
conversion of the trp 5 locus in JD1 (Kelly, 1983; Kelly and Parry, 1983). Cpp-17-one 
was also found not to affect the rate of sister chromatid exchange in human 
lymphocytes(LindahI-Kiessling ef a/., 1984). These latter results, while being at 
variance with the other mutagenicity data, are in keeping with the observed lack of 
carcinogenicity of this compound.
Carcinogenicity studies
The tumourigenic capacity of many cpp-17-ones has been examined. 
Repeated topical application of 120nmol of cpp-17-one to Theilers Original mice 
(T.O.), twice weekly for one year with observation for a second year yielded no 
tumours (Coombs and Croft,1969). Moreover, a 1.6 pmol dose of each compound was 
applied, topically, to the dorsal surface of T.O. mice followed by twice weekly 
promotion of the treated skin with croton oil (Coombs ef a/., 1978, Coombs ef a/., 1979, 
Bhatt et a/.,1982). Again cpp-17-one treatment did not initiate any tumours. 
Subcutaneous injection of cpp-17-one in T.O. mice produced a similar result (Coombs 
and Croft, 1969). Of eighteen animals injected with the compound, all eighteen were 
alive and tumourless at the end of the experiment. Despite the compound's observed 
mutagenicity in both bacterial and mammalian cell systems, it largely failed to bind to 
mouse skin DNA (Russel etal., 1985). In comparison 11 -methyl-cpp-17-one proved to 
be positive in all of the above mutagenicity and tumourigenicity tests.
It has been postulated that a correlation exists between out-of-plane 
deformation and carcinogenicity in the cpps (Coombs and Bhatt,1987). This may 
account for cpp-17-one's lack of carcinogenic activity, since X-ray crystallography has 
established that the bay-region torsional angle in the compound is only 2 .6°. 
Furthermore the dihedral angles between the rings are less that 2.6° in each case. 
However, 7-methyl-cpp-17-one, which does display carcinogenicity, has a bay-region 
torsional angle of 2° and dihedral angles only slightly greater than the corresponding 
angles in cpp-17-one. Thus this molecular strain theory does not adequately account 
for cpp-17-one's lack of carcinogenic activity. An alternative hypothesis was that the 
lack of carcinogenic activity may have been due to cpp-17-one being poorly 
metabolised, or metabolised in a manner which did not facilitate carcinogenic activity.
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Metabolic studies
The former was shown not to be the case, since Hadfield et al., (1984) 
established that cpp-17-one was extensively metabolised, yielding A- and D-ring 
hydroxylation products. Coombs and Crawley (1974, 1975) detected thirteen cpp-17- 
one metabolites in the urine of rats, that had been administered cpp-17-one by i.p. 
injection. The pathways of cpp-17-one's metabolism present a more feasible 
explanation of the compound's biological activity. The principal In vitro metabolites of 
the compound were isolated and tested for mutagenic activity (Coombs etaL, 1980); 
only those metabolised to yield 3,4-dihydroxy derivatives were found to be mutagenic.
It was therefore considered pertinent to investigate some of the biological 
activities of cpp-17-one in order to formulate possible hypotheses for the observed 
behaviour of the compound. The metabolic pathways of cpp-17-one were investigated 
in order to ascertain those which yielded reactive intermediates, as exemplified by 
their mutagenicity in the Ames test. Secondly, the cytochrome P-450 proteins which 
catalysed the activation pathways were determined.
It was hoped that these investigations might provide some explanation for 
the lack of carcinogenic activity in cpp-17-one, when other structurally related cpp-17- 
ones display considerable carcinogenic potential.
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3.2 Materials
15,16-Dihydrocyclopenta[a]phenanthren-17-one(for synthesis and characterisation 
see Coombs.,1966) and 16-hydroxy-15,16-dihydrocycIopenta[a]phenanthren-17- 
one(for synthesis and characterisation see Coombs.,1969) were the kind gift of Dr. 
M.M. Coombs, Dept, of Chemistry, University of Surrey, Guildford, Surrey, U.K.
3,4-Dihydroxy-3,4,15,16-tetrahydrocyclopenta[a]phenanthren-17-one(for synthesis 
and characterisation see Young ef a/., 1992) was the kind gift of Professor R.G. 
Harvey, Ben May Institute, University of Chicago, Chicago, Illinois.
3.3 Methods
3.3.1 Induction of rat cytochrome P-450
Male Wistar albino rats (~200g body wt.) were treated with daily 
intraperitoneal doses of cpp-17-one (25mg.kg-i) for three days. Animals were also 
dosed with prototypical cytochrome P-450 inducers as previously outlined (sec.2.2). 
All animals were sacrificed twenty-four hours after the last administration and hepatic 
S-9 was prepared as previously described (sec.2.2).
3.3.1.1 Characterisation of hepatic microsomai preparations
Microsomal fractions (25%(w/v)) were prepared as outlined in section 2.2.1 
and characterised as described in section 2.3.
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3.3.2 In vitro metabolism of cpp-17-one
In vitro metabolism of cpp-17-one was carried out in accordance with the 
protocol outlined in section 2.4, utilising microsomes from animals dosed with the 
various cytochrome P-450 inducers (sec.3.3.1).
3.3.3 Mutagenicity of cpp-17-one and its 3,4-dihydroxy derivative
The mutagenic potential of these compounds was determined in the Ames 
mutagenicity assay using Salmonella typhimurlum TA 100 and 10%(v/v) microsomal 
activation systems, as previously outlined in section 2.5. The microsomes deployed in 
these activation systems had been treated with archetypal cytochrome P-450 
inducers (sec.2.2).
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3.4 Results
To ensure that the microsomai preparations induced with the archetypal 
inducers showed the expected pattern of cytochrome P-450 activity, the mixed- 
function oxidase activities were assayed (Table 3.1). As expected, treatment with 
benzo[a]pyrene gave rise to a marked increase in Ethoxyresorufin-0- 
deethylase(CYPIA), while phenobarbitone, isoniazid, dexamethasone and clofibrate 
increased Pentoxyresorufin-0-depentylase(CYP2B), p-Nitrophenol oxidase(CYP2E), 
Erythromycin-N-demethyiase(CYP3A) and Laurie acid hydroxylase(CYP4A), 
respectively. The microsomes from rats treated with cpp-17-one displayed markedly 
increased ethoxyresorufin-O-deethylase activity, confirming previous work which 
found that cpp-17-one was a specific C YPIA  inducer (Ayrton et al. 
,1991).Pretreatment of rats with benzo[a]pyrene did not appear to elicit the induction 
of microsomal epoxide hydrolase activity apparent in Aroclor 1254-induced animals 
(Table 3.2).
Table 3.2: Hepatic microsomal Epoxide hydrolase activities of rats 
treated with various inducing agents.
Epoxide hydrolase activity was determined using benzo[a]pyrene-4,5-epoxide 
as substrate.Results are presented as mean ± SEM for 3 animals.
Inducer Epoxide hydrolase activity 
(nmol/min per mg protein)
Control 10.65 ± 1.09
Benzo[a]pyrene 9.54 ±1.62
Aroclor 1254 33.31 ± 3.70 ***
p<0.001
Incubation of cpp-17-one with hepatic microsomal digests from Aroclor 
1254-treated rats, yielded seven major peaks (fig.3.2).
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Injection
Fig 3.2: Reverse phase HPLC separation of the metabolites 
of cpp-17-one produced by Aroclor 1254-induced microsomes.
Detection by U.V. absorbance at 254nm.
Peak 1:1,2,15-trihydroxy-cpp-17-one; Peak 2 :1 ,2-dihydroxy-cpp-17-one;
Peak 3:3,4,15- or 3,4,16-trihydroxy-cpp-17-one; Peak 4 :3,4-dihydroxy-cpp-17-one; 
Peak 5 : 15-hydroxy-cpp-17-one; Peak 6 : 16-hydroxy-cpp-17-one; Peak 7: cpp-17-one. 
Peaks a,b and c did not appear to be microsomai in origin, but they could not be 
identified due to their poor U.V. absorption characteristics.
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The U.V. spectra of these metabolites suggested the following identities
Peak 7 was found to possess the oharaoteristio ohromophore of the highly 
conjugated 17-ketones (fig 3.3);
3 .  0 0 0
K> CO
c
G C reO  ® 0 0  CO (NMW- m ID vO
Kitoro hO ho ro
ro
CM
1 . 500 -
CD
0 . 000
300250190
Fig 3.3: U.V. absorption spectrum of peak 7 (fig 3.2).
Spectrum was obtained in methanolic solution.
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the fine detail of this spectrum is a facet of the conjugation through the three six 
membered rings and extended to the ketone double bond on C-17. This spectrum 
is,therefore, only observed when no addition has been made to the structure, 
consequently peak 7 was found to be cpp-17-one itself.
Peaks 5 and 6 were found to display spectra which were, to all intents and purposes, 
identical (fig 3.4). These spectra exhibit a slight loss of the fine detail apparent in 
figure 3.3; this suggested that the hydroxylation , indicated by the increase in polarity 
of these metabolites, must have occurred at a site which did not interrupt the 
conjugation of the system, namely the 15- or 16- positions. Comparison with 
published U.V. spectra demonstrated that the chromophores of these metabolites 
were the same as those of 15- or 16-hydroxy-cpp-17-one. Co-injection of peaks 5 
and 6 with an authentic sample of 16-hydroxy-cpp-17-one, on HPLC, showed the 
authentic sample to co-elute with peak 6. Thus peaks 5 and 6 were assigned the 
structures of 15- and 16-hydroxy-cpp-17-one, respectively.
The U.V. spectrum of peak 4 was found to be almost devoid of fine stucture (fig 3.5), 
suggesting hydroxylation at a point which interrupts the conjugation of the system. 
Comparison with published spectra suggested that such U.V. absorption was given 
by 3,4-dihydroxylated cpp-17-ones. This was not however diagnostic since 1,2- 
dihydroxy compounds show similar spectral characteristics, although the latter 
compounds show more marked absorption at ~320nm; the structure was preliminarily 
assigned by examining the spectrum of the metabolite following chemical reduction 
of the ketone function at C-17, using sodium borohydride (fig 3.5a). This reduction 
causes the absorbance maximum of 3,4-dihydroxy compounds to shift down around 
20nm from ~265nm to ~245nm. Such a shift was observed with peak 4, suggesting
3,4-dihydroxylation of the cpp-17-one. Furthermore peak 4 was found to co-elute, 
from HPLC, with an authentic sample of 3,4-dihydroxy-cpp-17-one. Peak 3 was found 
to have the same chromophore as that of peak 4 (figs 3.5 and 3.5a) and was 
therefore tentatively identified as a 3,4,15- or 3,4,16-trihydroxy-cpp-17-one.
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Peaks 1 and 2 were both found to possess the U.V. spectrum associated with 1,2- 
dihydroxyiated cpp-17-ones (fig 3.6). Sodium borohydride reduction of these 
metabolites resulted in spectra where the absorbance maxima split into a doublet (fig 
3.6a), where one peak of this doublet shifted down around 9nm to -256nm.This 
behaviour is known to be characteristic of 1,2-dihydroxylated compounds. Peak 2 
was considerably less polar than peak 1, suggesting further hydroxylation of the 1,2- 
dihydroxy compound in peak 1 ; the only possible sites for this further metabolism, 
which would not alter the chromophore were the 15- and 16- positions. It was 
.therefore, thought likely that peak 1 was the 1,2,15-trihydroxy-cpp-17-one found as 
the major metabolite in previous studies (Coombs and Bhatt, 1980). Thus peak 2 was 
assigned the structure of 1,2-dihydroxy-cpp-17-one. Peaks a,b and c could not be 
identified due to their poor U.V. absorption characteristics.
Metabolism o f cpp-17-one
Of the microsomal preparations used, those derived from animals treated 
with Aroclor 1254 were by far the most efficient at metabolising cpp-17-one (see 
fig.3.7). Treatment with cpp-17-one, did not appear to alter the pattern of metabolism 
from that of control microsomes. Microsomes from benzo[a]pyrene treated animals 
significantly increased overall metabolism of cpp-17-one, and specifically enhanced 
hydroxylation of the A-ring. Treatment with phenobarbitone appeared to have little 
effect on metabolism other than to direct hydroxylation towards the 15- position (peak 
5); an almost identical pattern of metabolism was produced by dexamethasone 
induced microsomes. Similarly, isoniazid treatment appeared to have little effect, 
except for some evidence of an increase in 16-hydroxylation (peak 6) and perhaps 
some indication of a slight ability to hydroxylate the A-ring (peak 3). Clofibrate- 
induced microsomes appeared to have very limited ability to metabolise cpp-17-one, 
and indeed, appeared to be unable to hydroxylate the A-ring.
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FIg 3.7: Metabolism of cpp-17-one by hepatic microsomes 
from rats pretreated with prototypic inducers of the 
cytochromes P-450.
Cpp-17-one (Im g) was incubated with ~60mg of hepatic 
microsomal protein in the presence of an NADPH generating 
system in 0.1 M potassium phosphate buffer (pH 7.4),in a shaking 
waterbath at 37°C, for 30 minutes. 70
Mutagenicity of cpp-17-one and its 3,4-dihydroxy derivative
In the Ames test, cpp-17-one could only be metabolised to mutagens by 
microsomes from Aroclor 1254-treated rats (figs. 3.8, 3.9). On the other hand 3,4- 
dihydroxy cpp-17-one could be activated to mutagens by either Aroclor 1254-induced 
microsomes or those derived from animals pretreated with benzo[a]pyrene (figs.3.10, 
3.11).
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Fig 3.8: Mutagenic activation of cpp-17-one by hepatic 
microsomes from rats pretreated with prototype 
cytochrome P-450 inducers.
The test was carried out using a 10%(v/v) microsomal activation 
system,utilising Salmonella typhlmurium TA100. Spontaneous 
reversion rate was 84 ± 3 (figure quoted as mean ± SEM for all 
seven tests.). AI I tests were carried out simultaneously using the 
same culture.
— Q—  = Control microsomes.
— ♦—  = Cpp-17-one-induced microsomes.
— D—  = Benzo[a]pyrene-induced microsomes.
0 = Phenobarbitone-induced microsomes.
— ■—  = Isoniazid induced-microsomes.
— □—  = Dexamethasone-induced microsomes.
 A—  = Clofibric acid-induced microsomes.
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Fig 3.9: Activation of cpp-17-one to mutagens by Aroclor 
1254-induced rat hepatic microsomes.
The test was carried out using a 10%(v/v) microsomal activation 
system,utilising Salmonella typhlmurium TA100. Spontaneous 
reversion rate was 87 ± 2 (figure quoted as mean ± SEM for all 
three tests.).AII tests were carried out simultaneously using the 
same culture.
— □—  = Control microsomes.
— #—  = Benzo[a]pyrene-induced microsomes.
— D—  = Aroclor 1254-induced microsomes.
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Fig 3.10: Activation of 3,4-dihydroxy-cpp-17-one to mutagens 
by hepatic microsomes from rats induced with various 
cytochrome P-450 inducing agents.
The test was carried out using a 10%(v/v) microsomal activation 
system,utilising Salmonella typhlmurium TA100. Spontaneous 
reversion rate was 87 ± 4 (figure quoted as mean ± SEM for all 
seven tests.).AII tests were carried out simultaneously using the 
same culture.
— G—  = Control microsomes.
— •—  = Cpp-17-one-induced microsomes.
— B—  = Benzo[a]pyrene-induced microsomes.
— e—  = Phenobarbitone-induced microsomes.
 I  = Isoniazid induced-microsomes.
 □ = Dexamethasone-induced microsomes.
. = Clofibric acid-induced microsomes.
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Fig 3.11: Activation of 3,4-dihydroxy-cpp-17-one to mutagens 
by Aroclor 1254-induced rat hepatic microsomes.
The test was carried out using a 10%(v/v) microsomal activation 
system,utilising Salmonella typhlmurium TA100. Spontaneous 
reversion rate was 85 ± 3  (figure quoted as mean ± SEM for both 
tests.).Ail tests were carried out simultaneously using the same 
culture.
— Q—  = control microsomes.
— #—  = Aroclor 1254-induced microsomes.
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3.5 Discussion
The presumed ultimate genotoxic form of the Gyciopenta[a]phenanthrenes 
is the 3,4-dihydroxy-1,2-epoxide. Thus, since cpp-17-one does not show 
carcinogenic activity, it may be inferred that this is, perhaps due to one or more of the 
following
(a)The inability of the constitutive enzyme systems, or those induced by the 
compound, to catalyse the pathways which lead to the formation of the diol-epoxide;
(b) poor electrophiiicity of the diol-epoxide of cpp-17-one and consequently lower 
levels of binding to DNA and (c) rapid detoxication of the diol-epoxide, either by 
conjugation and/or hydrolysis.
3.5.1 Metabolism of cpp-17-one
Relatively planar PAH, such as the cyclopenta[a]phenanthrenes act as 
substrates of the CYP1A subfamily of cytochromes P-450. Constitutive levels of these 
enzymes in rats are very low (Luster et a i, 1982 , Pickett et a i, 1981) thus explaining 
the low level of overall metabolism observed in control, microsomal preparations. 
Benzo[a]pyrene treatment enhanced the overall degree of metabolism, again 
emphasising that these compounds are substrates of CYP1 A. This enhancement was 
presumably a facet of the very large increase in CYP1A activity in these microsomes 
(table 3.1). Aroclor 1254-induced microsomes metabolised cpp-17-one most 
extensively. This was reflected by the fact that, of the inducing agents used in this 
study, Aroclor 1254 was the most potent CYP1A inducer. Thus as the CYP1A activity 
of the microsomes increased, a parallel increase in the overall metabolism of cpp-17- 
one occurred.
It is, perhaps, somewhat surprising that metabolites 2 and 3 (fig. 3.7) should emerge 
from HPLC in this order, since 2 appears to be dihydroxylated and 3 is apparently 
trihydroxylated. This apparent anomaly may be accounted for by the conformation of 
the hydroxyl groups. Nuclear magnetic resonance studies revealed that in 1,2- 
dihydroxylated cyclopenta[a]phenanthrenes, such as 2, the protons of the hydroxyl 
groups were not coupled (Hadfield, 1983). It was thus established that 1,2-
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dihydroxylated compounds adopted a diaxial configuration, whereas 3,4- 
dihydroxylated compounds, where the protons were coupled, appeared to assume a 
diequatorial configuration, and it is to be expected that a diaxial 1,2-dihydroxy 
compound should be rather more polar than a diequatorial 3,4-dihydroxy compound. 
The presence of the third hydroxyl group, on the D-ring, of metabolite 3 thus resulted 
in the two compounds eluting with very similar retention times.
The site of metabolism of the cpp-17-one was apparently cytochrome P-450 isoform 
specific. The major metabolites produced by control microsomes were the 15- and
16-hydroxy derivatives, with only trace amounts of A-ring metabolites. Thus in terms 
of activation, this pattern of metabolism was unproductive. The benzo[a]pyrene 
treated microsomes catalysed the formation of the 3,4-dihydroxy and 3,4,15 or 16- 
trihydroxy derivatives of cpp-17-one, as well as their 1,2-oxidised counterparts. Thus 
it appears that the CYP1A subfamily is responsible for A-ring epoxidation of cpp-17- 
one. The induction of CYP1A by cpp-17-one (see table 3.1) was apparently not 
sufficient to enhance the compound's own metabolism. In comparison to Aroclor 
1254 or benzo[a]pyrene, cpp-17-one is a relatively modest inducer of CYP1A. 
Consequently, the apparent failure of cpp-17-one to autoinduce its own metabolism, 
is perhaps not surprising. Isoniazid-, dexamethasone- and clofibrate-induced 
microsomes, showed little or no ability, beyond those of controls, to metabolise cpp-
17-one. The CYP2B subfamily appears to catalyse the formation of the 15-hydroxy 
derivative, as evidenced by the increase in the relative levels of this metabolite, 
facilitated by phenobarbitone induced microsomes. The overall metabolic profile of 
cpp-17-one by Aroclor 1254-induced microsomes is thus the cumulative result of the 
relatively site specific actions of CYP1A and CYP2B (Fig. 3.12).
3 .5 .2  Mutagenic activation of cpp-17-one
The mutagenicity studies of cpp-17-one are in good agreement with the 
metabolic studies. Cpp-17-one could only be metabolised to mutagens by activation 
systems comprising microsomes induced by Aroclor 1254. Even benzo[a]pyrene- 
induced microsomes, which also possessed well enhanced CYP1A levels were
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unable to activate the compound. The reason for this may lie in the activation 
pathway itself.
CYP450
OH
3,4-Dihydroxy- 
cpp-17-one
.CYP1A
OH
3,4,15-Trihydroxy- 
E.H. cpp-17-one
CYP1A
1,2-Dihydroxy- 
cpp-17-one
Cpp-17-one 
CYP450
CYP1A
CYP1A
E.H.
1,2,15-Trihydroxy 
-cpp-17-one
15-Hydroxy-cpp-17-one
Fig. 3.12: Putative metabolic scheme of 
cpp-17-one.
E.H.= Epoxide hydrolase.
The activation of the cpps is believed to be a three-step process, two of these steps 
are catalysed by CYPIA, but the central step, the hydrolysis of the 3,4-epoxide to the 
corresponding dihydrodiol, is catalysed by the microsomal epoxide hydrolase. In 
agreement with the work of Parkinson et al. (1983), determination of the epoxide
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hydrolase activity of the microsomal preparations revealed that the microsomes from 
Aroclor 1254-treated animals had induced epoxide hydrolase levels (Table 3.2). A 
large increase in CYPIA is thus not sufficient to activate cpp-17-one to mutagens. It 
was further apparent that the 15- and 16-hydroxy derivatives were not mutagenic per 
se since no mutagenicity was observed when control microsomes, where D-ring 
metabolites are major components, were used to activate the compound. These 
components can, however, be converted to mutagens if epoxidation at the 3,4 
position becomes a significant pathway of metabolism (Coombs and Bhatt, 1987).
Only Aroclor 1254- and benzo[a]pyrene-induced microsomes were able to 
activate 3,4-dihydroxy-cpp-17-one to mutagens. Thus it appears that catalysis of the 
final step in the metabolic activation of cpp-17-one, namely conversion of the 3,4-diol 
to the corresponding diol-epoxide, is also characteristic of the CYPIA sub-family. It 
has been noted that, in other PAH, e.g. benzo[a]pyrene, the conversion of the 7,8-diol 
to the ultimate carcinogen, the 7,8-diol-9,10-epoxide is catalysed,in man, by the 
orthologous protein to the rat CYP3A as well as CYPIA (Shimada ef a/.,1989). The 
rat CYP3A was, however, unable to catalyse this conversion (Shimada et al., 1989). 
In this study the dexamethasone induced microsomes were unable to activate 3,4- 
dihydroxy-cpp-17-one to mutagens. Thus the metabolic activation of cpp-17-one in 
the rat, to its ultimate genotoxic form, appears to proceed ,similarly to benzo[a]pyrene 
as in Figure 3.13. Molecular modelling of the possible syn- and anfz-diol-epoxides of 
cpp-17-one suggested that there was no steric hinderance to the formation of either 
conformer and therefore that both should be formed (Coombs and Bhatt , 1987) ; 
however previous studies have found that the metabolism of cpp-17-one in the 
presence of DNA resulted in the formation of adducts derived only from a sy/7-diol- 
epoxide (Hadfield et al., 1984). Mutagenicity studies on the chemically synthesised 
diol-epoxides of the unsubstituted and 11-methyl-cpp hydrocarbons (fig 3.14) have 
revealed that after 24hr in solution in DMSO, the mutagenicity of the compounds 
were much the same as those of freshly prepared solutions except for the syn- 
conformer of the unsubstituted cpp, whose activity fell to less than half. Thus the syn- 
diol-epoxides of unsubstituted cpp (such as cpp-17-one) may well be the least stable 
form of these genotoxins. This could have important implications for the explanation 
of cpp-17-ones' lack of carcinogenicity. If this is indeed the case then once again cpp-
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17-one appears to mirror the activity of benzo[a]pyrene, since it has been established 
that it is the (+)anf/-diol-epoxide rather than the (+)syn-diol-epoxide which is the most 
tumourigenic form of benzo[a]pyrene (Buening etal., 1978). Interestingly the syn-diol- 
epoxide of benzo[a]pyrene was however found to be mutagenic (Wood etal., 1977); 
in this cpp-17-one appears to closely resemble benzo[a]pyrene since it apparently 
only forms a syn-diol-epoxide and has been demonstrated to be mutagenic but not 
carcinogenic.
CYPIA
Cpp-17-one
CYPIA
3,4-Dihydroxy-1,2- 
epoxy-cpp-17-one.
3,4-Epoxy-cpp-17-one
3,4-Dihydroxy- 
cpp-17-one.
Fig. 3.13: Proposed metabolic activation of cpp-
17-one to its ultimate mutagenic form.
E.H.= Epoxide hydrolase.
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syn-cpp anti-cpp
Ha
OH
syn-11-methyl-cpp
HO
OH
anti-11-methyl-cpp
Fig 3.14: The (+) diol-epoxides of 16,17-dihydro-15-H-cyclopenta[a] 
phenanthrene and its 11-methyl homologue.
3.6 Conclusions
It would appear that the bioactivation of cpp-17-one is a highly selective 
process, in which a number of factors are intimately involved. Firstly, before 
significant activation can take place, the constitutive hepatic complement of CYPIA 
must be greatly augmented, since activation is only possible using Aroclor 1254- 
induced systems. Phenobarbitone induced systems were completely unable to 
activate cpp-17-one; thus the observed activation must have been due to the 
elevated CYPIA activity of the Aroclor 1254-induced microsomes. Secondly, the 
amplified CYPIA levels must be supplemented by enhanced epoxide hydrolase 
levels, in order to generate the proximate genotoxin namely 3,4-dihydroxy-cpp-17- 
one (fig.3.13). This is amply demonstrated by the inability of benzo[a]pyrene-induced
80
systems to activate cpp-17-one to mutagens despite high CYPIA activity, but their 
complete ability to activate the 3,4-diol to mutagens.
Thus, the lack of carcinogenicity of cpp-17-one may be accounted for by 
these factors; The compound's ability to enhance its own activation via CYPIA, 
following repeated administration appears to be limited. Moreover, that small fraction 
of the compound which is converted to the 3,4-epoxide is, apparently, not efficiently 
hydrolysed to the 3,4-diol. Presumably the constitutive levels of epoxide hydrolase 
are insufficient to convert the epoxide to the diol, before a significant portion of the 
epoxide rearranges to phenols or is detoxicated by conjugation with glutathione. 
Consequently only a small fraction of cpp-17-one appears to be converted to the 3,4- 
diol and thence to the ultimate mutagen. Finally the 3,4-dihydroxy-1,2-epoxide would 
then be subject to both detoxication and spontaneous hydrolysis/rearrangement, 
once again reducing the amount available to bind to DNA. Thus it appears that the 
lack of carcinogenicity of cpp-17-one may be due, at least in part , to the fact that 
insufficient quantities of diol-epoxide are generated, or survive long enough to bind in 
sufficient quantity to DNA.
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CHAPTER 4.
The metabolism and activation 
of 15,16-Dihydro-11-methylcyclopenta[a]phenanthren-17-one 
by Cytochrome P-450 proteins
82
4.1 Introduction
It has long been known that methyl group substitution in PAH, at specific 
sites, can confer carcinogenic potential on the molecule ,eg. chrysene (Dunlap and 
Warren, 1943) and benz[a]anthracene (Bachman etal., 1938). Bay-region methyl 
group substitution, such as in the above examples, can considerably enhance 
carcinogenic potency. Thus 15,16-dihydro-11-methylcyclopenta[a]phenanthren-17- 
one (11-CH3-CPP-17-one)(fig 4.1)
2
3
64
►16
Fig 4.1: 15,16-Dlhydro-11-m ethy!cyciopenta[a]phenanthren- 
17-one
was synthesised (Coombs, 1966) as part of a study to determine whether such methyl 
group substitution would confer carcinogenicity on the non-carcinogen, 15,16- 
dihydrocyclopenta[a]phenanthren-17-one (cpp-17-one)(sec. 3.1). The biological 
activity of ll-C H s-cpp-l 7-one has been extensively studied (Coombs and Bhatt, 
1987).
Mutagenicity studies
The compound was found to be mutagenic to Salmonella typhlmurium 
TA100 following metabolic activation in the Ames test (Coombs et al., 1976). A similar
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mutagenic response was observed in Chinese hamster V79 cells when H-CHa-cpp- 
17-one was activated by human Hep G2 cells (Bhatt et al., 1983). Moreover the 
compound Induced mitotic aneuploidy in the yeast Saccharomyces cerevlsiae 
{S.cerevisae) D6 and gene conversion at the trp 5 locus in S.cerevisiae JD1 (Kelly, 
1983 and Kelly and Parry, 1983). Indeed this work suggested that these yeast 
mutagenicity assays may be reliable in predicting carcinogenicity among the 17- 
ketones of the cpps. All of the non-qarcinogenic cpps tested in the yeast assay were 
negative, whereas several non-carcinogenic compounds are positive in the Ames 
Salmonella assay (Coombs and Bhatt, 1987); sensitivity of the yeast assay was 
rather poor however. Finally 1 l-CHg-cpp-l 7-one was found to increase the rate of 
sister chromatid exchange in human lymphocytes (Lindahl-Kiessling etal., 1984).
Carcinogenicity studies
The carcinogenic activity of 1 l-CHg-cpp-l 7-one has also been extensively 
probed. The compound's ability to initiate skin tumours and its potency as a complete 
carcinogen were tested in Theilers Original (T.O.) mice (Coombs etal., 1979). In both 
tests 1 l-CHg-cpp-l 7-one displayed carcinogenic potential similar to that of 
benzo[a]pyrene. In these skin painting tests {vide supra) skin tumours were observed 
at the site of application, whereas subcutaneous injection of 1 l-CHs-cpp-l7-one 
induced local sarcomas at the site of injection as well as papillomas and carcinomas 
on the ventral skin without necessitating promotion (Coombs and Croft, 1969). T.O. 
mice were treated with ll-C H s-cpp-l 7-one (3mg) by subcutaneous injection, and 
dorsal skin, remote from the site of injection, was promoted; such treatment resulted 
in skin tumours at the site of promotion in 65% of the mice (mean latent period, 33 
weeks)(Coombs et al., 1979). When a further group of mice were similarly injected, 
but left for six months before the promotion regime was instituted, a tumour incidence 
of 45% with a mean latent period of 24 weeks was recorded. The Iball indices of 
these two experiments were almost identical (28 for immediate promotion , 27 for 
delayed promotion), indicating that initiation by 1 l-CHg-cpp-l7-one may be a 
permanent and irreversible state. Similar tumourigenicity results have been obtained 
in Balb C (Coombs and Bhatt, 1987) , C57BI (Abbott, 1983) and Skh/HR-1 hairless 
(Baker et al., 1992) mice. Although most carcinogenicity studies on cpps have been
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carried out in mice, a few studies have been undertaken utilising Sprague Dawley 
(SD) rats. Intragastric instillation of 11-CH3-cpp-17-one into 27 virgin female SD rats 
induced mammary adenocarcinomas in six animals (Coombs eta l., 1979). In a 
further experiment using male rats, ll-CHg-cpp-l 7-one was found to induce lung 
adenomas and to increase the incidence of myeloid leukaemia (Bhatt etaL, 1991). 
Thus ll-CHs-cpp-l7-one, which differs only in one methyl group from the non- 
carcinogenic cpp-17-one (sec. 3.1), was found to be a potent carcinogen.
Consequently attempts have been made to explain why this bay-region 
methyl group substitution confers carcinogenicity on cpp-17-one. It has been 
postulated that a relationship exists between molecular strain and carcinogenicity 
among the cpps (Coombs and Bhatt, 1987). Indeed in ll-CH a-cpp-l 7-one there is 
considerable out of plain deformation in order to prevent severe steric interactions in 
the bay-region. This results in a bay-region torsional angle and ring dihedral angles 
all greater than the corresponding ones in the non-carcinogenic cpp-17-one. All of 
the 11-methyl substituted 17-ketones ,ie. the 11,12-dimethyl and the 7,11-dimethyl- 
cpp-17-ones, display this distortion and are strong carcinogens. Conversely, methyl 
substitution at C-1 does not result in this distortion of the ring system and the 
compound is not a carcinogen (Coombs and Bhatt, 1987). However not all 
methylated cpp-17-ones follow this pattern,eg. 7-methyl-cpp-17-one displays 
carcinogenic activity but not the distortion of the ring system observed in the other 
carcinogens. This molecular strain hypothesis, even without the exception of the 7- 
methyl compound, does not provide a satisfactory explanation of 11-CH3-cpp-17- 
ones' carcinogenicity.
Metabolic studies
An alternative hypothesis is that it is the manner in which the compound is 
metabolised which confers the carcinogenic activity. It has long been known that PAH 
require metabolic activation to express their carcinogenic potential, Sims et a i,  
(1974) identified a bay-region diol-epoxide as the active form of benzo[a]pyrene. It 
was later demonstrated that several phenanthrene derived hydrocarbons follow a 
similar activation route (Jerina et a i, 1978). Indeed the importance of metabolism in 
the activity of ll-CHs-cpp-l 7-one was readily demonstrated since the administration
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of the aryl hydrocarbon hydroxylase inhibitor, 7,8-benzoflavone, sharply reduced 
both in vitro binding to DNA and skin tumour formation (Coombs e ta l., 1975). 
Metabolism of ll-C H s-cpp-l 7-one appears to be qualitativeiy similar to that of the 
non-carcinogen cpp-17-one, in that it occurs principally at the terminal A- and D-rings 
with some activity directed towards the 11-methyl group itself. The proximate 
carcinogenic form of benzo[a]pyrene is the 7,8-dihydrodiol (7,8-diol), the equivalent 
compound in the cpps is the 3,4-dihydrodiol (3,4-diol); indeed 3,4-diol metabolites of 
ll-C H s-cpp-l 7-one display greater mutagenicity and higher levels of DNA binding 
than the parent compound (Coombs et al., 1980). Moreover 3,4-dihydroxy-11-CH3- 
cpp-17-one is a more efficient skin tumour initiator than the parent compound. In 
addition the other 3,4-dihydroxy derivatives of the compound, namely the 3,4,15- and
3,4,16-triols were active as skin tumour initiators, albeit to a lesser extent than the 
original compound. Metabolites derived from 1,2-dihydroxy- or 11-hydroxymethyl 
compounds were inactive as tumour initiators, thus the 3,4-diol of ll-C H s -cp p -l7- 
one was identified as the proximate carcinogen. Over 80% of the total DNA binding 
was found to arise from 3,4-diol derived material bound to deoxyguanosine (Abbott 
and Coombs, 1981). Thus as the compound appeared to behave in an analogous 
manner to benzo[a]pyrene it was thought likely that the 3,4-dihydroxy-11-CH3-CPP- 
17-one bound to DNA via a diol-epoxide; mass spectral studies revealed that when 
DNA was treated in vitro with II-C H 3-CPP-17-one, a 2,3,4-trihydroxylated derivative 
was bound to the exocyclic NZ-amino group of deoxyguanosine at C-1 (Wieber et 
a/.,1981).
It was therefore considered apposite to investigate some of the biological 
activities of 11-CH3-CPP-17-one in order to formulate possible hypotheses for the 
observed behaviour of the compound. The metabolic pathways of 11-CH3-cpp-17- 
one were investigated in order to determine those which yielded reactive 
intermediates, as exemplified by their mutagenicity in the Ames test. Secondly, the 
cytochrome P-450 proteins responsible for catalysing the metabolic pathways which 
result in the activation of II-C H 3-CPP-17-one were determined.
It was hoped that these investigations might furnish an explanation 
as to why II-C H 3-CPP-17-one should be such a potent carcinogen when very closely 
related cpps .eg. cpp-17-one (sec. 3.1) are apparently devoid of carcinogenicity.
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4.2 Materials
15,16-Dlhydro-11-methylcyc!openta[a]phenanthren-17-one (for synthesis and 
characterisa tion  see Coom bs.,1966) and 15,16 -d ih yd ro -11-i4C  H 3- 
cyclopenta[a]phenanthren-17-one (10.01 m C i.m m ol-i) (for synthesis and 
characterisation see Coombs and Crawley.,1974) were the kind gift of Dr. M.M. 
Coombs, Dept, of Chemistry, University of Surrey, Guildford, Surrey, U.K.
3,4-Dihydroxy-3,4,15,16-tetrahydro-11-methylcyclopenta[a]phenanthren-17-one 
(Young et al. , 1992) was the kind gift of Professor R.G. Harvey, Ben May Institute, 
University of Chicago, Chicago, Illinois.
4.3  Methods
4.3.1 induction of rat cytochrome P-450
Male Wistar albino rats (~200g body wt.) were treated with a single 
intraperitoneal dose of 11-CH3-cpp-17-one (25mg.kg-‘>). The animals were sacrificed 
twenty-four hours after the administration of the compound and hepatic S-9 was 
prepared as previously described (sec.2.2).
4.3.1.1 Characterisation of hepatic microsomal preparations
Microsomal fractions (25%{w/v)) were prepared as previously described in 
section 2.2.1. The levels of CYPIA, CYP2B and microsomal epoxide hydrolase were 
determined as described in section 2.3.
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4.3.2 In vitro metabolism of H-CHs-cpp-l7-one
In vitro metabolism of H-CHs-cpp-l 7-one was carried out in accordance 
with the protocol outlined in section 2.4, utilising microsomes from animals dosed 
with the various cytochrome P-450 inducers (sec.2.2).
4.3 .3  Mutagenicity of 11-CHs-cpp-l7-one and its 3,4-dihydroxy derivative
The mutagenic potential of these compounds was determined in the Ames 
mutagenicity assay using Salmonella typhlmurium TA100 and 10%(v/v) microsomal 
activation systems, as previously outlined in section 2.5. The microsomes deployed in 
these activation systems were prepared from animals treated with archetypal 
cytochrome P-450 inducers (sec.2.2).
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4.4 Results
Administration of a single intraperitoneal dose of 11-CHa-cpp-l 7-one 
resulted in a significant induction of the CYPIA subfamily as exemplified by an 
increase in the ethoxyresorufin-O-deethyiase activity of the hepatic microsomes 
(table 4.1). It appears that ll-C H s-cpp-l 7-one gives rise to modest induction of 
microsomal epoxide hydrolase activity (table 4.1 ).
Table 4.1: Selected hepatic microsomal mixed-function oxidase activities of 
rats treated with ll-C H s-cp p -l 7-one.
Figures are presented as mean ± SEM for at least 3 animals.
statistical evaluation was by the Student's t-test.
Control microsomes ll-C H s-cpp -l 7-one- 
induced microsomes
Total protein (mg/g liver) 27.7 ±1.1 24.0 ± 2.7
Total Cytochrome P-450 
(nmol/mg protein) 0.51 ± 0.05 0.51 ± 0.03
Ethoxyresorufin-0- 
deethylase 
(pmol/min per nmol P-450)
63.0 ±13.8 497 ± 1 2 6 "
Pentoxyresorufin-0- 
depentylase 
(pmol/min per nmol P-450)
12.7 ±5.1 30.5 ± 6.8
Epoxide hydrolase 
(nmol/min per mg protein) 6.42 ± 0.85 10.62 ± 1 .2 9 *
p< 0.05
The in vitro metabolism of ll-C H s-cpp-l 7-one by Aroclor 1254-induced 
microsomes resulted in eight U.V. absorbing peaks which were absent from control 
preparations (fig 4.2). The structures of the compounds which gave rise to peaks 
1,3,5,6,7 and 8 were determined by comparing their U.V. spectra with the published 
U.V. spectra of the cpps (Coombs and Bhatt, 1987):-
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jljL lU l ' Aj
Fig 4.2: Reverse phase HPLC separation of the metabolites
of 11-CHscpp-l7-one produced by Aroclor 1254-induced microsomes.
Detection by U.V. absorbance at 254nm.
ten ta tive  peak identifications
Peak 1 :1,2,15-trihydroxy-11-CH3-cpp-17-one; Peak3:3,4,15- or 3,4,16-trihydroxy-ll- 
CHs-cpp-l 7-one; Peak 5 :1 5-hydroxy-11 -hydroxymethyl-cpp-17-one;
Peak 6: 3,4-dihydroxy-11-CHs-cpp-l 7-one; Peak 7: IS-hydroxy-ll-CHs-cpp-l 7-one ; 
Peak 8 : 11-CHs-cpp-l 7-one.
Peaks 2 and 4 were not microsomal in origin, but they could not be 
identified due to their poor U.V. absorption characteristics.
Peak 8 possessed the spectrum characteristic of the highly conjugated 17- 
ketones of the cyclopenta[a]phenanthrenes (fig 4.3). This spectrum is only observed 
in unsubstituted systems retaining the complete phenanthrene ring structure
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conjugated at C-17 to a carbonyl group. Consequently peak 8 was 15,16-dihydro-11- 
methylcyclopenta[a]phenanthren-17-one, the parent compound. The spectrum of 
peak 7 (fig 4.4) shows a slight loss of the fine detail apparent in the spectrum of the 
starting material (peak 8); indicating that hydroxylation had occurred at a point which 
did not substantially alter the conjugation of the system. The 15- or 16-monohydroxy 
derivatives of the 17-ketones of the cpps give such spectra; given the preponderance 
of this metabolite, it was considered likely that it was the 15-hydroxy compound found 
as a major metabolite in all previous studies (Coombs etal., 1975, Coombs at a!., 
1976 and Coombs etal., 1980). Peak 6 possessed a spectrum associated with 3,4- 
dihydroxylated compounds (fig 4.5), but this was not however diagnostic since, at low 
concentrations, 1,2-dihydroxylated 17-ketones can show similar U.V. absorption 
characteristics. The sample was consequently subjected to chemical reduction using 
sodium borohydride (fig 4.6); the compound then displayed the 20nm shift 
characteristic of 3,4-dihydroxylated cpp-17-ones (sec. 3.4). Furthermore peak 6 was 
found to co-elute from HPLC with a chemically synthesised sample of 3,4-dihydroxy-
3,4,15,16-tetrahydro-11 -methylcyclopenta[a]phenanthren-17-one; peak 6 was thus 
identified as the 3,4-dihydrodiol of ll-CHg-cpp-l 7-one. The U.V. spectrum of peak 5 
(fig 4.7) was very similar to that of peak 7 (fig 4.4), the greater polarity of peak 5 
suggesting further hydroxylation at a site which did not affect the conjugation of the 
system; the only feasible site for this further hydroxylation was the 11-methyl group 
itself, indeed a 15-hydroxy-11-hydroxymethyl-cpp-17-one has been reported 
previously (Coombs and Bhatt, 1987). Peaks 2 and 4 were not present in sufficient 
quantities to provide good U.V. spectra for the purposes of identification. Peak 3 gave 
U.V. spectra (figs 4.8 and 4.9) characteristic of a 3,4-dihydroxylated compound and 
since it is more polar than the 3,4-dihydrodiol (peak 6) it was considered likely to be a 
3,4,15- or 3,4,16-trihydroxylated metabolite. Peak 1 was found to possess the U.V. 
absorption characteristics (figs 4.10 and 4.11) of the 1,2,15-triol encountered as a 
major metabolite in all previous metabolism studies of the 17-ketones of the cpps.
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Fig 4.7: U.V. absorption spectrum given by peak 5 (fig 4.2). 
Spectrum was obtained in methanoiic solution.
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Peak 1 was therefore assigned the structure of the 1,2,15-trio! of 11-CH3-cpp-17-one. 
The structures and the full chemical names of the identified metabolites are illustrated 
in figure 4.12.
H3C.
1 ) Peak 8 2) peak 7
HaC,
OH
OH
4) Peak 5
3) Peak 6
OH
H0 \''"
OH
O
5) Peak 3
OH
HO
OH
6) Peak 1
Fig 4.12: Structures and chemical names of the 
identified metabolites of 11-CH3-cpp-17-one.
1) 15,16-Dihydro-11 -methylcpp-17-one
2) 15,16-Dihydro-15-hydroxy-11 -methylcpp-17-one
3) 3,4-Dihydroxy-3,4,15,16-tetrahydro-11-methylcpp-17-one
4) 15,16-Dihydro-15-hydroxy-11 -hydroxymethyl-11 -methylcpp-17-one
5) 3,4,15,16-tetrahydro-3,4,15/16-trihydroxy-l 1 -methylcpp-17-one 
_6ijL,2,15,16-tetrahydro-1,2,15-trihydroxy-11 -methylcpp-17-one 97
Quantitation of the metabolism of 11-CHs-cpp-l7-one by microsomes 
induced for the various families of cytochrome P-450 was achieved by the use of a 
i4C-label in the 11-methyl group. The results of these experiments are shown in fig 
4.13 and table 4.2. Aroclor 1254-pretreated microsomes achieved the largest overall 
metabolism of ll-CH s-cpp-l 7-one, starting material accounting for only 20% of the 
recovered radioactivity. The principal metabolites of Aroclor 1254-induced 
microsomes were the 15-hydroxy-, 3,4-dihydroxy-, 15-hydroxy-11-hydroxymethyl- 
and the 1,2,15-trihydroxy derivatives. The levels of all of these metabolites were 
considerably higher than those generated by control microsomes. Indeed the 1,2,15- 
triol was a major metabolite only in the system utilising Aroclor 1254-induced 
microsomes. Induction of microsomes with ll-C H s-cpp-l 7-one resulted in modest 
increases in the levels of all of the principal metabolites. Benzo[a]pyrene treatment 
resulted in an increase in the level of 1,2,15-triol, but the most startling consequence 
of such pretreatment was the increase in the level of 3,4-dihydrodiol and the 
apparently complete abolition of the 11 -hydroxymethylase activity. Phénobarbital 
treatment appeared to have little effect other than to marginally increase the level of 
15-hydroxy-11 -CHg-cpp-l 7-one. Isoniazid-induced microsomes produced a pattern 
of metabolism similar to control microsomes. Dexamethasone pretreatment appeared 
to result in increases in the relative amounts of both the 15-hydroxy and 15-hydroxy- 
11-hydroxymethyl derivatives. Clofibrate-induced microsomes failed to metabolise 
significantly 1 l-CHs-cpp-l 7-one.
Table 4.2: Metabolism of H-CHs-cpp-l 7-one by microsomes 
induced with archetypal cytochrome P-450 inducers.
Each metabolite is expressed as a percentage of total radioactivity recovered. 
Baseline and uncollected minor peaks were typically around 15% of recovered 
activity. See figure 4.2.
Inducer Peak 1 Peak 3 Peak 5 Peak 6 Peak 7 Peak 8
Control ★ ★★ 6.50 1.38 14.99 62.14
1 l-CHs-cpp-l 7- 
one
0.75 *** 9.47 2.26 17.89 50.16
Benzo[a]pyrene 1.39 *** *** 10.70 15.47 53.00
Phenobarbitone *** 6.3 1.94 16.54 55.44
Isoniazid *** *** 5.11 0.91 11.72 65.86
Dexamethasone *** *** 10.33 0.93 19.77 46.69
Clofibrate *** *** 0.89 1.01 5.99 82.93
Aroclor 1254 8.12 4.54 11.58 4.66 26.00 20.71
= metabolite absent or at too low levels to permit identification
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Fig 4.13: Metabolism of 11-CHs-cpp-l7-one by hepatic 
microsomes from rats pretreated with prototypic 
inducers of the cytochromes P-450.
11-CH3-CPP-17-one (Img) was incubated with ~60mg of hepatic 
microsomal protein in the presence of an NADPH generating 
system in 0.1 M potassium phosphate buffer (pH 7.4),in a shaking 
waterbath at 37°C, for 30 minutes.
CH,
Clofibrate.
I
I
CH,
CH,o  h o '
OHOH
99
The mutagenicity of 11-CHs-cpp-l 7-one and its 3,4-dihydroxy derivative 
towards Salmonella typhimurium TA100 was examined. When the mutagenicity of 
11-CH3-CPP-17-one was evaluated using 10% microsomal activation systems, 
induced for the various classes of cytochrome P-450 (fig 4.14), only the system 
induced with benzo[a]pyrene (CYP 1A) was able to activate ll-C H s-cpp-l 7-one to 
mutagens. Similarly only those systems containing benzo[a]pyrene or ll-CHs-cpp- 
17-one induced microsomes were able to activate 3,4-dihydroxy-1 l-CHs-cpp-l 7-one 
to mutagens (fig 4.15).
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Fig 4.14: Mutagenic activation of ll-C H s -c p p -IT -o n e  by 
hepatic microsomes from rats pretreated with prototype 
cytochrome P-450 inducers.
The test was carried out using a 10%(v/v) microsomal activation 
system,utilising Salmonella typhimurium 00. Spontaneous 
reversion rate was 101 ± 7 (figure quoted as mean ± SEM for all 
seven tests.).AII tests were carried out simultaneously using the 
same culture.
= Control microsomes.
= 11-CH3-cpp-17-one-induced microsomes.
= Benzo[a]pyrene-induced microsomes.
= Phenobarbitone-induced microsomes.
• = Isoniazid induced-microsomes.
.= Dexamethasone-induced microsomes.
.= Clofibric acid-induced microsomes.
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Fig 4.15: Activation of 3,4-dihydroxy-11-CH3-cpp-17-one to 
mutagens by hepatic microsomes from rats induced 
with various cytochrome P-450 inducing agents.
The test was carried out using a 10%(v/v) microsomal activation 
system,utilising Salmonella typhimurium TA^OO. Spontaneous 
reversion rate was 81 ± 3 (figure quoted as mean ± SEM for all 
seven tests.).AII tests were carried out simultaneously using the 
same culture.
— B—  = Control microsomes.
- —#— = 11 -CHs-cpp-l 7-one-induced microsomes.
— B—  = Benzo[a]pyrene-induced microsomes.
# = Phenobarbitone-induced microsomes.
— ■—  = Isoniazid induced-microsomes.
— n—  = Dexamethasone-induced microsomes.
— A—  = Clofibric acid-induced microsomes.
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4.5 Discussion
4.5.1 Induction of mixed function oxidases
It appears that 11-CHa-cpp-l 7-one is a good inducer of ethoxyresorufin-0- 
deethylase (EROD) activity (CYP1A)(table 4.1), since after only a single 
intraperitoneal dose a significant induction was observed, in good agreement with 
previous studies of this compound (Ayrton et al., 1990). The compound was 
administered as a single dose because it was observed that the usual dose regimen 
of three doses on successive days resulted in toxicity. The toxicity of ll-C H s-cpp-l7- 
one in a variety of biological tests is well documented (Coombs et al., 1976 and 
Coombs and Bhatt, 1987). This induction of CYP1A may have important implications 
for the activity of ll-CHs-cpp-l 7-one as it has been established that CYP1A plays a 
central role in the carcinogenic activation of many PAH (Macnicoll etal., 1981, Wood 
et al., 1976; loannides etal., 1984). The modest increase in pentoxyresorufin-0- 
depentylase (PROD) activity (CYP2B)(table 4.1) is unlikely to be due to a direct 
increase in the level of CYP2B protein but rather due to the fact that CYP1A displays 
some ability to depentylate pentoxyresorufin (Lubet eta l., 1985 and Burke and 
Mayer, 1983). This phenomenon has also been observed in a previous study of the 
induction of mixed function oxidases by 11-CHs-cpp-17-one (Ayrton etal., 1990). The 
apparent induction of microsomal epoxide hydrolase (mEH) activity by 11 -CHs-cpp- 
17-one is very interesting in that it is known that mEH plays an important role in the 
metabolic activation of PAH (Oesch, 1984; Oesch et al., 1990). Thus it appears that 
ll-C H s-cpp-l 7-one, when administered as a single intraperitoneal dose , induces 
both of the principal enzymes implicated in the activation process of PAH to their 
ultimate carcinogenic forms (loannides and Parke, 1990). This ability may well have 
important ramifications as regards explaining the carcinogenic potential of 11 -CHs- 
cpp-17-one, indeed it has been postulated that such induction is a central 
determinant in the carcinogenicity of the PAH (loannides, 1990).
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4.5.2 In vitro metabolism of 11-CH3-cpp-17-one
It is known that comparatively planar molecules such as the PAH are 
substrates of the CYP1A subfamily of cytochromes P-450; since constitutive levels of 
these proteins are low (Luster et al., 1982 and Pickett et al., 1981) it was not 
surprising that the overall metabolism of ll-CHs-cpp-l 7-one by control microsomes 
was relatively poor (fig 4.13). There is however appreciable constitutive ability to 
hydroxylate 11-CHs-cpp-17-one at both the 15-CH2 and 11-CHs positions. Greatest 
overall metabolism of the compound was achieved by microsomes induced with 
Aroclor 1254 which is known to greatly augment the levels of CYP1A and CYP2B in 
hepatic microsomal preparations (Alvares and Kappas, 1977). The 1,2,15-triol was 
only a major metabolite in the Aroclor 1254-induced system, thus it appears that 1,2- 
hydroxylation of 11-CHs-cpp-17-one can only occur after considerable enhancement 
of the CYP1A or CYP2B activity of the microsomal fraction. Consequently it appears 
that hydroxylation of the A-ring of ll-CHs-cpp-l 7-one is the province of CYP1A since 
similar increases in A-ring (1,2 or 3,4-dihydroxy) metabolites are observed in 
experiments utilising microsomes induced with the specific CYP1A inducer 
benzo[a]pyrene (fig 4.13), but no such increase was observed when microsomes 
induced with the CYP2B inducer phenobarbitone were used. Benzo[a]pyrene 
pretreatment resulted in the production of significant levels of the 3,4-dihydrodiol, the 
proximate carcinogenic form of ll-CHs-cpp-l 7-one (Coombs and Bhatt, 1987); thus 
CYP1A is implicated in the activation of this carcinogen as it is with many others. It is 
surprising that although benzo[a]pyrene induces CYP1A it does not increase the 
levels of 1,2,15-triol to the same extent that Aroclor 1254 does; this fact does not 
contradict the assertion that CYP1A is responsible for A-ring metabolism of 11-CHs- 
cpp-17-one, since it has been established that metabolic production of the 1,2,15-triol 
proceeds via the 15-hydroxy compound (Hadfield, 1983) which may be generated by 
CYP2B (which is greatly augmented in Aroclor 1254-induced microsomal 
preparations). The abolition of the 11-hydroxymethylase activity in benzo[a]pyrene- 
induced microsomes (fig 4.13) is presumably a facet of the induction of CYP1A at the 
expense of constitutive enzyme forms. Microsomes pretreated with ll-C H s-cp p -l7- 
one gave rise to small increases in the levels of A-ring metabolites in line with the
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compound's ability to induce microsomal CYP1A activity (EROD). Induction of CYP2E 
by isoniazid did not facilitate metabolism of 11-CHs-cpp-l 7-one, indeed some of the 
minor metabolites were diminished. These findings are in agreement with the fact that 
CYP2E is known to be induced by and to act upon very small organic molecules .eg. 
ethanol and chloroform (Guengerich et al., 1991). Dexamethasone-induced 
microsomes appeared to be largely unable to increase the levels of A-ring 
metabolites; however, increases were observed in the levels of the 15-hydroxy and 
15-hydroxy-11 -hydroxymethyl metabolites, suggesting a possible role for CYP3A in 
these activities. Microsomes induced with sodium clofibrate appeared to be largely 
unable to metabolise ll-CHg-cpp-l 7-one.
4.5 .3  Mutagenicity of 11 -CHg-cpp-l7-one and its 3,4-dihydroxy derivative
Mutagenicity studies were carried out on ll-CHg-cpp-l7-one and its 3,4- 
dihydroxy derivative using Salmonella typhimurium TA 100 and 10%(v/v) activation 
systems containing microsomes induced for the various classes of cytochrome P-450. 
Of the activation systems tested only that induced with benzo[a]pyrene (CYP1A) was 
able to activate ll-C H s-cpp-l 7-one to mutagens (fig 4.14). These data are in 
keeping with the findings of the metabolism studies (fig 4.13) since, of the specific 
inducing agents, only benzo[a]pyrene was able to significantly increase the levels of 
the proximate genotoxin 3,4-dihydroxy-11 -CHs-cpp-17-one. These findings thus 
confirm the long held assumption that the metabolic conversion of ll-C H s -cp p -l7- 
one to its proximate carcinogenic form is catalysed in the rat by CYP1A. This 
transformation is however a two step process, only the first is catalysed by CYP 1A (fig 
4.16), the second is catalysed by mEH, which has been found to be induced by 11- 
CHs-cpp-17-one (table 4.1). In an entirely analogous manner it was found that the 
activation of the proximate carcinogen (the 3,4-dihydrodiol) to mutagens could only 
be achieved using benzo[a]pyrene or 11-CHs-cpp-17-one-induced microsomes (fig 
4.15). Thus it appears that the conversion of the 3,4-diol to the ultimate genotoxic 
form of 11-CHs-cpp-17-one, namely the 3,4-diol-1,2-epoxide, is also catalysed by 
CYP1A.
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II-C H 3-CPP-17-one
CYP1A
11-CH3-CPP-17-one-3,4-epoxide
EH
o
CYP1A
Ha
OH
OH
3,4-dihydroxy-1,2-epoxy 
-11-CH3-CPP-17-one
3,4-dihydroxy-11-CH3-CPP-17-one
Key
CYP1A = cytochrome P-4501A 
EH = microsomal epoxide hydrolase
Fig 4.16 : Putative scheme of the metabolic 
activation of I I -C H 3-CPP-17-one 
to its ultimate carcinogenic form.
Thus in its metabolic activation (fig 4.16) 11-CHs-cpp-17-one closely resembles that 
of benzo[a]pyrene, with activation following from the concerted actions of CYP1A and 
mEH.
Another possible determinant of the carcinogenicity of 11-CHs-cpp-17-one 
is the conformation of the diol-epoxide since in benzo[a]pyrene only the anth6\o\- 
epoxide is tumourigenic (Buening et a!., 1978). Molecular modelling of the possible
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diol-epoxides of 11-CHs-cpp-l 7-one has shown that due to unacceptably short non­
bonding distances the possible syn conformers (fig 4.17 a and b) are unlikely to be 
formed (Coombs and Bhatt, 1987).
(a)
Ha
OH
o
Ha
OH
(b)
Ha
OH
HO\'"'
OH
(C) (d)
Fig 4.17: The possible 3,4-dioi-1,2-epoxides 
of 11-CH3-cpp-17-one.
Thus the modelling predicted the formation of only anfZ-diol-epoxides (fig 4.17 c and 
d) with (d) being the most favoured conformation. Previous studies of the metabolism 
of 11-CH3-CPP-17-one in the presence of DNA established that only ant/'-diol- 
epoxides are formed (Hadfield et al., 1984). Thus part of the reason for the 
carcinogenic potency of ll-CHs-cpp-l 7-one may lie in its formation of only the anti 
conformer of the diol-epoxide. Experimental evidence to support such a hypothesis 
must await chemical synthesis of larger quantities of the diol-epoxides than has been 
possible to date.
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4.6 Conclusions
The carcinogenic activity of 11-CHg-cpp-l 7-one may be due to a number of 
contributory and/or competing determinants such as:- (a) structural features of the 
compound which facilitate the activation pathway(s), (b) the ability of the compound to 
induce its own metabolism to genotoxic intermediates, (c) possession of a favourable 
window of electrophilicity by the diol-epoxide or (d) a reduced ability of the 
detoxication systems to conjugate the diol-epoxide.
In a manner analogous to benzo[a]pyrene ll-C H s-cpp-l 7-one is activated 
to its ultimate genotoxic form by a combination of the activities of CYP1A and 
microsomal epoxide hydrolase (fig 4.16). However activation of 11-CHs-cpp-17-one 
and its 3,4-dihydrodiol to mutagens is only possible if microsomal CYP1A levels are 
greatly enhanced, as is amply demonstrated by the fact that only benzo[a]pyrene- 
induced microsomes were able to facilitate activation of the parent compound. 
Microsomes induced with 11-CHs-cpp-17-one were ,however, able to activate the
3,4-dihydrodiol thus the , by comparison to benzo[a]pyrene, relatively modest 
induction of CYP1A by 11-CHs-cpp-17-one was clearly sufficient to facilitate the final 
step of metabolic activation but not the entire process. Although the magnitude of the 
induction of CYP1A and mEH by 11-CHs-cpp-17-one (table 4.1) was not sufficient to 
bring about activation of the parent compound in the Ames test, the fact that the 
compound induces both of the enzymes responsible for its activation must result in an 
increase in the generation of the diol-epoxide and must therefore facilitate to some 
extent the carcinogenicity of the compound. Moreover this inductive effect was 
elicited by a single dose of 11-CHs-cpp-17-one whereas the carcinogenicity 
exhibited by the compound is the result of chronic exposure to 11-CHs-cpp-17-one; 
under these conditions of chronic exposure induction of CYP1A and mEH may well 
be greater. It should also be noted that CYP1A catalysed metabolism of 11-CHs-cpp- 
17-one gives rise to only one A-ring metabolite, namely the 3,4-dihydrodiol, 
suggesting a structural feature of 11-CHs-cpp-17-one which favours the activation 
pathway of metabolism.
Thus the carcinogenicity of 11-CHs-cpp17-one may be accounted for at 
least in part by some of the following factors: firstly the compound is metabolically
107
activated to give relatively large quantities of the proximate and presumably the 
ultimate genotoxins, and secondly the compound has the ability to induce both of the 
enzyme systems responsible for its activation. The possibility that the diol-epoxide of 
11-CH3-CPP-17-one may not be readily conjugated by the cellular detoxication 
systems does however merit serious consideration.
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CHAPTER 5.
induction of cytochrome P-450 proteins by the 
11-alkoxycyclopenta[a]phenanthren-17-ones.
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5.0 Introduction
The presence of a methyl or hydroxyl substituent at C-11 (fig 5.1) in the 
cyclopenta[a]phenanthren-17-ones (cpp-17-ones) has been found to confer 
carcinogenicity on the parent compound, cpp-17-one (Coombs and Bhatt, 1987; chp. 
3; chp. 4).
Fig 5.1: General structure of the 11-substituted 
cpp-17-ones.
However, it has been noted that the ability of such a substituent at C-11 to activate the 
parent compound is size-limited; whereas the ll-C H s-cpp -l 7-one is a potent 
mutagen ( Coombs et al., 1976 ) and carcinogen (Coombs et al., 1979), the ethyl 
analogue is only weakly active (Coombs and Bhatt, 1987), increasing the size of the 
group further to the butyl derivative abolishes activity completely. This size limitation 
to activity has also been investigated in the more synthetically accessible 11- 
alkoxycyclopenta[a]phenanthren-17-ones (Bhatt et al., 1982). This series was found 
to display a graded response, the biological activity of the compound decreasing with 
increasing size of the substituent at C-11. The 11 -butoxy compound is however 
anomalous, displaying weak initiating activity and mutagenicity to Saccharomyces 
cerevisiae JD1 and D6. The significance of this finding of activity in 11-butoxy-cpp- 
17-one is not immediately clear, since the tumours from which the Iball index is 
derived were all papillomas and the mutagenicity data from the two test systems 
conflict. It must be borne in mind .however, that the yeast mutagenicity assay has 
proven to be a reliable indicator of the tumourigenicity of the cpp and while it has 
generated one false negative result all of the compounds which are positive in this 
yeast assay give rise to skin tumours (table 5.1) (Coombs and Bhatt, 1987).
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Substituent Iball index
Mutagenicity to 
S.typhimurium 
(revertants/nmol)
Mutagenicity to 
S.cerevisiae JD1
Mutagenicity to 
S.cerevisiae D6
-OCHs 32 3.1 + +
-OC2H5 23 1.8 + +
-OC3H7 0.3 - -
-OC4H9 5 <0.2 + +
Table 5.1: Carcinogenicty of some 11 -alkoxy-cpp-17-ones to Theilers original mice 
(Iball index) and mutagenicity of the same compounds towards Salm onella  
typhimurium TA 100 and Saœharomyces cerevisiae JD1 and D6 (Kelly, 1983).
Thus it is apparent that the 11-alkoxy-cpp-17-ones may provide an important model 
system with which to examine the structural prerequisites for tumourigenic activity in 
the cpp-17-ones. It was therefore considered pertinent to investigate the ability of the 
first four members of the 11-alkoxy-cpp-17-ones to induce the enzymes responsible 
for the metabolic activation of the cpp and .moreover, to investigate the ability of the 
rat hepatic cytochromes P-450 to activate these compounds to mutagens in the Ames 
test.
I l l
5.1 Materials
11 -Acetoxy-15,16-dihydrocyclopenta[a]phenanthren-17-one (Robinson, 1938) 
was the kind gift of Dr. M.M. Coombs, University of Surrey, Guildford, Surrey, U.K. 
3,4-Dichloronitrobenzene (DCNB) and 1-chloro-2,4-dinitrobenzene (CDNB) were 
purchased from the Aldrich chemical company, Gillingham, Dorset, U.K.
5.2  Methods
5.2.1 Synthesis of the 11 -alkoxy-cpp-17-ones
Potassium hydroxide (30M; 12ml) was added to a suspension comprising 
methanol (200ml) and 11 -acetoxy-cpp-17-one (20g); the resultant solution was 
stirred for 48hr at room temperature. The solution was then decanted into a beaker 
containing distilled water (1.51) and acidified by dropwise addition of concentrated 
HCI. The precipitate formed as a result of the acidification was collected and dried in 
an evacuated desiccator over CaCla-
The 11 -hydroxy-cpp-17-one prepared above was then used in the preparation of 
the 11-alkoxy-cpp-17-ones. The following (or multiples thereof) were placed in a 
double-necked round bottomed flask; 11-hydroxy-cpp-17-one (Immol), K2CO3 
(1.5mmol) and CH3CN (21ml). The flask was then heated under reflux and when a 
gentle reflux had been established the appropriate alkyl iodide (3mmol) was added 
to the flask and refluxing was allowed to continue for 24hr. The reaction mixture was 
filtered through a hot sintered funnel and the filtrate cooled on ice, resulting in a 
precipitate of the 11-alkoxy-cpp-17-ones. The precipitates were washed exhaustively 
with CH3CN and water and dried in an evacuated desiccator over CaCl2. The identity 
of each product was verified by melting points in addition to ultraviolet, infra-red, 1H 
nmr and 70eV electron impact mass spectra.
5.2 .2  Induction of rat hepatic cytochromes P-450
Male Wistar albino rats (~200g body wt.) received a single intraperitoneal dose of 
the appropriate 11-alkoxy-cpp-17-one (25mg.kg-i) on three successive days, 
whereas control animals were treated with the vehicle, corn oil. The animals were
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sacrificed 24hr after the final dose and hepatic S-9 was prepared as previously 
described (sec. 2.2).
5 .2 .2.1 Characterisation of hepatic preparations
Microsomal and cytosolic fractions (25%(w/v)) were prepared as described in 
section 2.2.1. The microsomal levels of CYP1A and epoxide hydrolase were 
determined as outlined in section 2.3. Changes in CYP1A protein were investigated 
by western blot analysis as described previously (sec. 2.7).
Determination of cytosolic glutathione-S-transferase levels
The conjugation of glutathione to chlorinated nitrobenzenes is known to be a 
characteristic activity of the glutathione-S-transferases (GST). As no one substrate is 
appropriate for all of the classes of GST it was decided to assay the activity of the 
cytosolic fractions towards both 3,4-dichloronitrobenzene (DCNB) and 1-chloro-2,4- 
dinitrobenzene (CDNB) which are known to be substrates of the majority of GST, the 
method is essentially that of Habig etal., 1974.
Solutions:
Sodium phosphate buffer (0.1 M; pH7.5)
DCNB (25mM in ethanol)
CDNB (25mM in ethanol)
Glutathione (reduced form; 25mM)
Cytosol (25%(w/v) diluted 1:4 with 1.15%(w/v) KCI)
Procedure
The following were placed In 4.5ml polyethylene spectrophotometer cuvettes:-
sample(ml) reference(ml)
0.1M Na.Phos. buffer, pH 7.5 1.8 1.9
25mM DCNB (or CDNB) 0.1 0.1
25mM glutathione 0.5 0.5
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The reaction was initiated by the addition of diluted cytosol (0.1ml) to the sample 
cuvette, the reaction being followed by measuring the change in absorbance 
between the sample and reference cuvettes at 345nm (DCNB) or 340nm (CDNB) 
with time. The activity of the GST was calculated using the absorption coefficients 
given below;
8  DCNB;345nm =  8.5m M -1.Cm -1- 
£cDNB;340nm =  9.6m M -1 .cm-1.
5.2 .3  Binding of the 11-alkoxy-cpp-17-ones to the Ah receptor
The ability of the first four members of the 11-alkoxy-cpp-17-one series to bind to 
the Ah receptor was investigated as outlined in section 2.6.
5 .2 .4  Mutagenicity of the 11-aikoxy-cpp-17-ones
The mutagenicity of the 11-alkoxy-cpp-17-ones was examined in the Ames 
Salmonella assay using S.typhimurium  TA100 and various hepatic activation 
systems as described previously in section 2.5.
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5.3 Results
5.3.1 Analysis of the synthesised 11-alkoxy-cpp-17-ones
The identities of the synthesised compounds (sec. 5.2) were verified by 
ascertaining their melting points in addition to obtaining their ultraviolet, infra-red, 1H 
nmr and mass spectra.
11-hydroxy-cpp-17-one
HO.
2 ,
3
64
to  -.1- to
350 400300250200
Fig. 5.2: U.V. spectrum of 11-hydroxy-15,16-dihydro 
cyclopenta[a]phenanthren-17-one.
Spectrum obtained in methanoiic solution.
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IH H-HfOROXr-CPP-l’ -ONE IN d6-DMS0.
JUN21264.00I
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Fig 5.4: 11-hydroxy-15,16-dihydro-cpp-17-one 1H nmr spectrum (Dg- 
DMSO, Me4Si); 5 11.00 (1H ,s, 11-OH), 9.90 (1H ,dd, 1-H), 8.00 (3H ,m, 
aromatic), 7.77 (2H ,m, aromatic), 7.30 (IN  ,s, 12-H), 3.35 (2H ,m, 15-CH2 + 
H2O), 2.75 (2H ,m, 16-CH2). 2.50 (DMSO).
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11-WIethoxy-cpp-17-one
M.pt. = 176-180°C (Literature value= 179°C)
abs
1.500
0.000
350300250200
Fig. 5.5: U.V. spectrum of 11-methoxy-15,16-dihydro- 
cyciopenta[a]phenanthren-17-one.
Spectrum obtained in methanolic solution.
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Fig 5.7: 11-methoxy-15,16-dihydro-cpp-17-one 1H nmr spectrum
(CDCI3, Me4SI); 6 9.75 (1H ,dd, 1-H), 7.90 (3H ,m, aromatic), 7.66 (2H 
,m, aromatic), 7.38 (IH ,s, 12-H), 7.25 (CHCI3), 4.16 (3H ,s, I 8-CH3), 3.40 
(2H ,m, 15-CH2), 2.85 (2H ,m, I 6-CH2), 1.57 (H2O in CDCI3).
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Fig 5.8: 70eV impact mass spectrum of 11 -methoxy-15,16-dihydro-cpp-
17-one. (M.wt.= 262).
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11-Ethoxy-cpp-17-one
64
16
M.pt= 189-192°C (Literature vaiue= 191-193°C)
£B
0 . 850 -
- 0 .300 400350300250200
Fig. 5.9: U.V. spectrum of 11-ethoxy-15,16-dihydro-
cyclopenta[a]phenanthren-17-one.
Spectrum obtained in methanolic solution.
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Fig 5.11: 11-ethoxy-15,16-dlhydro-cpp-17-one 1H nmr spectrum
(CDCI3, Me4SI): 8 9.86 (IH  ,dd, 1-H), 7.90 (3H ,m. aromatic), 7.69 (2H 
,m, aromatic), 7.36 (1H ,s, 12-H), 7.26 (CHCI3), 4.36 (2H ,q, I 8-CH2), 3.40 
(2H ,m, 15-CH2 ), 2.85 (2H ,m, 16-CH2), 1.70 (3H ,t, 19-CH3),1.59 (H2O in 
CDCI3).
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Fig 5.12: 70eV Impact mass spectrum of 11-ethoxy-15,16-dihydro-cpp-
17-one. (M.wt.= 276).
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11-propoxy-cpp-17-one
20 19 18
CH3.CH2.CH2.O
M.pt= 178-180°C (Literature value= 181-182°C)
1 . 500 -
400350300250
Fig. 5.13: U.V. spectrum of 11-propoxy-15,16-dihydro- 
cyclopenta[a]phenanthren-17-one.
Spectrum obtained in methanolic solution.
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IH 11-PR0P0XT-CP?-Î7-0N£ IN CDCL3.
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Fig 5.15: 11-propoxy-15,16-dihydro-cpp-17-one 1H nmr spectrum
(CDCI3, Me4Si): 8 9.86 (1H ,dd, 1-H), 7.94 (3H ,m, aromatic), 7.66 (2H 
,m, aromatic), 7.37 (1H ,s, 12-H), 7.26 (CHCis), 4.27 (2H ,t, 18-CH2), 3.41 
(2H ,m, 15-CH2 ), 2.85 (2H ,m, I 6-CH2), 2.08 (2H ,sex, I 9-CH2), 1.59 (H2O 
in CDCis), 1.22 (3H ,t, 2O-CH3).
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Fig 5.16: 70eV Impact mass spectrum of 11-propoxy-15,16-dlhydro-cpp-
17-one. (M.wt.= 290).
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11-Butoxy-cpp-17-one
CH,.CH9.CHp.CHp.O.
64
M.pt= 153-156°C (Literature value= 156-157°C)
350300250200
Fig. 5.17: U.V. spectrum of 11 -butoxy-15,16-dihydro- 
cyc!openta[a]phenanthren-17-one.
Spectrum obtained in methanolic solution.
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Fig 5.19: 11-butoxy-15,16-dihydro-cpp-17-one 1H nmr spectrum
(CDCI3, MeaSi); Ô 9.85 (IH ,dd, 1-H), 7.90 (3H ,m, aromatic), 7.67 (2H 
,m, aromatic), 7.38 (IH ,s, 12-H), 7.26 (CHCI3), 4.31 (2H ,t, I 8-CH2), 3.42 
(2H ,m, I 5-CH2 ). 2.86 (2H ,m, I 6-CH2). 2.08 (2H ,quin, I 9-CH2), 1.66 (2H 
,sex, 2O-CH2). 1.58 (H2O in CDCI3), 1.06 (3H ,t, 2I-CH3).
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Fig 5.20: 70eV impact mass spectrum of 11 -butoxy-15,1 G-dihydro-cpp- 
17-one. (M.wt.= 304).
Each compound was found to be one substance on reverse-phase HPLC (using a 
30-100% linear methanol gradient executed over 1 hr).
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5.3 .2  Induction of xenobiotic metabolising enzymes by the 11-alkoxy-cpp-17- 
ones
All four compounds were found to induce both isozymes of the CYP1A sub-family 
of cytochromes P-450, as witnessed by the significant increase in ethoxy- and 
methoxy-resorufin-O-dealkylase (EROD and MROD) activities (table 5.2). It was 
apparent however that the methoxy and ethoxy compounds were more potent 
inducers of rat hepatic CYP1A activity. These findings are in keeping with studies of 
other cpp-17-ones (Ayrton et al., 1990; Boyd et al., 1993; sec. 4). This induction of 
EROD activity by the methoxy and ethoxy derivatives was found to be in the region of 
ten-fold as opposed to the three-fold induction brought about by the propoxy and 
butoxy derivatives. Levels of CYP1A2 activity (MROD)(tabIe 5.2) were found to be 
approximately five to six-fold higher in the methoxy- and ethoxy- treated groups
whereas the propoxy- and butoxy-treated groups displayed a more modest two to 
three-fold increase. The levels of CYP1A proteins were shown to have increased 
markedly by the western blot analysis (fig 5.21 ).
1A1
Bu Pr 1A2 Et Me Co 
Ar
Fig. 5.21: Western blot analysis of microsomal protein from rats
treated with various 11-alkoxy-cpp-17-ones, probed 
w ith an anti-rat anti CYP1A polyclonal antibody.
Co= control microsomes ; Me= 11-methoxy-treated microsomes ; Et= 11-ethoxy- 
treated microsomes ; Ar= Arocior 1254-induced microsomes (positive control); 
Pr= 11-propoxy-treated microsomes ; Bu= 11-butoxy-treated microsomes . 20|ig 
of protein were employed in all cases.
No increase in microsomal epoxide hydrolase (mEH) activity was observed with 
any of the compounds tested, although a diminishment of mEH activity was observed 
in the 11-propoxy treated group (table 5.2). No modulation of the cytosolic GST 
activities was observed in any of the treatment groups.
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5.3 .3  Binding of the 11-aikoxy-cpp-17-ones to the Ah receptor
The 11-methoxy derivative was found to bind to the rat cytosolic Ah receptor with 
relatively high affinity (fig 5.22a), with 50% of the bound 3H-TCDD being displaced at 
a concentration of 1x10-7M. Similarly the 11-ethoxy compound displays affinity for the 
Ah receptor but at a much iower level (fig 5.22b); displacement did occur but total 
displacement of the TCDD from the receptor was never achieved, indeed 50% 
displacement was never reached. In the case of the propoxy- and butoxy- derivatives 
(figs 5.22c and 5.22d) there was no significant evidence of displacement.
5 .3 .4  Mutagenicity of the 11 -alkoxy-cpp-17-ones
The mutagenicity of 11 -methoxy-cpp-17-one, in common with the other cpp, was 
examined at 2,5,7 and 10 pg/plate using 10% hepatic microsomal activation systems 
(table 5.3). Under these conditions no mutagenic response was elicited from 11- 
methoxy-cpp-17-one which was known to be the most mutagenic member of the 
series (Bhatt et al., 1982). It was therefore decided to employ a higher concentration 
range (table 5.4) using microsomes from animals induced with Arocior 1254 in a 10% 
activation system. Since even these large concentrations were unable to provoke a 
response it was decided to increase the concentration of the activation system (table 
5.5), however even this failed to elicit a response. Finally the activation system 
employed was changed from microsomes to arocior 1254-induced 8-9 (fig 5.23). 
Thus the 11-methoxy compound was confirmed as the most mutagenic member of 
the series; while the 11-ethoxy derivative did display some mutagenic response it 
never doubled the spontaneous reversion rate, again in keeping with previous 
findings on the 11 -alkoxy-cpp-17-ones (Bhatt et al., 1982). Though this work oniy 
served to confirm previous mutagenicity studies it was considered important since 
these previous studies had utilised hepatic S-9 as the activation system. Since the 
present study had concerned microsomes it was decided to examine the 
mutagenicity of the compounds using microsomal activation systems; when these 
systems failed to activate the 11-methoxy compound it was decided to revert to the 
use of S-9 in order to establish that the 11-alkoxy-cpp-17-ones were mutagenic.
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Fig. 5.22 a,b: Binding of 11 -alkoxy-cpp-17-ones to the rat 
cytosolic Ah receptor.
Figures represent the ability of the respective opp- 
17-ones to displace 3H-TCDD.
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Table 5.3: Ames mutagenicity assay of 11-methoxy-cpp-17-one using 
various 10% microsomal activation systems.
The tester strain used was Salmonella typhimurium TA100 . Figures are presented 
as mean number of revenants ± SEM of triplicate determinations. 2-aminoanthracene 
(2AA)(5pg/pIate) served as the positive control.
11 -methoxy-cppi 7-one 
conc. (ng/piate)
Control microsomes 11 -methoxy-cpp-17-one- 
induced microsomes
Aroclorl 254-induced 
microsomes
0 93+6 105 ±5 100 ± 6
2 109±5 108 ±3 140±13
5 109 + 5 122 + 7 141 ±11
7 109±15 97±9 140±3
10 100±9 115±4 133±12
2AA 2360 ±198 2045 + 314 851 ±35
Table 5.4: Ames mutagenicity assay of 11-methoxy-cpp-17-one using a 
10% microsomal activation system induced with Arocior 1254.
The tester strain used was Salmonella typhimurium TA 100. Figures are presented 
as mean ± SEM for triplicate determinations.
11-methoxy-cpp-17-one 
conc.(ug/plate)
Number of revenants
0 107±10
10 145±5
20 159 ± 8
40 143±9
50 113±9
100 125±13
500 132 ±9
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Table 5.5: Ames mutagenicity assay of 11-methoxy-cpp-17-one using 
various concentrations of Arocior 1254-induced microsomes in the 
activation system.
The tester strain used was Salmonella typhimurium TA 100 and the compound 
concentration was SOpg/piate. Figures are presented as mean ± SEM of triplicate 
determinations. 2-aminoanthracene (5pg/plate) served as the positive control.
Microsomal
concentration
Number of histidine 
revertants per plate
Blank 105±8
positive control 1045 + 208
10% 129+16
20% 133±10
30% 133±3
160 -
120 -
0)
>0)
80 -
(0
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■aQ>Ü
Z3•oc
40 -
50 6020 400 1 0 30
11 -alkoxy-cpp-17-one conc.(pg/plate)
Fig 5.23: Activation of the 11-alkoxy-cpp-17-ones to mutagens by 
Arocior 1254-induced rat hepatic S-9.
The test was carried out using a 10%(v/v) S-9 activation system and 
utilising Salmonella typhimurium TA^ 00. Spontaneous reversion 
rate was 90 ± 4. All tests were carried out simultaneously using the 
same culture.
11 -methoxy-cpp-17-one 
11 -ethoxy-cpp-17-one 
11 -propoxy-cpp-17-one 
11 -butoxy-cpp-17-one 136
5.4 Discussion
5.4.1 Induction of xenobiotic metabolising enzymes
Ail four 11 -alkoxy-cpp-17-ones used in this study were able to induce the 1A sub­
family of cytochromes P-450, but a clear difference existed between the magnitude of 
the response. The compounds with shorter alkoxy chains ie. the methoxy- and ethoxy 
derivatives elicited a far greater induction than the longer chain members of the 
series (table 5.2). The greatest inductive response to these compounds was seen in 
the ethoxyresorufin-O-deethylase (EROD) activity, a marker of CYP1A1 (Alvares and 
Kappas, 1977)(table 5.2). The greater induction of CYP1A1 by the methoxy- and 
ethoxy- derivatives appears to reflect the tumourigenic potential of the series since 
only the methoxy- and ethoxy- compounds have been shown to be significantly 
tumourigenic (Bhatt et al., 1982). This relatively potent induction of CYP1A1 could 
have considerable implications for the observed behaviour of the methoxy- and 
ethoxy-cpp-17-ones. CYP1A1 has long been implicated in the activation of PAH to 
genotoxic intermediates (loannides and Parke, 1990); indeed it has been 
demonstrated that 7,8-benzoflavone (an inhibitor of CYP1A) can diminish the 
tumourigenic potential of the cpp (Coombs and Bhatt, 1987). Moreover it has recently 
been demonstrated that CYP1A1 plays a central role in the in vitro metabolism of 
cpp-17-ones to genotoxic intermediates (Boyd etal., 1993; chp. 4); thus the ability of 
the methoxy- and ethoxy- derivatives to induce the cytochrome P-450 family 
implicated in the activation of the cpp-17-ones may indeed have a bearing on the 
tumourigenicity, since induction of CYP1A1 would inevitably lead to an increase in 
the levels of the ultimate tumourigenic form of these compounds. It has been 
postulated that induction of CYP1A1 is a central determinant of carcinogenic activity 
(loannides, 1990); such an hypothesis would however not be fully supported by the 
11-alkoxy-cpp-17-ones, since the 11-ethoxy compound was found to result in higher 
levels of CYP1A1 than the 11-methoxy derivative (table 5.2 and fig 5.21) yet is a less 
potent tumour initiator (Bhatt etal., 1982). Furthermore tumour initiation experiments 
on the 11-alkoxy-cpp-17-ones have found some very weak tumourigenic capacity in 
the 11-butoxy compound (Bhatt etal., 1982) yet this compound has no more ability
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than its apparently inactive 11-propoxy counterpart to induce CYP1A1. It must be 
noted that the tumours produced by the butoxy derivative were all papillomas and 
that such tumours can occasionally be produced by the croton oil used as a promoter 
in these experiments; it would be surprising however if so many spontaneous 
tumours had arisen in the same experiment let alone the same group.
Usually the PAH which induce CYP1A1 are also substrates of the enzyme and this 
may provide the basis for an explanation of the biological activity of the 11-alkoxy- 
cpp-17-ones. X-ray crystallographic studies (Kashino etal., 1986) have demonstrated 
that a strong interaction exists between the ether oxygen and 1-H in 11-methoxy-cpp- 
17-one. This interaction across the bay-region has a tendency to render the ring 
system essentially flat; similar interactions are inferred in the other compounds of the 
series since it has been noted that the introduction of an oxygen function on C-11 
results in a downfield shift in the nmr signal of 1-H of around Ippm (sec. 5.3.1 ; 1-H of 
1 l-CHs-cpp-17-one 5 -8.9). Thus it seems likely that all of the 11-alkoxy-cpp-17-ones 
used in this study possess the sine qua non of substrates of CYP1A1, namely a 
planar ring system. It therefore seems probable that the reason for the differentiation 
between the members of the series lies in the length of the alkoxy side-chain (fig. 
5.24). Current models of the active site of CYP1A1 (Lewis and Moereels, 1992; 
personal communication with Dr. D.F.V. Lewis) envisage the substrate passing ,end 
on , through an access channel before achieving a suitable configuration for 
catalysis. This access channel is believed to be relatively low, hence the requirement 
for relatively planar substrates. Given the increasingly large profile of the molecule as 
the length of the alkoxy-chain increases, it is attractive to speculate that this 
increasing size would cause increasing difficulties in accessing the CYP1A1 active 
site. Consequently it may be that at least part of the reason for the lack of activity in 
the larger members of the 11-alkoxy-cpp-17-ones is that they have difficulty in 
gaining entry to the CYP1A1 active site and consequently their metabolism results in 
lower levels of reactive intermediates than are produced from the compounds with 
smaller side-chains.
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Fig 5.24: Computer simulations of the structures of the 11-alkoxy-cpp- 
17-ones.
a= 11-methoxy-cpp-17-one; b= 11-ethoxy-cpp-17-one; c= 11-propoxy-cpp-17-one; 
d= 11-butoxy-cpp-17-one. Structures generated using the Sybyl software of Tripos 
associates, St Louis, Missouri.
In addition to the observed induction of CYP1A1 (EROD) the 11-alkoxy compounds 
examined in this study manifested a somewhat lesser capacity to induce CYP1A2 as 
shown by the increase in the methoxyresorufin-O-demethylase (MROD) activities of 
the treated groups (Numkung etal., 1988). It was at first thought that these increases 
might have been due to the slight ability of CYP1A1, which is known to be highly
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induced, to catalyse this reaction (Burke and Mayer, 1983). However it is clear from 
the western blot analysis (fig. 5.21) that CYP1A2 does increase in the treated groups; 
indeed it is generally observed that compounds which are good inducers of CYP1A1 
often , but not always, elicit a smaller increase in CYP1A2, presumably due to their 
somewhat similar substrate specificities. CYP1A2 is believed to be involved in the N- 
hydroxylation, and therefore activation, of various arylamines (Hammons etal., 1985; 
Yamazoe etal., 1984). Given the observed activities of CYP1A2 it is unlikely that the 
induction of this isoform by the 11-alkoxy-cpp-17-ones has any serious bearing on 
their biological activity.
The enzyme epoxide hydrolase is considered to play a central role in the 
activation of PAH carcinogens to their proximate carcinogenic forms (Oesch, 1984; 
Oesch and Guenthner, 1983). None of the 11-alkoxy-cpp-17-ones were able to 
increase the levels of microsomal epoxide hydrolase (mEH) and therefore the 
capacity of the second stage of the activation pathway (fig. 5.25). The 11-propoxy 
compound .however, exhibited an apparently significant ability to lower mEH activity 
(table 5.2), whether this was due to a decrease in the synthesis of mEH protein or 
direct inhibition of the enzyme was not investigated. This apparent decrease raises 
an interesting possibility however; it has been stated previously that the 11-alkoxy- 
cpp-17-ones display decreasing tumourigenic capacity as the length of the alkoxy 
chain increases, with the apparent aberration of the weak activity shown by the 11- 
butoxy compound (table 5.1).
cpp CYP1A1 primary epoxide
mEH dihydrodiol 
(proximate carcinogen)
diol-epoxide 
(Ultimate carcinogen)
Fig. 5.25: Putative scheme of the metabolic activation of the cpp.
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It is attractive to speculate that the aberration in this sliding scale of activity is not the 
weak activity of the 11-butoxy compound (Iball index= 5) but rather the apparent 
inactivity of the 11-propoxy compound. If it is supposed that the weak activity of the 
11-butoxy compound is real, and not an artefact of the experimental procedures, and 
that the 11-alkoxy-cpp-17-ones are metabolised to their reactive forms in the same 
manner as the other cpp-17-ones, then it is relatively easy to envisage how a 
tumourigenic potential of an equal or slightly greater magnitude to that of the butoxy 
compound could be abolished by a reduction in the capacity of the activation system, 
due to a decrease in the mEH activity of that system. In the past attempts have been 
made to explain the activity of the 11-butoxy compound with the hypothesis that 
during metabolism a fraction of the material is subject to side-chain cleavage, 
resulting in a molecule with a shorter side-chain and therefore some tumourigenic 
activity (personal communication with Dr. M.M. Coombs). In an effort to provide 
evidence for this hypothesis the 11 -pentoxy compound was synthesised (Bhatt etal., 
1982) and found to be inactive. It was then argued that for such side-chain cleavage 
to be possible perhaps an even number of carbon atoms was required; however 
even the 11-hexoxy compound was found to be inactive (Coombs and Bhatt, 1987). 
Thus it remains possible that it is the 11-propoxy compound's inactivity that is 
aberrant and that tumourigenic potential in the 11-alkoxy-cpp-17-ones is completely 
abolished not by the addition of a third carbon atom to the side-chain, but the addition 
of a fifth.
An alternative reason for the inactivity of the longer chain members of the 
11-alkoxy series has been put forward, in that reactive intermediates are formed but 
that they are efficiently deactivated by elevated levels of the enzymes responsible for 
their deactivation. One of the most important systems involved in the deactivation of 
the reactive intermediates of the PAH are the GST (Glatt etal., 1983). GST activities 
were apparently unaffected by treatment with the 11-alkoxy-cpp-17-ones at the doses 
studied (table 5.2), casting doubt on this hypothesis. A further possible hypothesis 
which might explain the differing activities of the 11-alkoxy-cpp-17-ones is that bay- 
region diol-epoxides are formed in all cases but that they have very different 
genotoxic potentials. Since the diol-epoxides of these compounds have never been 
synthesised any such hypothesis is purely speculation but it can not be ruled out at
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this stage. The statistically significant lowering of the total cytochrome P-450 in the 
11-butoxy-treated group is thought unlikely to be biologically significant, since it was 
noted that individuals in the control and ethoxy-treated groups also possessed 
CYP450 levels of this order.
5.4 .2  Binding of the 11 -aikoxy-cpp-17-ones to the Ah receptor
It is considered that induction of CYP1A1 by xenobiotics proceeds via a cytosolic 
receptor protein, designated the Ah receptor (Fujisawa-sehara et a i, 1987; Neuhold 
et al., 1989). The four 11-alkoxy compounds investigated in this study were examined 
for their ability to bind to this Ah receptor; the 11-methoxy compound was found to 
bind to the receptor with relatively high affinity, achieving 50% displacement of the 
bound TCDD at a concentration of 1x1Q-7M (fig 5.22a). As the length of the alkoxy 
chain increased so the affinity of the compounds for the receptor decreased. The 11- 
ethoxy compound showed some ability to displace TCDD from the receptor (fig. 
5.22b) and the 11 -propoxy and butoxy derivatives showed virtually no affinity for the 
receptor. These Ah receptor binding-affinities of the 11 -alkoxy-cpp-17-ones are rather 
at variance with the observed induction of CYP1A1 by the compounds (table 5.2). 
The 11-ethoxy compound was found to have induced CYP1A1 to a similar extent to 
the 11-methoxy compound, yet the ethoxy derivative has a far lower affinity for the 
receptor (table 5.2; figs 5.21 and 5.22). Moreover, though the propoxy and butoxy 
derivatives displayed little or no affinity for the Ah receptor they do nevertheless 
appear to induce GYP1A1, albeit to a lesser extent(table 5.2; figs. 5.21 and 5.22). 
There would appear to be two possible explanations of these data; firstly that an 
alternative mechanism is operating in the induction by the ethoxy derivative. One 
such alternative might involve the stabilisation of the constitutive CYP1A1 protein, (fig 
5.21 ) but it is unlikely to account for the dramatic accumulation seen in the ethoxy- 
treated animals (fig 5.21 ). It has been observed that induction of some GYP450S by 
compounds such as acetone and ethanol occurs by stabilisation of the mRNA 
encoding the GYP450 (Song eta!., 1986, Hong eta!., 1987). It is possible that such a 
mechanism operates in the case of 11 -ethoxy-cpp-17-one, however no such 
mechanism has been observed among the PAH inducers of GYP450.
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The second possible explanation of the binding data is that extensive induction of 
CYP1A1 can be brought about by a much lower level of binding to the Ah receptor. 
Moreover it is also possible that the 11 -ethoxy-cpp-17-one—Ah receptor complex has 
a lower dissociation constant than that found with the methoxy compound, thus 
potentiating the action of the receptor on the xenobiotic responsive element (Nebert 
and Gonzalez, 1987).
It may be that an explanation of the induction of CYP1A1 by the 11-ethoxy 
compound, in the absence of significant binding to the Ah receptor, is provided by 
receptor multiplicity. It has been reported that at least two kinetically different forms of 
the Ah receptor exist in rat liver (Landers et al., 1991). Moreover it is known that in a 
number of species other proteins exist which are capable of binding PAH .eg. the 4S 
PBP (polycyclic aromatic hydrocarbon binding protein)(Peryt et al., 1992) found in 
mice, rats, rabbits and humans. This PBP does not however bind TCDD and therefore 
binding of a PAH to it will not be detected in the TCDD binding assay used in this 
study. It has been controversially proposed that this PBP may act in a similar manner 
to the Ah receptor in the induction of CYP450, however it has been shown that 
induction can occur in the absence of binding to either the Ah receptor or the PBP 
(Merchant et al., 1992). The observation that significant induction of CYP1A1 can 
occur in the absence of binding to the Ah receptor is by no means novel .eg. it has 
recently been demonstrated that the drug omeprazole, which is a potent inducer of 
human CYP1A1 and 1A2, is not a ligand of the Ah receptor (Daujat etal., 1992). Thus 
it is apparent that there are likely to be mechanisms of receptor-mediated induction of 
CYP450 of which little or nothing is known.
5.4 .3  Mutagenicity of the ll-afkoxy-cpp-17-ones
The microsomal activation systems failed to elicit a mutagenic response from the 
11-alkoxy-cpp-17-ones apparently regardless of the concentrations either of the 
compound or of the activation system (tables 5.3, 5.4, 5.5; fig 5.23); indeed a 
mutagenic response was only elicited when the activation system contained hepatic 
8-9 from rats treated with the potent CYP1A and mEH inducer, Aroclor 1254 (Alvares 
and Kappas, 1977). It is generally known that the use of 8-9 rather than microsomes
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in the activation system for the PAH greatly increases the number of revertants which 
arise. This discrepancy between S-9 and microsomal systems may be accounted for 
by a number of factors such as; a) the existence of higher levels of dehydrogenase 
activity, vital to activation, in the S-9 fraction, b) the 8-9 fraction contains a number of 
cytosolic enzymes capable of acting on PAH metabolites, it may be that some of 
these metabolites are mutagenic (Worth and Thorgeirsson, 1978, Wood etal., 1981). 
It has also been postulated that these cytosolic activities and the generally high 
protein environment might in some way stabilise mutagenic metabolites produced by 
the microsomal CYP450S and thereby potentiate their action. From these data it is 
apparent that the 11-alkoxy-cpp-17-ones are only weakly mutagenic, despite the 
observed tumourigenic potential of the methoxy and ethoxy compounds. Indeed in 
common with earlier studies, the ethoxy compound, while displaying some response 
in the assay was never significantly mutagenic. This discrepancy between 
mutagenicity and carcinogenicity , while relatively rare in the cpp, is also seen in 11- 
hydroxy-cpp-17-one (Coombs and Bhatt, 1987; Bhatt etal., 1982) and is widely found 
in other PAH.
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5.5 Conclusion
The first four members of the 11-alkoxy-cpp-17-one series are all capable of inducing 
CYP1A1, the cytochrome P-450 isoform shown to be involved in the activation of cpp- 
17-ones to their reactive forms. This induction appears to be correlated with the 
tumourigenic activity of the compounds in so far as the most strongly carcinogenic 
members of the series, namely the 11-methoxy and 11-ethoxy derivatives, are also 
the most potent inducers of CYP1A1. This induction may well be part of the 
explanation for the activity of the compounds since it may well lead to an increase in 
the capacity of the metabolic pathways of the animal to generate the reactive 
intermediates of the 11 -alkoxy-cpp-17-ones. Moreover it is postulated that the 11- 
propoxy derivative may be aberrant in that it appears to result in a lowering of the 
levels of an enzyme vital to the metabolic activation of the cpp, namely microsomal 
epoxide hydrolase.
The binding of the 11-alkoxy-cpp-17-ones to the Ah receptor presents a dilemma, in 
that the compounds all induce CYP1A1 yet only the methoxy derivative has high 
affinity for the receptor. These data may indicate another mechanism of induction of 
CYP1A1 or more likely they may be indicative of our lack of complete understanding 
of the mechanism of induction. It may be that binding to the receptor with such high 
affinity is not necessary for large scale induction to ensue.
Given the apparently weak mutagenicity of the 11-alkoxy-cpp-17-ones towards 
Salmonella typhimurium it was not possible to determine whether the observed 
induction of CYP1A1 was sufficient to bring about the compounds own activation to 
mutagens.
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CHAPTER 6.
In vitro metabolism of 15,16-dihydro-6-methyl-cyclopenta[a]
phenanthren-17-one
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6.0  Introduction
15,16-Dihydrocyclopenta[a]phenanthren-17-one, the non-carcinogenic parent 
compound of the 17-ketones of the cpps, is rendered a carcinogen by substitution of 
a methyl group at one or both of two aryl positions, namely 0-1 and C-11 (Coombs 
and Bhatt, 1987, chps. 3,4)(fig 6.1).
2
3
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Fig. 6.1: General structure of the cpp-17-ones
Methyl substitution at any of the other possible aryl positions does not facilitate 
carcinogenic activity (Coombs et ai., 1973). This differential activity among the 
compounds monomethylated at the various benzylic sites raised the question of why 
such differences should occur among these isomers. In the case of the A-ring methyl 
derivatives ie. the 1-,2-,3-, and 4-methyl-cpp-17-ones (fig 6.1), such inactivity is 
relatively easy to rationalise in that the presence of a methyl residue in this ring might 
hinder the formation of either the proximate genotoxin (the 3,4-dihydrodiol) or the 
ultimate genotoxin (the 3,4-diol-1,2-epoxide). The effect of such méthylation could 
manifest itself in a number of ways, eg. in the case of 1 -methyl-cpp-17-one it has 
been observed that, although the 3,4-dihydroepoxide is formed during in vitro 
metabolism, it rapidly rearranges to form the corresponding 4-phenol presumably 
due to the electron releasing effect of the p-methyl substituent (Coombs et ai., 1985). 
Indeed in vitro metabolism of 1-methyl-cpp-17-one produced a number of phenolic 
compounds which were largely absent from the metabolic profiles of cpp-17-one and 
its methyl derivatives where méthylation occurs at one of the four non-A-ring aromatic
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positions (Coombs and Bhatt, 1987). Moreover it is clear that méthylation of any of the 
A-ring sites would alter the nature of the primary epoxide formed; since these species 
would no longer be dihydroepoxides they might be treated differently by the epoxide 
metabolising enzymes. Thus it is relatively easy to rationalise the inactivity of the A- 
ring methyl derivatives of cpp-17-one. The remaining two positions where 
méthylation results in an inactive compound are C-6 and C-12. The in vitro 
metabolism of 12-methyl-cpp-17-one was found to be very similar to that of its active 
11-methyl analogue (Hadfield et ai., 1984 ) and was later shown to bind in vivoXo 
mouse skin DNA, to about one third of the extent seen with the II-C H 3 derivative 
(Russell et ai., 1985). In the same study it was demonstrated that the persistence of 
the adducts of the 12-methyl derivative was one half that of its active II-C H 3 
homologue. Consequently it appears that at least part of the reason for the lack of 
activity of 12-CHs-cpp-17-one is that the DNA damage caused by this compound is 
much more efficiently repaired. Thus only the inactivity of 6-methyl-cpp-17-one 
remains to be explained. Preliminary in vitro metabolism studies with 6-CH3-cpp-17- 
one revealed that it forms a 3,4-dihydro derivative, but that this metabolite adopts a 
pseudo-diaxial conformation rather than the pseudo-diequatorial conformation 
observed in the 3,4-dihydro derivatives of all other cpp-17-ones (Coombs and Bhatt, 
1987, chps. 3,4). It was, therefore, proposed that a possible reason for the inactivity of 
6-C H 3-CPP-17-one was that its 3,4-dihydroxy derivative adopted the wrong 
configuration and consequently could not be further metabolised to a diol-epoxide.
It was thus considered of interest to investigate the in vitro metabolism of 6-CH3- 
cpp-17-one in more detail in order to more fully establish the identities of its principal 
metabolites and to confirm the nature of the 3,4-dihydroxy derivative of 6-CH3-cpp- 
17-one. Finally the mutagenic potential of the 3,4-dihydroxy derivative of the 6-CH3- 
cpp-17-one was evaluated in the Ames test (Maron and Ames, 1983).
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6.1 Materials
15,16-dihydro-6-methyl-cyclopenta[a]phenanthren-17-one (G-CHs-cpp-l 7-one) 
was the kind gift of Dr. M.M. Coombs, Dept, of Chemistry, University of Surrey. 
Kieselgel 60H was purchased from E. Merck, Darmstadt, Germany. 
Trimethylsilylimidazole was purchased from the Aldrich chemical company, 
Gillingham, Dorset, U.K.
6.2 Methods
6 .2.1 Purification of 6-CH3-cpp-17-one
Due to a dark colouration associated with the sample of B-CHs-cpp-l 7-one, the 
compound was purified using a silica column. Kieselgel 60H silica was solvated 
using dichloromethane and the resulting slurry was poured into a (55 x 2.5cm) 
sintered glass column. Further silica slurry was added and dichloromethane allowed 
to pass through the column until a settled silica bed of around 20cm was obtained. 6- 
CHs-cpp-l 7-one (~ lOOmg) was dissolved in dichloromethane (~ 5ml) and pipetted 
gently onto the surface of the column. The compound was subsequently eluted using 
dichloromethane, passage of the compound through the column being monitored by 
means of its fluorescence under U.V. light (254nm). The G-CHs-cpp-l 7-one was 
recovered by evaporation of the solvent under reduced pressure at 45°C. Ultra-violet 
and 1 H-nmr spectra in addition to a melting point determination were used to confirm 
the identity of the compound.
6.2 .2  In vitro metabolism of 6-CH3-cpp-17-one
The in vitro metabolism of G-CHa-cpp-17-one was carried out using hepatic 
microsomal preparations from rats pretreated with Aroclor 1254, and the metabolites 
separated by HPLC as previously described (sec. 2.4), except that the microsomes 
from 1g of liver were employed rather than the usual 2g.
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6.2 .3  Investigation of the mutagenic potential of 6-CH3-cpp-17-one and its 
principal in vitro metabolites
The mutagenicity of B-CHs-cpp-l 7-one and of its metabolites collected following 
HPLC separation was examined in the Ames test using Salmonella typhimurium 
TA100 as previously described (sec. 2.5) and employing 10%(v/v) hepatic microsomal 
activation systems from rats pretreated with Aroclor 1254.
6.2 .4  Mass spectrometry of the principal in vitro metabolites of 6-CH3-cpp-17- 
one
The main U.V. absorbing peaks from the HPLC separation of the metabolites of 6- 
CHs-cpp-l 7-one were evaporated to dryness under reduced pressure at 30®C, and 
subjected to 70eV electron impact mass spectrometry by direct probe insertion of 
ethyl acetate solutions using a VG quatro instrument (probe temperature= 80®C). The 
number of hydroxyl residues present was determined by the addition of 
trimethylsilylimidazole to the ethyl acetate solutions of the metabolites, resulting in the 
formation of trimethylsilyl (TMS) derivatives of each of the hydroxyl residues present; 
mass spectra of the derivatised compounds were then obtained as before.
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6.3 Results
The purified material was confirmed as G-CHs-cpp-l7-one by U.V. absorption (fig 
G.2) and 1 H-nmr (fig G.3) spectra as well as a melting point determination (M.pt= 207- 
208°C; Literature value= 210-212®C).
in vitro metabolism of G-CHa-cpp-l 7-one
' In vitro metabolism of G-CHg-cpp-l 7-one by Aroclor 1254-induced rat hepatic
microsomes resulted in the production of 4 main U.V. absorbing peaks (fig G.4). The
I U.V. spectrum of peak 4 was found to be that associated with an unsubstituted cpp- 
17-one (fig 6.5) and was therefore likely to be the parent compound. Moreover peak 4 
co-eluted from reverse-phase HPLC with an authentic sample of G-CHa-cpp-l 7-one. 
The mass spectrum of peak 4 (fig 6.6) gives no reason to doubt this assignment.
Peak 3 possessed a U.V. spectrum displaying a slight loss of fine structure 
associated with hydroxylation of the 15-position of the cpp-17-ketones (fig 6.7) and 
was therefore tentatively assigned the identity of the 15-hydroxy derivative of 6-CH3- 
cpp-17-one. The molecular weight and proposed fragmentation pattern of peak 3 was 
consistent with this assignment (fig 6.8). The presence of an ion of m/z 203 is not 
consistent with the proposed structure. This peak is however possible if the hydroxyl 
residue is located on the 6-CH3 group, since it can be accounted for by M+ -CH2OH- 
CO. Thus it may be that a small amount of the 6-hydroxymethyl residue is present. In 
addition the molecular weight of the trimethylsilyl (TMS) derivative of peak 3 was that 
of M+ + Si(CH3)3, thereby indicating the presence of one hydroxyl residue (fig 6.9). 
Peak 2 elicited the U.V. spectral characteristics of a 3,4-dihydro derivative of a cpp- 
17-one (fig 6.10), especially the ~20nm shift of the main band following reduction of 
the 17-ketone with sodium borohydride. The mass spectral data of peak 2 were 
consistent with that of a 3,4-dihydro derivative of e-CHs-cpp-l7-one (fig 6.11). 
Moreover the molecular weight of the TMS derivative was that of M+ + 2[Si(CH3)3] 
thus confirming that peak 2 was in fact the 3,4-dihydrodiol of G-CHs-cpp-l7-one (fig 
6.12). Peak 1 displayed the U.V. spectrum associated with 1,2-dihydro derivatives of 
cpp-17-ones, showing the characteristic splitting of the maximum band.
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Fig 6.2: U.V. absorption spectrum  of 6 -C H 3-cpp-17-one,
Spectrum was obtained in methanolic solution.
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Injection
Fig 6.4: Reverse phase HPLC separation of the metabolites of
6 -CH3 -CPP- 1 7-one produced by Aroclor 1254-induced microsomes.
Detection by U.V. absorbance at 254nm.
Peak 1: 1,2,15-trihydroxy-6-CH3-cpp-17-one + 1,2-dihydroxy-6-hydroxymethyl-cpp-17-on( 
Peak 2: 3,4-dihydroxy-6-CH3-cpp-17-one ;
Peak 3: 1 S-hydroxy-G-CHg-cpp-l 7-one; Peak 4: S-CHs-cpp-l7-one.
Peak a did not appear to be microsomal in origin, but could not be
identified due to poor U.V. absorption characteristics. 153
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Fig 6.5: U.V. absorption spectrum of peak 4 (fig 6.4).
Spectrum was obtained in methanolic solution.
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Fig 6 .6 : 70eV electron impact mass spectrometry and proposed fragmentation 
of peak 4 (fig 6.4).
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Fig 6.7: U.V. absorption spectrum of peak 3 (fig 6.4).
Spectrum was obtained in methanolic solution.
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Fig 6 .8 : 70eV electron Impact mass spectrometry and proposed fragmentation 
of peak 3 (fig 6.4).
157
G 3> 
G »-J M= 
►Higs
OJcr*
T1
(5*
O)
<o
-s ]
œ H*
— co
->jo
<
es
N
3D)U)(/}
CO
entoto
H-to0)
■O<DO
-TO
3(D
"%*<
co
co
co • 
en- 
G.
1— 4
3"
(D
G- —G  
-  CO
^CO 
. to<fi)
en-<<D
CO
VD
vOOS
CO
158
fi)
III03 3  =■
g S.®
Ill
lit
m 'a .»
-----CL Q-
? | - 5 -
3(D O  (D
rx “** 5® B, B
III
3 3 CO
- '( 0  9. 
S o  
a c o .
® œdd
m
~ ~  o
O
c
o'3
Q.
C
O-  O ’O Ô
0 5 3
"II
5 m
CD CO
K)0
0.521
0.402
215.0
226.0 nm
nm
TI
cq‘ 268.0 nm 1.157
O)
0.269
0.301
301.0
307.0
313.0
320.0
nm
nm
nm
nmC
<
0.089343.0 nmfi) w
O' %-
0. 110368.0 nm
= I
a<s.
II
2TO- <D V -
O o
!: i
3  IS) 1.761209 nm
227.0 nm
237.0 nm
1.392
1.485
oi-
M -.Î  m
279.0 nm 
288
0.224
0.247nm
o-
0 1 -
159
MS Data, EI+ 
165
GARYS 18 (0.990) 
1001 185344
189
262
234
152
192
178
202
28021955
203 23623311563
263249
113 126 281
68 264
300150 200 250100
.+ .+
.+
-CO
HO' (-28)
OH CH; 
280
CH
262-CH:
CH,
234
1-15) :-28)-cc
.-i-
(-15)-CH
HO'
HO247
CH
234(-28).+
219(-15)
CH
206 HO-CH;
219 
-CC (-28)
(-15?
191
Fig 6.11: 70eV electron impact mass spectrometry and proposed fragmentation 
of peak 2 (fig 6.4).
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following reduction of the carbonyl residue using sodium borohydride (fig 6.13). The 
considerably more polar character of peak 1 indicated that it had been further 
metabolised at a position which did not affect the chromophore. It was therefore 
considered likely that peak 1 was the 1,2,15-trihydroxy derivative identified as a 
major metabolite of other cpp-17-ones (chps. 3,4, Coombs and Bhatt, 1987). Mass 
spectrometry of peak 1 confirmed a molecular weight consistent with that of a 
trihydroxylated derivative and this was further confirmed by the TMS derivative 
having a molecular weight of M+ + 3[Si(CH3)3] (figs 6.14, 6.15). However in the 
proposed fragmentation of a 1,2,15-trihydroxy derivative (fig 6.16) it was not possible 
to account for ions of molecular weight 265, 247, or 219 which are present in the 
mass spectrum of peak 1. An alternative site of the third hydroxyl residue, which 
would also have no effect on the chromophore, is the 6-methyl residue. Precedent for 
such hydroxymethyl derivatives is well established since such metabolites are 
observed in the in vitro metabolism of 11-CH3-cpp-17-one (chp. 4, Coombs and 
Bhatt, 1987). If it is assumed that peak 1 is 1,2-dihydroxy-6-hydroxymethyl-cpp-17- 
one, fragmentations accounting for ions of molecular weights 265, 247 and 219 can 
be proposed (fig 6.17). Thus the mass spectrometry provided evidence for the identity 
of peak 1 as both 1,2,15-trihydroxy-cpp-17-one and 1,2-dihydroxy-6-hydroxymethyl- 
cpp-17-one. This may account for the rather broad nature of peak 1 (fig 6.4) and 
indeed 1,2,15-trihydroxy and 1,2-dihydroxy-6-hydroxymethyl derivatives might be 
expected to have very similar retention times. Considerable difficulty has been 
encountered in the past in separating 15-hydroxy-11 -CH3-cpp-17-one and 11- 
hydroxymethyl-cpp-17-one by HPLC (M.M. Coombs, private communication). Due to 
mechanical failure (a severe injector port leak) during a later HPLC separation of the 
metabolites of 6-CH3-cpp-17-one it was discovered that peak 1 did indeed comprise 
two compounds (fig 6.18). Subsequent attempts to reproduce the highly unusual 
gradient characteristics which permitted separation of this "peak" met with no 
success.
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Fig 6.14: 70eV electron impact mass spectrometry of peak 1 (fig 6.4).
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Fig 6.15: 70eV electron impact mass spectrometry of the trimethylsilyl 
derivative of peak 1 (fig 6.4).
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CHs x-H gO  
296 /
.+ CHo
Fig 6.16: Proposed fragmentation of a 1,2,15-trihydroxy derivative of 
6 -C H 3 -CPP-1 7-one.
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CHpOH CHpOH
-CH2OH
CHpOH
-CHpOH
CHgOH 
250
CHpOH
219
Fig 6.17: Proposed fragmentation of a 1 ,2 -dihydroxy-6 -hydroxymethyl 
derivative of 6 -CH3 -CPP-1 7-one.
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Injection Leak corrected
Fig 6.18; Reverse phase HPLC separation of the metabolites of
6-CH3-cpp-17-one produced by Aroclor 1254-induced microsomes.
Detection by U.V. absorbance at 254nm. Separation conditions altered by severe 
solvent leak.
167
31
(5
O)
CO
Ol
13
%
ÇI
6
I
CO
CO
O
%
COo
X
ro
boO)
13
X
a>
6
X
ro
CO
X
CO
CD
6
X
CO
-n1
G )
X
Q .
CD
4^
X
3
ro
X
CD
b
X
y>
X
004^
X
ro
O
CO
CD
X
3
CO
X
ifi
T i(f>
a“Tc
3
o
D
CO
O
p
s
<D
0)
0 3
00
CO
'si
b
CD
CO
•Vi
X
<D00
X
Q .
ro
CD
CO
OL
-T
0
X
* <
1
(O
p
o >■
«"+(0
Q)
3"
» <
a
CD
I
,3
<D
3"
* <
I
O
T5
T3
O
3
<D
3
3
S'l
§■!
ÿ - |
o
§
V*
t
%
è’-i
168
Conformation of the 3,4-dihydrodioI derivative of G-CHs-cpp-l 7-one
The 3,4-dihydrodiol derivative of e-CHs-cpp-l 7-one was collected from two 
separate metabolism experiments (~300^g ), dissolved in D^-methanol (-0.5ml) and 
a iH-nmr spectrum was obtained (fig 6.19). The 0-4 proton emerged at -5.01 ppm 
and displayed only very minor splitting.
Mutagenicity of S-CHs-cpp-IT-one and its principal metabolites
6-CH3-CPP-17-one was tested for mutagenicity in the Ames test at 2,5,7 and 
lOpg/plate ( a concentration range over which the mutagenic cpp-17-ones show 
activity) using a 10%(v/v) hepatic microsomal activation system derived from rats 
pretreated with Aroclor 1254. In addition, larger concentrations namely 20 and 
50jig/plate were also employed since previous mutagenicity studies had suggested 
that 6-CH3-CPP-17-one was inactive at the lower concentrations employed. No 
mutagenic activity was observed at the concentrations used (table 6.1). Samples of 
the metabolites of 6-CH3-cpp-17-one were prepared following separation by HPLC 
and their concentrations estimated by U.V. spectroscopy. These metabolites were 
then dissolved in DMSO and deployed in an Ames test at 7pg/plate with a 1 0 %(v/v) 
Aroclor 1254-induced microsomal activation system (table 6.2). Moreover, the 3,4- 
dihydrodiol (present in the largest quantities) was tested at 2,5 and 10pg/plate (table 
6.3). No significant activity was detected with any of the metabolites at the 
concentrations tested.
Table 6.1: Mutagenicity of 6-CH3-cpp-17-one using an Aroclor 
1254-induced rat hepatic microsomal activation system.
The tester strain was Salmonella typhimurium TA100 and the spontaneous 
reversion rate was 93 ± 11. 2-Aminoanthracene (2AA)(5|ig/plate) served as 
a positive control.
Concentration of 6-CH3-cpp-17-one 
(ug/plate)
Number of histidine revertants 
per plate (mean ± SD)
2 101 ± 4
5 103 ±7
7 105 ± 5
10 102 ±8
20 101 ±17
50 103115
2AA 343 + 8
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Table 6.2: Mutagenicity of 6-CH3-cpp-17-one and its principal 
in vitro metabolites (fig 6.4) using an Aroclor 1254-induced rat 
hepatic microsomal activation system.
The tester strain was Salmonella typhimurium TAIOO and the spontaneous 
reversion rate was 128 ± 5. 2-aminoanthracene (2AA)(5pg/plate) served as 
a positive control. Each metabolite was tested at -Tpg/plate.
HPLC peak Number of histidine revertants 
per plate (mean ± SD)
Peak 1 129 ± 5
Peak 2 183 ±13
Peaks 134 ± 8
Peak 4 141 ± 8
2AA 959 ±103
Table 6.3: Mutagenicity test of 3,4-dihydrodioi of 6-CH3-cpp- 
17-one (peak 2) using an Aroclor 1254-induced rat hepatic microsomal 
activation system.
The tester strain was Salmonella typhimurium TA100 and the spontaneous 
reversion rate was 128 ± 5. 2-Aminoanthracene (2AA)(5|ig/plate) served as 
a positive control.
Concentration of 3,4-dihydrodiol 
(ng/plate)
Number of histidine revertants 
per plate (mean ± SD)
2 162 ±13
5 180 ±10
7 183 ±13
10 180 ±12
2AA 959 ±103
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6.4 Discussion
Metabolism of 6-CH3-cpp-17-one
Aroclor 1254-induced hepatic microsomes were employed in the metabolism of 6- 
CHa-cpp-17-one because such systems were the most efficient catalysts of the in 
vitro metabolism of other cpp-17-ones (chps. 3,4, Boyd eta!., 1993). Metabolism of 6- 
CHs-cpp-17-one appears to proceed more readily than that of other cpp-17-ones 
since the usual quantity of microsomal activation system (sec. 2.4) had to be halved 
in order to prevent complete metabolism of the compound.
The in vitro metabolism of S-CHs-cpp-l 7-one resulted in the production of four main 
metabolites (fig 6.4), namely the 15-monohydroxy derivative, the 3,4-dihydrodiol, the 
1,2-dihydrodiol-6-hydroxymethyl derivative and the 1,2,15/16-trihydroxy compound 
(fig 6.20). Thus the metabolic profile of 6-CHs-cpp-l 7-one is very similar to that of 
other cpp-17-ones and it appears to be metabolised in a qualitatively similar manner 
to its carcinogenic II-C H 3 analogue (chp. 4, Coombs and Bhatt, 1987). 
Consequently the lack of carcinogenic activity in 6-CH3-cpp-17-one can not be 
attributed to differential metabolism.
Mutagenicity of 6 -CH3 -CPP- 1 7-one
Aroclor 1254-induced microsomal activation systems failed to elicit any mutagenic 
response from 6-CH3-CPP-17-one (table 6.1) suggesting that the products of the 
metabolism of 6-CH3-cpp-17-one (figs 6.4, 6.20) were per se devoid of genotoxicity 
and were incapable of further metabolism to mutagens. This conclusion was 
confirmed by the fact that none of these metabolites provoked a positive mutagenic 
response (table 6.2). These mutagenicity data are at considerable variance with 
similar data obtained for both the unsubstituted and II-C H 3 cpp-17-ones (Boyd etal., 
1993 , chps. 3,4). In the case of other cpp-17-ones the metabolic generation of a 3,4- 
dihydrodiol induces mutagenic activity and when the d id  itself is used as the 
promutagen, considerably greater mutagenicity was observed, consistent with the 
finding that the 3,4-dihydrodiol is the proximate genotoxic form of the cpp-17-ones 
(Coombs etal., 1979a).
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6 -CH3-CPP-1 7-one (peak 4) 15-hydroxy-6-CH3-cpp-17-one (peak 3)
HO
3,4-dihydroxy-6-CH3-cpp-17-one (peak 2)
OH
HO.
OH
OH
HO.
J
1,2,15-trihydroxy-6-CH3-cpp-17-one and 1,2-dihydroxy- 
6-hydroxymethyl-cpp-17-one (peak 1)
Fig 6.20: Proposed structures of the principal in vitro metabolites of 6-CH3- 
cpp-17-one (fig 6.4).
Thus 6-CH3-CPP-17-one is anomalous in that it is metabolised to generate significant 
quatities of a 3,4-dihydrodiol, indeed this compound is the major metabolite, yet no 
genotoxicity is observed. The genotoxic 3,4-dihydrodiols of 11-CHs-cpp-l 7-one and 
by analogy cpp-17-one have been demonstrated to adopt a pseudo-diequatorial 
conformation (Hadfield, 1983); these diequatorial 3,4-dihydrodiols are then further 
metabolised to generate the 3,4-diol-1,2-epoxides, the ultimate genotoxins. The 3,4-
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dihydrodiol of G-CHg-cpp-l 7-one behaved rather differently in that it was observed to 
be considerably more polar than the 3,4-dihydrodiol of H-CHs-cpp-l7-one (chp. 4). 
Moreover the iH-nmr spectrum of the 3,4-dihydrodiol of B-CHa-cpp-l7-one (fig 6.19) 
showed very little splitting of the signal from the C-4 proton confirming that the 
dihedral angle between the C-3 and C-4 protons was large and acute. Consequently 
the C-3 and C-4 hydroxyl residues were shown to adopt a pseudo-diaxial rather than 
a pseudo-diequatorial conformation. Thus it would appear that the 3,4-dihydrodiol in 
a diaxial conformation is not readily metabolised by the CYP1A proteins to form the 
corresponding diol-epoxide. This is supported by the observation that, whereas the 
diequatorial 3,4-dihydrodiol of ll-C H a-cpp-l 7-one and its unsubstituted analogue 
are activated to mutagens by CYP1A, the 1,2-dihydroxy derivatives of these 
compounds which are known to be diaxial are not activated to mutagens (Coombs 
and Bhatt, 1987, Hadfield, 1983). It is attractive to speculate that this inability of 
CYP1A to metabolise pseudo-diaxial A-ring dihydrodiols of cpp-17-ones might be 
partly due to the larger "depth" of these diaxial dihydrodiols (fig 6.21).
Furthermore the diaxial A-ring dihydrodiols are considerably more polar than their 
diequatorial homologues and this increased polarity could also interfere with the 
siting of the compounds in the CYP1A active site. It may be that these diaxial 
dihydrodiols are not easily accommodated in the CYP1A active site and are therefore 
not further metabolised to diol-epoxides and are consequently not genotoxic. 
Alternatively it may be that the increased polarity of the diaxial dihydrodiols facilitates 
their excretion in vivo and thereby lessens the toxicological impact of the compounds.
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Fig 6.21: Computer simulations of the 3-dimensional structures of 
the 3,4-dihydrodiols of (a) cpp-17-one, (b) 11-CH3-cpp-17-one 
and (c) 6-CH3-CPP-17-one and the 1,2-dihydrodiol of 11-CH3-cpp- 
17-one (d)
Structures are shown in the nominal minimum energy states according
to the standard parameters of the "MM2 force field" (Burkert and Allinger, 1982).
(a) and (b) are diequatorial; (c) and (d) are diaxial.
6.5 Conclusions
6-CH3-CPP-17-one was metabolised in a qualitatively similar way to its 
biologically active II-CH3 isomer to yield metabolites of the A- and/or D-rings (fig 
6.20). The major in vitro metabolite was the 3,4-dihydrodiol but, unlike other cpp-17- 
ones, the 3,4-diol derivative of 6-CH3-CPP-17-one was not metabolised to mutagens. 
The 3,4-diol of 6-CH3-CPP-17-one adopted a pseudo-diaxial conformation, rather 
than the diequatorial conformation found in the other cpp-17-ones and this diaxial 
conformation may prevent the further metabolism of the 3,4-diol to the diol-epoxide. 
Thus it appears that for genotoxic activity a cpp-17-one must be metabolised to form a
3,4-dihydrodiol and this diol must adopt a diequatorial conformation so as to facilitate 
further metabolism to the diol-epoxide.
174
CHAPTER 7.
The in vitro metabolic activation of the 11-trifiuoromethyl analogue of 
the potent carcinogen 15,16-dihydro-11-methyl- 
cyclopenta[a]phenanthren-17-one to mutagens.
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7.0 introduction
15,16-dihydrocyciopenta[a]phenanthren-17-one (cpp-17-one) (fig. 1), the parent 
compound of the 17-ketones of the cyciopenta[a]phenanthrenes (cpp) has been 
demonstrated to be devoid of intrinsic carcinogenicity (Coombs and Croft, 1966); 
however, substitution of a methyl group at C-11 (fig 7.1) confers considerable 
carcinogenic activity on the molecule (Coombs and Bhatt, 1987).
4 6
R=-H;-CH3;-CF3 
Fig 7.1: General structure of the cpp-17-ones
This 11-methyl derivative induces skin tumours in a number of mouse strains 
(Coombs and Croft, 1966; Coombs and Croft, 1969; Abbott, 1983; Coombs and Bhatt, 
1987) as well as a variety of other soft tissue tumours following subcutaneous 
injection to rats and mice (Coombs and Croft, 1969; Coombs and Bhatt, 1987). More 
recently 1 l-CHs-cpp-l 7-one has been reported to increase the rate of myeloid 
leukaemia in male Sprague-Dawley rats and furthermore the compound was found 
to act as a potent initiator of silica-induced mesothelioma (Bhatt etaf., 1991). This 
carcinogenicity is considered to be mediated through the metabolic activation of the 
ll-CHs-cpp-l7-one to a bay-region diol-epoxide (Hadfield etal., 1984; Coombs and 
Bhatt, 1987). It was therefore considered to be of interest to examine whether the 
steric or electronic effects of the II-C H 3 group had the greater bearing on the 
activation of the compound to reactive intermediates. For this purpose it was decided 
to synthesise an analogue of 11-CH3-cpp-17-one, possessing a group at C-11 which 
was spatially similar to -CH3 ,yet electronically very different. The most appropriate 
candidate for this replacement was considered to be -CF3, due to the similarity in size 
of hydrogen and fluorine (van der Waals radii H= 1.2Â; F= 1.35Â) and their very 
different affinities for electrons (H= 0.8eV; F= 3.448eV)(Weast, 1981).
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Consequently the in vitro metabolism of 11-CFs-cpp-l 7-one by rat hepatic 
microsomal preparations was investigated and the identities of the principal 
metabolites determined. Moreover the compound and its metabolites were tested for 
mutagenic activity in the Ames assay (Maron and Ames, 1983).
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7.1 Materials
11-CF3-CPP-17-one was the kind gift of Dr. M.M. Coombs, Dept, of Chemistry, 
University of Surrey. For synthesis and characterisation see Coombs and Zepik, 
1992.
7.2 Methods
7.2.1 in vitro metabolism of 11-CFs-cpp-l7-one
The in vitro metabolism of II-CF3-CPP-17-one by Aroclor 1254-induced rat 
hepatic microsomal preparations was studied as previously described (sec. 2.4).
7.2 .2  Activation of 11-CF3-cpp-17-one and its principal in vitro metabolites to 
mutagens
The mutagenicity of II-CF3-CPP-17-one and its metabolites was evaluated in the 
Ames test using Salmonella typhimurium TA100 as previousiy described (sec. 2.5), 
and employing 10%(v/v) hepatic microsomal activation systems from rats pretreated 
with Aroclor 1254.
7.2 .3  Mass spectrometry of the principal in vitro metabolites of 11-CFs-cpp- 
17-one
Mass spectral analysis of the U.V. absorbing peaks from the HPLC separation of 
the in vitro metabolites of 11-CP3-cpp-17-one was carried out as previously 
described (sec. 6.2.4).
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7.3 Results
Incubation of 11-CFs-cpp-l 7-one with microsomal preparations from Aroclor 1254 
treated rats revealed the presence of five major peaks which were absent from blank 
microsomal preparations (fig 7.2). Peak 5, being the least polar compound present 
was presumed to be the ll-CFs-cpp-l 7-one itself and indeed was found to possess 
the U.V. absorption spectrum of 1 l-CFg-cpp-l7-one (fig 7.3). The mass spectrum of 
peak 5 gave no reason to doubt the proposed structure (fig 7.4).
Peak 4 was assigned the structure of a D-ring monohydroxy derivative since it was 
observed to be somewhat more polar than the parent compound (peak 5) and its U.V. 
spectrum was found to be very similar to that of ll-C Fs-cpp-l 7-one as expected, 
since they possess the same chromophore (fig 7.5). It is likely that the compound is in 
fact the 15-hydroxy derivative, a major metabolite of other cpp-17-ones (Coombs and 
Bhatt, 1987). The mass spectrum of peak 4 confirmed the proposed structure of the 
compound (fig 7.6). The molecular weight of the trimethylsilyl (TMS) derivative of 
peak 4 was found to be M+ + Si(CH3)3 thus confirming that the compound was a 
monohydroxylated derivative (fig 7.7).
Peak 3 was found to inhabit the region of the chromatograph usually occupied by a 
diequatorial dihydrodiol of the A-ring, which in other cpp-17-ones was the 3,4- 
dihydrodiol. Moreover peak 3 possessed the characteristic shift in U.V. absorption 
shown by the 3,4-dihydro-cpp-17-ones (Coombs and Bhatt, 1987) following chemical 
reduction of the carbonyl function at C-17 (figs 7.8a, 7.8b). The mass spectrum of 
peak 3 was consistent with that of a dihydrodiol derivative of 11-CP3-cpp-17-one (fig 
7.9). The TMS derivative of peak 3 had a molecular weight equivalent to M+ + 
2[Si(CH3)3] (fig 7.10).
Peaks 1 and 2 were observed to elute from HPLC in the area usually inhabited by the 
diaxial 1,2-dihydrodiols, moreover, following chemical reduction of the carbonyl 
function at C-17 both compounds were observed to display the shift in U.V. 
absorption associated with 1,2-dihydro-cpp-17-ones (Coombs and Bhatt, 1987)(figs 
7.11a and 7.11b, figs 7.12a and 7.12b). Since peak 1 was rather more polar than 
peak 2 it was considered likely that peak 2 was the 1,2-dihydrodiol and that peak 1 
was the 1,2,15 trihydroxy derivative found as a major metabolite of other cpp-17-ones 
(Coombs and Bhatt, 1987). The mass spectra of peaks 1 and 2 were consistent with
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Injection
Fig 7.2: H .P.L.C . profile of the in vitro m etabo lites  of 15,16-
c lih y d ro -1 1 -tr iflu o ro m e th y lc y c lo p e n ta [a ]p h e n a n th re n -1 7 -o n e .
Metabolism was carried out as previously described. Trace monitored by 
U.V. absorption at 254nm.
Peak 1: 1,2,15-trihydroxy-11 -CFg-cpp-l 7-one; Peak 2: 1,2-dihydroxy-11- 
CFs-cpp-l7-one; Peak 3: 3,4-dihydroxy-11 -CFs-cpp-l7-one; Peak 4: 15- 
hydroxy-ll-CFs-cpp-l 7-one; Peak 5: ll-CFs-cpp-l 7-one.
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Fig 7.3: U.V. absorption spectrum of peak 5 (fig 7.2)
Spectrum obtained in methanolic solution.
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Data File: PHD5
11CF3M SP-MS/EI+
Acquired on 26/01/1993
MS D a t a ,  E I+PHD5 9 ( 0 .4 9 5 )  
1001 6 6 3 5 5 23 0 0
2 0 3
202
7.FS-
101
2 51 3 0 1
2 0 41 1 6100 200 225/^^1 4 9 2 7 15$l70 87, 1 5 0  
I 1 67
1 4 0 1 9 9 252
w—r-i 
h / z  5 0 1 5 0100 200 2 5 0 3 0 0
+ .+ .
-CO
(28)
m . . -OF; -GO
(28)
221
Fig 7.4: 70eV electron im pact mass spectrom etry and proposed fragm entation  
of peak 5 (fig 7.2).
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Fig 7.5: U.V. absorption spectrum  of peak 4 (fig 2)
Spectrum obtained in methanolic solution.
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Data File: PHD4B Acquired on 26/01/1993
11CF3 15-OL SP-MS/EI+
PHD4B 7  ( 0 . 3 8 5 ) MS D a t a ,  E I+
7 5 7 7 61001
2 03
2 2 5
2 5 1 2 7 0
2 9 8
2 0 5
2 7 1220 2 6 9249
3172 7 32 1 8  
2 0 7  ' 243 2 9 9  
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3 1 4  
-3 0 3  \
287259
2 13 2972 6 0 3 1 8 3 3 42 7 9
2 40220 2 6 0 2 8 0 3 0 0 3 2 0 3 4 0 3 6 0 3 8 0
-CO 
OH (28) OH (69)
(18)/_HoO
Fig 7.6: 70eV electron impact mass spectrometry and proposed fragmentation
of peak 4 (fig 7.2).
184
Tj
5"
fi) (D 
<D
^  a
o
3
fi)0)(A
(A
■o
<D
a—To
3
<D
-T
« <
O
<D
3
<D
3"
* <
W
* <
ao
“T
<fi)
<■
o
§
CO
tn
~ tn CD
g
CO
CO
COCO
COWS \  f= M ►—
CO
\co
CO
h-co
.so CO
■cntn- ----- ^
B — \co N
• -----  Cfl Cfl
CO CO
- o
-\co00
.00
M
CO<0
H - '^ co
tn
CO
CO
<0^co00
so
\C0
so
CO
CO
00
185
CO■D
(Da
2
3
013
(D
Q .
3a
3"fi)
3O
a
eno
o
3
2!
5"
N
co
f i )
c
<
f i )cr(0o
o
3
V>
TS
(DO
"Tc
3
■o<Dfi)77
W
(Q
ro
01-
2 6 8 . 0  nm 976
2 9 9 . 0  nmo -
ut-
o
COT3
CDa
2
3
0
1
3
CD
Q .
3a
3"fi)
3
5‘
8
O
3
C
3
O
5
3
0  3
=  CQ
1—" 00
ê  FT
O
3"
(D
3
ô 'fi)
<Dac
o
o
3
=r
CD
Ofi)
“ Tor
G
3
* <
C
<
fi)or
( / )o
o
3
( / )
13
CD
O
a  «
c
3
O
•o
ofi)
77
W
CQ
N
ÎO
2 .403
6 0 9nm
9182 4 6 nmcn-
0 . 0 5 1;76.0 nm
;lî:i 81!
o-
nm
3 6 $ ,0  nm
3 7 3 .0  nm
3 8 0 . 0  nm
nm
o
186
Data File: PHD3B Acquired on 26/01/1993
1 1 C F 3 3 ,4 -D I0 L  S P -M S /E I+
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Fig 7.9: 70eV electron impact mass spectrometry and proposed fragmentation
of peak 3 (fig 7.2).
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their being a trihydroxy and a dihydroxy derivative respectively (figs 7.13a, 7.13b). 
Moreover the TMS derivatives exhibited the expected molecular weights ie. M+ + 
2[Si(CH3)3](peak 2) and M+ + 3[Si(CH3)3](peak 1) (figs 7.14a, 7.14b).
Mutagenic activation of ll-C Fs-cpp-l 7-one and of its principai in vitro 
metabolites in the Ames test
II-CF3-CPP-17-one was examined for mutagenic potential in the Ames test using 
Salmonella typhimurium TA100 and a 10%(v/v) microsomal activation system 
utilising microsomes from rats pretreated with Arolcor 1254 (fig 7.15).
The compound elicited a positive mutagenic response following metabolic activation. 
It was consequently decided to ascertain which of the In vitro metabolites were 
responsible for this mutagenicity. The five principal peaks present after in vitro 
metabolism of ll-CFs-cpp-l 7-one were collected and the amounts estimated by U.V. 
spectroscopy. The five compounds were then dissolved in DMSO and each was 
tested, with metabolic activation, at 7|ig/plate [ the most mutagenic concentration of 
II-C F 3-CPP-17-one (fig 7.15)] (fig 7.16).
Only peaks 5 (II-C F 3-CPP-17-one) and 3 (the 3,4-dihydrodiol) were found to be 
mutagenic. To confirm the mutagenicity of the 3,4-dihydrodiol (peak 3) the assay was 
repeated at four concentrations of the compound (fig 7.17), giving rise to a good 
dose/response relationship.
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Fig 7.13a: 70eV electron impact mass spectrometry and proposed
fragmentation of peak 2 (fig 7.2).
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Fig 7.13b: 70eV electron impact mass spectrometry and proposed
fragmentation of peak 1 (fig 7.2).
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Fig 7.14a: 70eV electron im pact mass spectrom etry of the trim ethyls iiy i 
derivative of peak 2 (fig 7.2).
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Fig 7.14b: 70eV electron impact mass spectrometry of the trimethylsiiyi
derivative of peak 1 (fig 7.2).
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Fig 7.15: Activation of 11-CF3-cpp-17-one to mutagens by hepatic 
microsomal preparations from rats pretreated with Aroclor 
1254.
The test was carried out using Salmonella typhimurium TA100 utilising
a 10 %(v/v) microsomal activation system. Spontaneous reversion rate
was 82 ± 11. Figures are presented as mean ± S.D. of triplicates.
—•—  = without activation 
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Fig 7.16: Mutagenicity of the principal substances separated by 
HPLC following in vitro metabolism of ll-CFs-cpp-IT-one
All compounds tested at 7|ig/plate using Salmonella typhimurium TA100 
utilising a 10%{v/v) microsomal activation system prepared from the livers 
of rats pretreated with Aroclor 1254.
Spontaneous reversion rate was 87 ± 9. Figures are presented 
as mean ± S.D. of triplicates.
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Fig 7.17: Activation of 3,4-dihydroxy-11-CF3-cpp-17-one to mutagens 
by hepatic microsomal preparations from rats pretreated with 
Aroclor 1254.
The test was carried out using Salmonella typhimurium TA100 utilising a 
10%(v/v) microsomal activation system. Spontaneous reversion rate was 
81 ±12 . Figures are presented as mean ± S.D. of triplicates.
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7.4  Discussion
The in vitro metabolism of 11-CF3-cpp-17-one by hepatic microsomal preparations 
from rats pretreated with Aroclor 1254 resulted in the production of four principal 
metabolites (fig 7.2); 15-hydroxy-11 -CFg-cpp-l7-one (peak 4), 3 ,4-dihydroxy-11-CF3- 
cpp-17-one (peak 3), 1,2-dihydroxy-11-CF3-cpp-17-one (peak 2), 1,2,15-trihydroxy- 
11-CF3-CPP-17-one (peak 1). Thus II-C F 3-CPP-17-one is metabolised in a 
qualitatively similar manner to 11-CH3-cpp-17-one(Coombs and Bhatt, 1987; Boyd et 
ai., 1993) in that metabolism can occur at two sites on the A-ring and at one of two 
positions on the D-ring (fig 7.18). Although the metabolism of 11-CF3-CPP-17-one 
proceeds in a qualitatively similar manner, in terms of the major metabolites 
produced, to that of 11-CH3-cpp-17-one, the overall metabolic profile of II-C F 3-CPP- 
17-one is much simpler (fig 7.2). Metabolism of II-C H 3-CPP-17-one produces a 
much more complex pattern of minor metabolites (Coombs and Bhatt, 1987) which 
are largely absent in the metabolism of its 11-GF3 analogue.
HO''
3,4-dihydroxy-3,4,15,16-tetrahydro-cpp-17-one 
(peak 3)
15-hydroxy-15,16-dihydro-cpp-17-one 
(peak 4)
1,2-dihydroxy-l ,2,15,16-tetrahydro-cpp-l 7-one 
(peak 2)
1,2,15-trihydro xy-1,2,15,16-tetrahydro- 
cpp-l 7-one (peak 1)
Fig 7.18; Sites of metaboiism of 11-CFg-cpp-l7-one and the structures of the 
principal metabolites.
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The activation of 11-CF3-cpp-17-one to genotoxic intermediates appears to proceed 
via the 3,4-dihydrodiol since this was the only metabolite found to be mutagenic (fig 
7.16) and .moreover, was observed to be a more potent mutagen than the parent 
compound. The cpp-17-ones are considered to exert their observed genotoxicity 
through a bay-region 3,4-diol-1,2-epoxide (Coombs and Bhatt, 1987) and it has been 
established that this reactive intermediate is generated from the parent compound via 
the 3,4-dihydrodiol, which is more mutagenic than the parent compound (Boyd etal., 
1993; Coombs and Bhatt, 1987). Thus it appears that ll-CFs-cpp-l7-one is activated 
to genotoxic species (fig 7.19) in an entirely analogous manner to 11-CH3-cpp-17- 
one.
Fig 7.19: Putative scheme of the metabolic activation of 
II-C F 3-CPP-17-one
The electronic nature of the -CF3 substituent at C-11 is radically different from that of 
the -CH3 group that it mimics, yet qualitatively similar metabolism occurs especially in 
the apparent activation of the compound to genotoxins (figs 7.15,7.16 and 7.17). 
Given the apparent similarity of the metabolism and activation of II-C H 3-CPP-17-one 
with those of its II-C F 3 analogue it would appear that the electronic nature of the
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substituent at C-11 is not critical in determining whether or not the compound is 
activated to genotoxic intermediates; consequently the central effect of the substituent 
at C-11 would appear to be of a steric nature. Whether the electronic nature of the 
substituent at C-11 affects the carcinogenicity of the molecule is a question which can 
not be adequately addressed through the medium of these metabolic studies and 
must therefore await the results of longer term tumourigenicity experiments.
7.5  Conclusion
1 l-CFs-cpp-l 7-one is metabolised at the 1,2- and 3,4- positions of the A-ring, 
yielding 3,4-dihydroxy-3,4,15,16-tetrahydro-11 -CF3-cyclopenta[a]phenanthren-17- 
one, 1,2-dihydroxy-1,2,15,16-tetrahydro-11 -CF3-cycl0penta[a]phenanthren-17-one 
and 1,2,15-trihydroxy-1,2,15,16-tetrahydro-11 -CF3-cyclopenta[a]phenanthren-17- 
one; in addition hydroxylation also occurs at one of the two available D-ring positions 
generating 15-hydroxy-15,16-dihydro-11 -CF3-cpp-17-one or feasibly its 16-hydroxy 
analogue. Moreover 11-CF3-cpp-17-one is metabolised to genotoxic intermediates 
through the same pathway as 11-CH3-cpp-17-one, suggesting that the electronic 
nature of the substituent at C-11 is less critical than its spatial configuration.
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CHAPTER 8.
Species differences In the metabolism of 15,16-dihydro-11- 
methylcylopenta[a]phenanthren-17-one: Preliminary studies.
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8.0 Introduction
The cyclopenta[a]phenanthren-17-ones (fig 8.1), like all biologically active PAH 
series, require metabolic activation in order to express their observed genotoxicity.
2
3
64
R= H or CHg
Fig 8.1: General structure of the cpp-17-ones
The potent carcinogen 11-CHs-cpp-l7-one (fig 8.1)(Coombs etal., 1979) has been 
shown to exert its carcinogenicity via a 3,4-dihydrodiol-1,2-epoxide (Coombs et a!., 
1979a). In the rat, metabolism of the parent compound ,11-GH3-cpp-17-one, to the 
proximate genotoxin, the 3,4-dihydrodiol, and further metabolism of this intermediate 
to mutagens, is catalysed selectively by cytochrome P-4501A1 (GYP1A1)(Boyd etal., 
1993a). Thus in common with most other PAH carcinogens, the activation of II-G H 3- 
cpp-17-one appears to be mediated by GYP1A1 (Parke etal., 1990), consequently 
the levels of GYP1A1 proteins will partly determine whether or not 11-GH3-cpp-17- 
one exerts its toxic/carcinogenic effects.
Cytochrome P-4501A1 proteins are known to be present in a wide variety of 
animal species eg. rat, mouse, hamster, guinea pig, rabbit and man. Although 
orthologous proteins exist in these different species their levels, substrate 
specificities and inducibility vary greatly (loannides and Parke, 1990). Immunological 
studies have revealed the presence of GYP1A at low levels in the liver of rats and at 
higher levels in rabbit and guinea pig liver, no detectable levels of GYP1A protein 
were found in hamster liver, however (loannides and Parke, 1990). Relatively high 
ethoxyresorufin-O-deethylase (a GYP1A marker) activities have been reported in 
beagle dogs (McKillop, 1985). GYP1A1 can be induced eg. by 3-methylcholanthrene
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(3-MC) (loannides and Parke, 1990), but the magnitude of the response to inducing 
agents such as 3-MC is species specific. Inductive response to 3-MC in rats is much 
greater than in hamsters and guinea pigs (Cheng etal., 1984). The differing affinities 
of various species CYP1A1 proteins towards certain substrates is amply 
demonstrated by the report, that using Aroclor 1254-induced liver preparations it was 
observed that hamster liver was as effective at metabolising benzo[a]pyrene as rat 
liver, in which ethoxyresorufin-O-deethylase (a CYP1A marker) levels were fourteen 
times higher than those of the hamster (Hyde etaL, 1987). Moreover, it is believed 
that the poor response of guinea pig to CYP1A inducing agents may at least in part 
explain the resistance of this species to 2-acetamidofluorene hepatocarcinogenesis, 
since activation of this compound is mediated by CYP1A (Âstrom and DePierre, 
1985).
Consequently it was considered pertinent to investigate the capacity of a variety of 
species of metabolise ll-CHg-cpp-l 7-one and to attempt to ascertain the identities of 
the metabolites formed.
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8.1 Materials
15,16-Dihydro-11-i4CH3-cyclopenta[a]phenanthren-17-one (4.2mCi/mmol) and 
15,16-dihydro-16-hydroxy-11-CH3-cyclopenta[a]phenanthren-17-one were the kind 
gift of Dr. M.M. Coombs, Dept, of Chemistry, University of Surrey. For syntheses see 
Coombs and Crawley, 1974 and Coombs, 1969.
3,4-Dihydroxy-3,4,15,16-tetrahydro-11 -methylcyclopenta[a]phenanthren-17-one was
the kind gift of Prof. R.G. Harvey, Ben May Institute, University of Chicago, Chicago, 
Illinois.
Liver samples from an untreated beagle dog and an untreated cynomolgous monkey 
were the kind gift of Dr. T.J.B. Gray, Sterling Winthrop ., Northumberland, U.K.
8.2 Methods
8.2.1 Preparation of microsomal fractions
Pooled livers from four male Syrian golden hamsters, four male Wistar albino rats 
and twenty male Balb C mice, one beagle dog and one cynomolgous monkey were 
used to prepare microsomes as previously described (sec. 2.2.1).
8.2 .2  Characterisation of hepatic microsomal preparations
The hepatic microsomal preparations (see above) were characterised with 
respect to their mixed function oxidase activities as previously outlined (sec. 2.3).
8.2 .3  In vitro metabolism of 11-i4CH3-cpp-17-one by hepatic microsomal
preparations
In vitro metabolism of 11-i4CH3-cpp-17-one by hepatic microsomal preparations 
and quantitation of the metabolites formed were carried out as described previously 
(sec. 4.3.2).
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8.3 Results
8.3.1 Characterisation of hepatic microsomal preparations
In accordance with the literature (loannides and Parke, 1990) considerable 
variation in mixed-function oxidase activities was observed among the various 
animal species (table 8.1). Ethoxyresorufin-O-deethylase(EROD) activity was found 
to be highest in hamster, dog and monkey with the latter two species demonstrating 
levels 17 and 47 times those of control rat respectively. By contrast the Balb 0  mouse 
displayed very low EROD activity and no discernible pentoxyresorufin-O-depentylase 
activity (PROD). The microsomal epoxide hydrolase (mEH) activity in the monkey was 
markedly higher when compared to the other species.
Table 8.1 : Hepatic microsomal mixed-function oxidase activities of the animal 
species used in the metabolic studies.
Figures represent determinations of the activities of single or pooled samples.
Species Ethoxyresorufin
-0-deethylase
activity
(pmol/min per 
nmol P-450)
Pentoxyresorufin 
-0-depentyIase 
activity (pmol/min 
per nmol P-450)
Epoxide
hydrolase
activty
(nmol/min
per mg
protein)
Total cytochrome 
P-450 (nmol/mg 
protein)
Microsomal 
protein 
(mg/g 
liver)
Rat 16.5 2.1 3.6 0.42 24.2
Mouse 1.8 ND 0.6 0.26 37.6
Hamster 47.9 1.6 7.3 0.45 15.0
Dog 294.8 26.6 9.3 0.34 13.8
Monkey 792.0 10.3 65.7 1.1 20.4
ND= no detectable activity.
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8.3 .2  In vitro metabolism of 11-i4C H 3-cpp-17-one by various hepatic 
microsomal preparations
8 .3.2.1 The Rat
In vitro metabolism of 11-CHs-cpp-l 7-one by rat liver microsomes resulted in the 
production of eight U.V. absorbing peaks (fig 8.2, table 8.2). Peak 8, being the least 
polar compound present was thought likely to be unmetabolised ll-CHs-cpp-17- 
one. Further investigation revealed peak 8 to possess the U.V. spectrum 
characteristic of ll-CHg-cpp-l7-one (fig 8.3); moreover it co-eluted from HPLC with 
an authentic sample of 11-CHs-cpp-l7-one. Scintillation counting established that 
peak 8 accounted for 93% (table 8.2) of the total radioactivity present on the 
chromatogram.
Peak 7 which accounted for 0.75% of total radioactivity (table 8.2), was observed 
to elute from HPLC with the same retention time as the 15-hydroxy derivative of 11- 
CHs-cpp-17-one. The U.V. spectrum of peak 7 (fig 8.4) was similar to that produced 
by 15-hydroxy-cpp-17-one (fig 8.5a), though the minor band at -285nm is usually 
only a shoulder in the 15-hydroxy compound. An alternative identity for this peak 
could be the II-C H 2OH derivative which is known to elute from HPLC with a similar 
retention time to the 15-hydroxy derivative (private communication, M.M. Coombs). 
The U.V. spectrum of the II-C H 2OH derivative (fig 8.5b) however has a more 
pronounced "peak " at ~285nm than that shown by metabolite peak 7. It is therefore 
postulated that peak 7 (fig 8.2) is a mixture of 15-hydroxy-11-CHs- and II-C H 2OH- 
cpp-17-one which are extremely difficult to separate by reverse-phase HPLC.
The other peaks were present at too low levels to permit identification (table 8.2).
8 .3 .2 .2  The Mouse
The murine in vitro metabolism of 11-CHs-cpp-l 7-one resulted in the production 
of seven U.V. absorbing peaks (fig 8.6, table 8.3). Peak 7 was shown to possess the 
U.V. spectrum (fig 8.7) associated with 11-CHs-cpp-l 7-one and was thereafter found 
to co-elute from HPLC with 11-CHs-cpp-l7-one. Peak 7 was therefore demonstrated 
to be unmetabolised 11-CHs-cpp-l 7-one and accounted for 96% of the total 
radioactivity (table 8.3).
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Fig 8.2: Reverse phase HPLC separation of the metabolites
of II-C H 3 -CPP-1 7-one produced by control rat microsomes.
Detection by U.V. absorbance at 254nm.
Table 8.2: Quantitation of the U.V. absorbing peaks produced by
in vitro metabolism of 11-CHs-cpp-l7-one by control rat hepatic 
microsomes.
Fraction Peak radioactivity 
(pCi)
% of total radioactivity 
recovered
peak 1 2.71 X  10-3 0.03
peak 2 0.011 0.13
peak 3 0.055 0.64
peak 4 0.021 0.24
peak 5 8.9x10-3 0.1
peak 6 0.017 0.2
peak 7 0.065 0.75
peak 8 8.03 93
baseline 0.44 5.1
206
12 53
Fig 8.3: U.V. absorption spectrum of peak 8  (fig 8.2).
Spectrum was obtained in methanolic solution.
2 . 1
1 . 3
Fig 8.4: U.V. absorption spectrum of peak 7 (fig 8.2).
Spectrum was obtained in methanolic solution.
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Fig 8.5a: U.V. absorption spectrum of 15-hydroxy-i 1 -CHs-cpp- 
17-one.
Spectrum was obtained in methanolic solution.
%bt
Fig 8.5b: U.V. absorption spectrum of 11-CH20H-cpp-17-one.
Spectrum was obtained in methanolic solution.
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Fig 8 .6 : Reverse phase HPLC separation of the metabolites
of 11-CH3-cpp-17-one produced by control mouse microsomes.
Detection by U.V. absorbance at 254nm.
Table 8.3: Quantitation of the U.V. absorbing peaks produced by in  
vitro metabolism of 11-CHs-cpp-l7-one by control mouse 
hepatic microsomes.
Fraction Peak radioactivity 
(pCi)
% of total radioactivity 
recovered
peak 1 4.6x10-4 0.005
peak 2 1.5x10-3 0.017
peak 3 0.025 0.29
peak 4 0.011 0.13
peak 5 3.53x10-3 0.04
peak 6 0.044 0.51
peak 7 8.35 96
baseline 0.27 3.1
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Fig 8.7: U.V. absorption spectrum of peak 7 (fig 8 .6 ).
Spectrum was obtained in methanolic solution.
1.
253
Fig 8 .8 : U.V. absorption spectrum of peak 6  (fig 8 .6 ).
Spectrum was obtained in methanolic solution. 210
Peak 6, which accounted for 0.51% of the total radioactivity, was shown to have a 
similar retention time to the 15-hydroxy derivative of 11-CHs-cpp-l 7-one. However, 
as in the case of the analogous metabolite in the rat, the U.V. spectrum (fig 8.8) 
appeared to suggest the presence of both 15-hydroxy-11-CHs- and ll-CHsOH-cpp- 
17-one (sec. 8.3.2.1).
All of the remaining peaks accounted for very little of the total radioactivity (table 8.3); 
however, attempts were made to obtain U.V. spectra from peak 3 (fig 8.9a). The 
unsymmetrical nature of the band at 261 nm is suggestive of the presence of more 
than one substance. It is, however, interesting to note that reduction of the carbonyl 
function with sodium borohydride results in the production of the doublet absorption 
band (fig 8.9b) which is characteristic of 1,2-dihydro-cpp-17-ones (Coombs and 
Bhatt, 1987). Given the retention time of peak 3, and based on previous studies of the 
metabolites of this compound (Boyd et al., 1993a) it is postulated that one of the 
substances which comprise peak 3 may be a 1,2-dihydrodiol of 11-CHs-cpp-l 7-one.
8 .3 .2 .3  The Hamster
The in vitro metabolism of 11-CHs-cpp-l 7-one by hamster microsomes resulted in 
the generation of four main U.V. absorbing peaks (fig 8.10, table 8.4). Peak 4 was 
found to possess the U.V. spectrum associated with 11-CHs-cpp-17-one (fig 8.11), in 
addition peak 4 co-eluted from HPLC with 11-CHs-cpp-17-one. Peak 4 therefore 
comprised unmetabolised 11-CHs-cpp-17-one and accounted for 85% of total 
radioactivity.
Peak 3 which accounted for 8.6% of total radioactivity eluted from HPLC with a 
similar retention time to 15-hydroxy-11 -CHs-cpp-17-one. Once again, as in the case 
of the analogous mouse and rat metabolites, the U.V. spectrum (fig 8.12) suggested a 
possible mixture of 15-hydroxy-11-CH3 and II-C H 2OH derivatives (secs. 8.3.2.1, 
8.3.2.2).
The U.V. spectra obtained from peak 2 (fig 8.13), especially that obtained after 
chemical reduction (fig 8.13b) suggested that peak 2 might be a 1,2-dihydro-cpp-17- 
one. Given the polarity of the compound it is tentatively ascribed the identity of the 
1,2-dihydrodiol of 11-CHs-cpp-l 7-one.
211
fi)
3  S 3
III
2 .0 ) o
S ' i lo ^  
S ®  Œ 
§ § . 5 -
s | |
l l i
t î s
III
8 2 ,?
-■  en J3
g â |
a  3 s .
û q . 2
Pli
Z ô y . w  nm
00
<o
c
<
c
3 O
5
3
O 
3
-*■ ; î  -•  r ^ o o
3--U
% o
Si
11
I"
"O
o  <D-h fi) 
7T
Z15.W nm
(Q
00
b>
nm
212
Injection
Fig 8.10: Reverse phase HPLC separation of the metabolites
of 11-CH3 -CPP-1 7-one produced by control hamster microsomes.
Detection by U.V. absorbance at 254nm.
Table 8.4: Quantitation of the U.V. absorbing peaks produced by in  
vitro metabolism of 11-CHs-cpp-l7-one by control hamster 
hepatic microsomes.
Fraction Peak radioactivity 
(pCi)
% of total radioactivity 
recovered
peak 1 0.01 0.13
peak 2 0.063 0.81
peak 3 0.67 8.58
peak 4 6.67 85
baseline 0.38 4.87
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Fig 8.11: U.V. absorption spectrum of peak 4 (fig 8.10).
Spectrum was obtained in methanolic solution.
lbs
Fig 8.12: U.V. absorption spectrum of peak 3 (fig 8.10).
Spectrum was obtained in methanolic solution. 214
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The remaining U.V. absorbing peaks could not be identified due to the low levels 
generated during metabolism (table 8.4).
8 .3 .2 .4  The Dog
Canine in vitro metabolism of 11-CHs-cpp-l 7-one resulted in the production of six 
major U.V. absorbing peaks (fig 8.14, table 8.5). Peak 6 was observed to possess the 
U.V. spectrum (fig 8.15) associated with 11-CHs-cpp-l 7-one and was found to co­
elute with 11-CHs-cpp-17-one from HPLC. Peak 6 therefore constituted 
unmetabolised 11-CHs-cpp-17-one and accounted for 87% of total radioactivity.
Peak 5 which accounted for 4% of the total radioactivity displayed the retention time 
associated with 15-hydroxy-11 -CHs-cpp-17-one and 11 -CHsOH-cpp-l7-one. The 
U.V. spectrum of peak 5 (fig 8.16), in an analogous manner to the previous 
metabolism systems (sec. 8.3.2.1 etseq.), suggested that peak 5 might contain both 
15-hydroxy-11-CHs-cpp-17-one and 1 l-CHsOH-cpp-l7-one.
Peak 4 accounted for 1% of the total radioactivity and possessed the U.V, spectral 
characteristics (fig 8.17) of a 3,4-dihydro-cpp-17-one, particularly the characteristic 
shift following chemical reduction of the carbonyl function (fig 8.17b). Given the 
polarity of the compound and based on previous studies (Boyd et ai., 1993a) the 
peak was tentatively identified as the 3,4-dihydrodiol of 11-CHs-cpp-17-one.
Peak 2 accounted for 1.2% of total radioactivity and displayed the U.V. spectral 
characteristics of a 1,2-dihydro-cpp-17-one (fig 8.18), based on polarity peak 2 is 
tentatively assigned the structure of a 1,2-dihydrodiol. The rather uneven appearance 
of the U.V. spectrum (fig 8.18a) suggests that a second substance might be present. 
The remaining metabolites were not present in sufficient quantities for identification to 
be possible (table 8.5).
8 .3 .2 .5  The Monkey
In vitro metabolism of 11-CHs-cpp-17-one by monkey hepatic microsomes 
resulted in the generation of a large number of U.V. absorbing peaks of which eight 
were collected (fig 8.19, table 8.6). Peak 8 was observed to display the U.V. spectrum 
associated with 11-CHs-cpp-17-one (fig 8.20), was found to co-elute with 11-CHs- 
cpp-17-one from HPLC and accounted for 21% of total radioactivity (table 8.6).
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Fig 8.14: Reverse phase HPLC separation of the metabolites
of 11-CH3-cpp-17-one produced by control dog microsomes.
Detection by U.V. absorbance at 254nm.
Table 8.5: Quantitation of the U.V. absorbing peaks produced by in
vitro metabolism of 11 -CHs-cpp-l7-one by control dog hepatic 
microsomes.
Fraction Peak radioactivity 
(pCi)
% of total radioactivity 
recovered
peak 1 0.025 0.3
peak 2 0.096 1.2
peak 3 0.023 0.3
peak 4 0.087 1.0
peak 5 0.33 4.0
peak 6 7.21 87
baseline 0.38 4.87
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Fig 8.15: U.V. absorption spectrum of peak 6  (fig 8.14).
Spectrum was obtained in methanolic solution.
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Fig 8.16: U.V. absorption spectrum of peak 5 (fig 8.14).
Spectrum was obtained in methanolic solution.
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Injection
Fig 8.19: Reverse phase HPLC separation of the metabolites
of 11-CH3-opp-17-one produced by control monkey microsomes.
Detection by U.V. absorbance at 254nm.
Table 8 .6 : Quantitation of the U.V. absorbing peaks produced by in  
vitro metabolism of 1 1 -CHa-cpp-l7-one by control monkey 
hepatic microsomes.
Fraction Peak radioactivity 
(pCi)
% of total radioactivity 
recovered
peak 1 0.035 0.4
peak 2 0.3 3.5
peak 3 0.06 0.7
peak 4 0.17 2.0
peak 5 0.15 1.7
peak 6 0.97 11.0
peak 7 3.17 36.5
peak 8 1.85 21.0
baseline 1.98 23.0
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Fig 8.20: U.V. absorption spectrum of peak 8 (fig 8.19).
Spectrum was obtained in methanolic solution.
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Fig 8.21: U.V. absorption spectrum of peak 7 (fig 8.19).
Spectrum was obtained in methanolic solution. 222
Peak 7 which contained 36.5% of the total radioactivity present (table 8.6) displayed 
a U.V. spectrum (fig 8.21) similar to that of 11-CHs-cpp-l7-one , but due to the 
greater polarity of peak 7 it was provisionally assigned as 16-hydroxy-1 l-CHs-cpp- 
17-one. This assignment was verified when peak 7 was observed to co-elute from 
HPLC with a synthetic sample of 16-hydroxy-11 -CHs-cpp-l7-one.
Peak 6 which accounted for 11% of total radioactivity possessed the U.V. spectral 
characteristics (fig 8.22) of a 3,4-dihydro-cpp-17-one (Coombs and Bhatt, 1987). 
Given the polarity of the compound it was provisionally assigned the identity of the
3,4-dihydrodiol of 1 l-CHs-cpp-l 7-one, the proximate carcinogenic form. This 
assignment was verified by the observation that peak 6 co-eluted from HPLC with a 
synthetic sample of the 3,4-dihydrodiol of ll-CHg-cpp-l 7-one.
Peak 5 contained 1.7% of the total radioactivity present and possessed the U.V. 
spectral characteristics (fig 8.23) of a 3,4-dihydro-cpp-17-one. Given that peak 5 is 
more polar than peak 6 (the 3,4-dihydrodiol), it is tentatively suggested that peak 5 
may be a 3,4,7-triol where the third hydroxyl residue is in a position on the molecule 
that would not alter the U.V. chromophore ie. 15/16 or II-C H 3.
Similarly peak 4 contained 2% of the total radioactivity present and possessed the 
U.V. spectral characteristics (fig 8.24) of a 3,4-dihydro-cpp-17-one, again suggesting 
a 3,4,7-triol identity.
Thus peaks 4 and 5 appear to be either the 3,4,15- and 3,4,16-triols or a 3,4,15/16- 
triol and the 3,4-diol-11-CH20H derivative.
Peak 2 which contained 3.5% of the total radioactivity was found to possess the U.V. 
spectral characteristics of a 1,2-dihydro-cpp-17-one (fig 8.25). Again, given the 
polarity of the compound it is preliminarily assigned as the 1,2-dihydrodiol of II-C H 3- 
cpp-17-one. Though as before the U.V. spectrum gives some indication of the 
presence of other substances (fig 8.25a).
Identification of the remaining U.V. absorbing peaks (fig 8.18) was not attempted.
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8.4 Discussion
The metabolism of H-CHs-cpp-l 7-one by control rat hepatic microsomes 
proceeded in the same manner as previously reported (Boyd et aL, 1993a) with 
metabolism principally at the D-ring and the II-C H 3  group (fig 8.2). The overall level 
of metabolism was however lower, at only 7%, than previously found (-20%). In the 
Baib C mouse a similar pattern was observed with metabolism mainly occurring at 
the II-C H 3  group and at the D-ring (fig 8 .6 ). As in the case of the rat metabolism, the 
overall level of metabolism was very low, indeed appreciably lower (tables 8.2, 8.3) 
than with rat microsomes. This difference may be, at least in part, accounted for by 
the apparently lower levels of CYP1 A (EROD) and epoxide hydrolase (table 8 .2 ), 
enzymes catalysing the metabolism of the A-ring of 11-CH3 -CPP-1 7-one in the rat 
(Boyd ef a/., 1993a).
Similarly the hamster, with higher levels of EROD and epoxide hydrolase was 
apparently more capable of metabolising 11 -CH3 -CPP- 1 7-one, since 15% 
metabolism was observed (table 8.4). Once again metabolism occurred mainly at the 
D-ring and the II-G H 3  group, though rather more A-ring metabolism may have taken 
place since small quantities of 1 ,2 -dihydrodiol appear to have been formed.
In the case of the dog, interpretation is fraught with difficulty since the metabolic 
pattern produced is that of a single animal. However it can be seen that the higher 
levels of EROD and epoxide hydrolase resulted in increased A-ring metabolism of 
II-C H 3 -CPP-1 7-one (tables 8.4, 8.5); however, at 13% overall metabolism is in fact 
lower than in the hamster, presumably due to the latter species higher levels of 
constitutive D-ring and II-C H 3  metabolism.
By far the greatest overall level of metabolism , some 79%, was seen in the system 
which employed the hepatic microsomes from a cynomoigous monkey. Once again 
interpretation is made extremely hazardous since the data was obtained from a 
single animal. However, bearing this in mind, there is an apparent correlation 
between greatest metabolism of 11-CH3-cpp-17-one and highest levels of EROD and 
epoxide hydrolase. Recent studies have indicated that the cynomoigous monkey has 
high EROD, similar to that seen in the present study, and it is believed that this high 
activity is due to CYP1A1 expression (M.D. Burke, private communication). Over 18%
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of the total cpps recovered appeared to be in the form of A-ring metabolites, the vast 
majority of which appeared to be 3,4-dihydroxy compounds , the proximate genotoxic 
forms of 11-CH3-CPP-17-one. it is attractive to speculate from these data, that as in 
the case of the rat, A-ring metabolism of 11-CH3-CPP-17-one might be the province of 
monkey CYP1A1 and epoxide hydrolase.
It should however be borne in mind that the activities of other monkey CYP450s were 
not determined. Primates are known to possess high levels of CYP3A which in man 
has been shown to act upon the 7,8-dihydrodiol of benzo[a]pyrene and metabolise it 
to the corresponding diol-epoxide (Shimada eta!., 1989). Thus the possibility exists 
that other monkey CYP450S are contributing to the observed A-ring metabolism of 
II-C H 3-CPP-17-one.
An unexpected observation was that the main metabolite of monkey microsomal 
metabolism of 11 -CH3 -CPP- 1 7-one was the 16-hydroxy derivative. At almost 37%, 
this appears to suggest considerable preference for this particular D-ring site by the 
constitutive monkey microsomal enzymes. This is particularly interesting in that in all 
of the rat metabolism studies which have been carried out on the cpp-17-ones 
(Coombs and Bhatt, 1987, Boyd et al., 1993, Boyd et a i, 1993a), 16-hydroxy 
derivatives have been very minor components, dwarfed by their 15-hydroxy 
counterparts.
Thus, these data suggest that primates such as the cynomoigous monkey may 
possibly be as, or even more, efficient metaboiisers of the A-ring of the cpp-17-ones 
as the CYP1A induced rodents which have been used to date. Indeed the large scale 
generation of the 3,4-dihydrodiol seen with the monkey preparations, if it is indicative 
of the true situation and is not merely a facet of this one animal, could have 
considerable implications for the carcinogenicity of the cyciopenta[a]phenanthrenes 
in such primates and indeed man.
Whilst these very preliminary studies have proved interesting, their most important 
outcome is the obvious imperative to examine in more detail the metabolism of the 
cpp-17-ones by higher animals, with all its possible ramifications for the biological 
activity of the compounds in these animals.
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8.5 Conclusion
Control rat and mouse metabolism of 11-CHs-cpp-l 7-one appeared to produce 
small quantities of 15-hydroxy-11 -CHs-cpp-l 7-one and 11 -CH20H-cpp-17-one, with 
a similar pattern being observed when hamster systems were used though overall 
metabolism was rather greater. Dog microsomes produced a similar overall rate of 
metabolism to the hamster but showed rather more ability to metabolise the A-ring 
apparently producing a 3,4-dihydrodiol and a 1,2-dihydrodiol in very small amounts. 
Monkey microsomes displayed the greatest capacity for A-ring metabolism and were 
observed to generate relatively large quantities of the 3,4-dihydrodiol which has 
been identified as the proximate genotoxic form of ll-CHa-cpp-l 7-one. A generally 
good relationship appears to exist between microsomal EROD levels on the one 
hand, and overall metabolism ,as well as A-ring oxidation, of 1 l-CHg-cpp-l 7-one on 
the other hand.
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CHAPTER 9.
General Discussion
231
9.0 Introduction
The purpose of the work reported in this thesis is to, at least partially, rationalise 
the differing carcinogenic activities of various members of the cpp-17-ones. Much of 
the carcinogenicity data on these compounds was obtained using the mouse skin 
assay (Coombs and Bhatt, 1987) whereas the work outlined here concerns the 
metabolism of the cpp-17-ones by rat iiver preparations. It may be argued that this 
approach is flawed in terms of achieving the objective of the study in that two different 
situations are being compared. However, the fact that the cpp-17-ones have aiso 
been tested for activity in rats using intra-peritoneal, intra-muscular, subcutaneous 
and intra-gastric administration with the production of lung adenomas, 
adenocarcinomas and fibroadenomas confirms the carcinogenicity of the 
compounds, and to a certain extent validates the approach used in this study. 
Moreover, it has recently been demonstrated that although the liver is not a target 
organ for PAH carcinogenesis, it is intimately involved in the metabolism and 
distribution of carcinogenic intermediates to target sites (Wail etal., 1992).
The cyclopenta[a]phenanthren-17-ones, in common with many other PAH series, 
exhibit the bay-region methyl effect wherein substitution of a methyl residue into the 
bay-region of a parent compound can confer carcinogenic activity on the molecule 
(fig 9.1)(Coombs and Bhatt, 1987, Harvey, 1991).
cpp-17-one 
non-carcinogenic
ll-CHg-cpp-l 7-one 
carcinogenic
Fig 9.1: Structures of cpp-17-one and its 11-methyl homologue
The question of why two such similar molecules (fig 9.1) should display such 
contrasting activities has been widely raised; during the course of this work various
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strategies have been employed in order to probe the differences between these 
molecules (fig 9.1).
9.1 in vitro metabolic studies
In vitro metabolic studies of cpp-17-one and its II-C H 3 analogue revealed that 
the compounds are metabolised in a qualitatively similar manner yielding 
metabolites of the A- and/or D-rings (fig 9.2).
Fig 9.2: Principal in vitro metabolites of the cpp-17-ones produced 
by Aroclor 1254-induced rat hepatic microsomes.
In addition hydroxylation of the -CH3 residue can occur in the 11-methyl analogue. 
Thus the two compounds do not appear to differ greatly in the manner of their 
metabolism. It was, however, decided to investigate the relative contributions of the 
various xenobiotic-metabolising cytochromes P-450 to the overall metabolism of the 
cpp-17-ones.
Only those microsomal samples derived from rats pretreated with inducers of CYP1A 
,ie. Aroclor 1254 and benzo[a]pyrene, were capable of significant metabolism of the 
A-ring of the cpp-17-ones. Furthermore, mutagenicity studies revealed that only those 
activation systems with induced CYP1A activity are capable of converting cpp-17-one 
and II-C H 3 -CPP- 1 7-one to mutagens. Moreover it is established that the final stage 
of activation ,ie. conversion of the 3,4-dihydrodiol to the 3,4-diol-1,2-epoxide, is also
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a unique province of CYP1A1. Since it is known that the ultimate genotoxic form of 
the cpps is the A-ring diol-epoxide (Coombs et al., 1979a, Papaparaskeva-Petrides 
etal., 1993) it is apparent that CYP1A1 mediates the activation of the cpp-17-ones. 
Consequently both cpp-17-one and ll-C H a-cpp-l7 -one are metabolised in 
qualitatively similar ways and by the same enzyme systems, thus the difference in 
activity cannot be attributed to differential metabolism or to differential catalysis of 
metabolism.
An interesting quantitative difference does emerge ,however, when a comparison is 
made of the metabolism of cpp-17-one and its 11-methyl analogue by microsomes 
from rats pretreated with benzo[a]pyrene (a specific CYP1A inducer). While the 
principal A-ring metabolites of the benzo[a]pyrene-induced metabolism of cpp-17- 
one were the 1,2-dihydroxy derivatives ,which are known to be inactive (Coombs and 
Bhatt, 1982), the principal A-ring metabolite of ll-C H s-cpp-l 7-one was the 3,4- 
dihydrodiol, the proximate carcinogenic form of this compound. Consequently it 
appears that CYP1A1 preferentially oxidises cpp-17-one via the deactivation 
pathway ,ie. at 1,2 ,but preferentially metabolises 1 l-CHs-cpp-l 7-one via the 
activation pathway ,ie. at 3,4. It may be that the presence of the II-C H 3 group, by 
some steric interaction with the CYP1A1 active site, alters the positioning of the 
molecule in the active site and thus places the 3,4 bond in the most advantageous 
position for metabolism.
Preliminary investigations into the capacity of control hepatic microsomes from a 
variety of species to metabolise II-C H 3-CPP-17-one, found that the three rodents 
,rats, mice and hamsters had very little ability to metabolise the compound. Whilst a 
dog sample was rather more metabolically competent, it did not display great 
capacity to act on the A-ring. However, monkey microsomes were observed to be 
remarkably efficient A-ring metaboiisers. These data must be treated with caution 
since in the case of the dog and monkey the samples were derived from only one 
animal, though clearly these findings merit further investigation.
The cyclopenta[a]phenanthrenes, in common with many PAH, induce the 
cytochrome P-450 isoforms involved in their metabolism (loannides, 1990, Ayrton et 
al., 1990), consequently it was decided to investigate whether differences in the 
inductive capacity of cpp-17-one and its 11-methyl analogue, could to some extent
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account for the difference in carcinogenic potential. The compounds could not be 
tested using the same dosing regime since it was found that 1 l-CHa-cpp-l 7-one 
was toxic over the three day regime employed successfully for cpp-17-one. Both 
compounds were found to induce CYP1A1 (EROD activity) to a similar extent, 
although it must be emphasised that the methylated derivative was administered as 
a single dose whereas three doses of the parent compound were given. Thus direct 
comparison is fraught with difficulty. In addition, unlike cpp-17-one, 11-CH3-cpp-17- 
one induced epoxide hydrolase activity. While the magnitude of this induction is very 
modest (,ie. 50%) it is noted that even potent mEH inducers such as Aroclor 1254 
only result in a three-fold induction.
Thus metabolic differences are apparent between cpp-17-one and its 
carcinogenic 11-methyl analogue;
1) II-C H 3-CPP-17-one is preferentially metabolised by CYP1A1 at the 3,4- position 
(,ie. the activation pathway) whereas cpp-17-one is preferentially metabolised at 1,2 
,ie. the deactivation pathway.
2) II-C H 3-CPP-17-one appears to more efficiently induce CYP1A1 and mEH, the 
enzymes responsible for its activation.
Consequently it has been possible to determine some of the factors which might 
have a bearing on the differential activities of cpp-17-one and its 11-methyl 
homologue; this however still leaves the question of what is the nature of the 11-CH3 
groups' effect.
9.2 Effect of the II-C H 3 group
Any chemical moiety has two principal effects on the molecule of which it is part, 
namely steric and electronic. Investigations have therefore been carried out which 
were designed to elucidate the respective roles of these effects.
9.2.1 Steric effects
Cpp-17-ones were synthesised which were substituted with alkoxy chains 
of increasing length (C1-C4). The 11 -alkoxy-cpp-17-ones were tested for their ability 
to induce the enzyme systems involved in the activation of the cpp-17-ones. Ability to 
induce CYP1A1 was found to decline as the length of the alkoxy chain increased, 
since the propoxy and butoxy derivatives were relatively modest inducers in
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comparison to the methoxy and ethoxy derivatives. This relationship was evident in 
the mutagenicity of the compounds, since only 11  -methoxy-cpp-17-one could be 
activated to mutagens; while the ethoxy compound showed some activity, it never 
achieved significance. These data are in keeping with the observed carcinogenic 
activities of the compounds, where the activity is abolished when the alkoxy chain is 
extended to C3  (Bhatt et at., 1982). A similar effect is noted in the 1 1 -alkyl series 
where extension of the chain to C2  drastically diminishes biological activity (Coombs 
et al., 1973). These data therefore indicate a fairly strict size limit to the activation 
mechanism. This may be rationalised on the grounds of the active site of CYP1A1 
which is considered to be accessed through a rather narrow "slot" (private 
communication, D.F.V. Lewis). Computer-generated models of the 1 1 -alkoxy 
compounds show that the "thickness" of the molecule increases greatly as the chain 
is lengthened; this increased size may preclude the compound from access to the 
CYP1A1 active site and therefore activation. Alternatively it is possible that entry of 
the compounds, to the active site, is effected but that the increased size may prevent 
efficient catalysis due to improper positioning of the molecule.
9.2 .2  Electronic effects
The electronic effects of the II-C H 3  group have been probed using an 11- 
CF3  derivative of II-C H 3 -CPP-1 7-one. The II-C F 3  group has a similar size to the 
I I -C H 3  group but a vastly different electronic effect. The II-C F 3  derivative was 
found to be mutagenic and to be metabolised in an entirely analogous manner to its 
II -C H 3  homologue. Mutagenicity tests on the metabolites of II-C F 3 -CPP-1 7-one 
revealed that activation to mutagens proceeded via a 3,4-dihydrodiol just as in the 
case of II-C H 3 -CPP-1 7-one. Consequently altering the electronic nature of the 
substituent at 0 - 1 1  does not appear to prevent its activation to mutagens, whether 
such alteration would prevent the compound being a carcinogen is a question which 
must await full carcinogenicity testing of II-C F 3 -CPP-1 7-one.
9.3 Conformation of the proximate carcinogen
The proximate genotoxic form of the cpps has been established to be the 3,4- 
dihydrodiol (Coombs etal., 1979a, Papaparaskeva-Petrides etal., 1993) (fig 9.3).
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Fig 9.3: Structures of the 3,4- and 1,2-dihydrodiols of the cpp-17-ones
While it is observed that the cyc!openta[a]phenanthren-17-ones can be metabolised 
in vitro to 1,2-dihydrodiol derivatives (Boyd et ai., 1993), these metabolites are 
neither mutagenic nor carcinogenic (Coombs and Bhatt, 1982). These data suggest 
that the cpps do not form the so called "reverse" diol-epoxides which have recently 
been proposed as an additional genotoxic form of the chrysenes (Glatt et al., 1993). 
Since 1,2-dihydrodiols of the cpps do not appear to be further metabolised In the A- 
ring to yield genotoxic intermediates, the question arises as to why there should be 
this difference in the activity of the two A-ring dihydrodiols of the cpp-17-ones. It has 
been observed that the 3,4-dihydrodiol of ll-G Ha-cpp-l7-one adopts a pseudo- 
diequatorial conformation whereas the 1,2-dihydrodiol adopts a pseudo-diaxial 
conformation, presumably due to steric hindrance in the bay-region (Hadfield, 1983). 
The hypothesis has been put forward that it is this difference in conformation, rather 
than the different sites of metabolism, which makes the activities of the 1,2- and 3,4- 
dihydrodiols so disparate (M.M. Coombs, private communication). The pseudo- 
diaxial 1,2-dihydrodiols are far broader than the pseudo-diequatorial 3,4- 
dihydrodiols (fig 9.4), it may be postulated, that this far greater breadth either 
prevents or at least gravely hinders entry of the 1,2-dihydrodiols to the CYP1A1 
active site;
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Fig 9.4: Computer generated structures of the (a) 1,2- and 
(b) 3,4- dihydrodiols of ll-C H a-cp p -l7 -o n e.
Structures are shown in the nominal minimum energy state using the 
standard parameters of the MM2 force field (Burkert and Allinger, 1982.)
alternatively this greater breadth might alter the positioning of the molecule in the 
active site and thus impede metabolism.
This belief that it is the conformation of the A-ring dihydrodiol rather than its 
position which is the critical factor in activity has been confirmed. In vitro metabolism 
studies of G-CHs-cpp-l 7-one revealed that the principal metabolite of this compound 
was the 3,4-dihydrodiol; however 6-CH3-cpp-17-one is neither mutagenic nor 
carcinogenic (Coombs and Bhatt, 1987). In addition the 3,4-dihydrodiol metabolite of 
e-CHs-cpp-l 7-one is not capable of being activated to mutagens. This is surprising
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since it has been observed in other cpp-17-ones that production of appreciable 
amounts of 3,4-dihydrodiol always results in mutagenicity (chps. 3,4).
The 3,4-dihydrodiol of 6-CH3-CPP-17-one does however differ from the 3,4-diols of 
other cpp-17-ones in that it occurs in a pseudo-diaxial conformation ,cf. the inactive
1,2-dihydrodiols of cpp-17-one and its 11-methyl analogue. Thus it seems that any 
A-ring dihydrodiol of the cpps which exists in a diaxial conformation is inactive, 
regardless of the position of the hydroxyl residues.
9.4 Conclusions
On the basis of the present work a number of inferences may be drawn about the 
conditions necessary for genotoxic activity among the cpp-17-ones:- 
1 ) The compounds must be capable of being activated in sufficient quantity to the 
3,4-dihydrodiol.
2) The 3,4-dihydrodiol must adopt a diequatorial conformation in order to be 
activated to the diol-epoxide.
3) Substitution at C-11, which can confer carcinogenicity on cpp-17-one, must be by 
a relatively small group, as introduction of a bulky group at this position diminishes 
and eventually abolishes biological activity, thus establishing a fairly strict size limit 
for activation.
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The in vitro metabolism and activation to mutagens of 15,16-dihydrocycIopenta[a]phenanthren-17-one (CPP-17-one) were 
investigated using hepatic preparations from rats pretreated with prototype inducers of the cytochrome P-450-dependent 
mixed-function oxidases. Aroclor 1254-induced microsomes were the most effective metabolisers of this compound, the major 
metabolites being oxidation products of the bay region A ring. To a lesser extent hydroxylation of the non-aromatic D ring 
occurred, the products being the 15- and 16-hydroxyderivatives. Oxidation of the A ring was also achieved with microsomes from 
benzo[a]pyrene-treated rats but not with those from rats treated with clofibrate, phenobarbitone, isoniazid, dexamethasone and 
CPP-17-one itself, where the metabolites were primarily the oxidation products of the D ring. When CPP-17-one was used as a 
promutagen in the Ames test, only microsomes from Aroclor 1254-treated rats could elicit a positive mutagenic response. When
3,4-dihydrodihydroxy-CPP-l7-one, the precursor of the ultimate mutagen, was used as the promutagen, a positive response was 
observed with microsomes from Aroclor 1254- and benzo[a]pyrene-treated rats. It is concluded that (a) CPP-17-one is 
metabolised through oxidation of the D ring to produce non-mutagenic products and only through A ring oxidation mutagens are 
produced, (b) only the CYPIA (cytochrome P-450 family 1, subfamily A) family (induced by benzo[a]pyrene and Aroclor 1254) 
could oxidise the A ring, and (c) Aroclor 1254-induced hepatic microsomes are the most effective catalysts of the metabolism and 
activation of CPP-17-one because, in addition to the high CYPIA activity, they are also characterised by high levels of 
microsomal epoxide hydrolase.
Cyelopenta[a]phenanthrenes; Polycyclic aromatic hydrocarbons; (Zytochrome P450; Mixed-function oxidases; Bioactivation
1 . In t r o d u c t io n
Thé polycyclic aromatic hydrocarbons comprise one 
of the jlargest and most ubiquitous classes of chemical 
carcinogens (Harvey, 1991). Some are potent carcino­
gens, inducing tumors at a number of sites including 
the lung and skin. Like most carcinogens they express 
their carcinogenicity through metabolites and the ulti­
mate carcinogens interact readily and covalently with 
D N A  to set in motion the series of events leading to 
tumorigenesis.
Dihydrodiol-epoxides are believed to serve as the 
ultimate eareinogenie forms of polycyclic aromatic hy-
Correspondepce to: C. loannides. Molecular Toxicology Group, D i­
vision o f Toxicology, School of Biological Sciences, University of 
Surrey, Guiléford, Surrey G U 2 5 X H , U K . Tel. (0)483-300800; Fax 
(0)483-576978
drocarbons and these are generated following two oxi­
dations, catalysed by the cytochrome P-450-dependent 
mixed-function oxidases, and an epoxide hydrolysis 
catalysed by the epoxide hydratase. An initial oxidation 
forms the primary epoxides which are hydrolysed to 
the corresponding trans-diols that undergo a second 
oxidation to form the dihydrodiol-epoxide (Pelkonen 
and Nebert, 1982). The polycyelic aromatic hydrocar­
bons are selectively oxidised by the C Y P IA  subfamily, 
and particularly the A1 protein (for review see loan­
nides and Parke, 1990). However, in humans a protein 
of the CYP3 family can catalyse the second, but not 
the first, oxidation of polycyclic aromatic hydrocarbons 
such as benzo[a]pyrene, i.e., the conversion of the 
dihydrodiol to the dihydrodiol-epoxide. Since this cy­
tochrome P-450 protein eannot catalyse the primary 
epoxidation this must be catalysed by another P-450 
protein, possibly C Y P lA l (Shimada et al., 1989).
Cydopenta[a]phenanthrenes form a series of poly-
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cyclic aromatic hydrocarbons which are analogues of 
the steroids (Coombs and Croft, 1969), and are gener­
ated during the heating of edible oils (Coombs and 
Bhatt, 1987). Some of them are carcinogenic in various 
animal models and, in the presence of an appropriate 
activation system, they display mutagenicity in a num­
ber of short-term tests (Coombs et al., 1973, 1976; 
Bhatt et al., 1983). However, the unsubstituted parent 
compound, 15,16-dihydrocyclopenta[a]phenanthren-17- 
one (CPP-17-one) is devoid of carcinogenicity, in con­
trast to derivatives with a methyl group in the 11-posi­
tion, in a number of animal models (Coombs and 
Croft, 1969; Coombs and Bhatt, 1978; Coombs et al., 
1979; Bhatt et al., 1983). In the Ames test, however, 
CPP-17-one exhibits a positive mutagenic response in 
the presence of a hepatic activation system derived 
from rats pretreated with Aroclor 1254 (Coombs et al., 
1976). Moreover, CPP-17-one administration induces 
the C Y P lA l proteins catalysing its activation, a char­
acteristic of carcinogenic polycyclic aromatic hydrocar­
bons (Ayrton et al., 1990).
The purpose of the present study is two-fold: (a) to 
investigate the pathways of metabolism of CP with 
emphasis on those yielding reactive intermediates as 
exemplified by mutagenicity in the Ames test, and (b) 
to determine which cytochrome P-450 proteins catalyse 
the activation pathways. Such information may provide 
a rationale for the lack of carcinogenicity of CPP-17- 
one.
2 . M a t e r ia ls  a n d  m e th o d s
Pentoxyresorufin, ethoxyresorufin and resorufin 
(Molecular Probes, Eugene, OR, USA), Aroclor 1254 
(Robens Institute, Guildford, Surrey, UK), [^ '^ Cjlauric 
acid (Amersham International, Amersham, UK), phe­
nobarbitone (BDH, Poole, Dorset, UK ), benzo-
[a]pyrene, dexamethasone, clofibrate, p-nitrophenol, 
erythromycin, isoniazid and all cofactors (Sigma Chem­
ical Co., Poole, Dorset, UK) were all purehased. The 
synthesis and characterisations of 15,16-dihydrocyclo- 
penta[a]phenanthren-17-one (Coombs, 1966) and its 
16-monohydroxy- (Coombs, 1969) and 3,4-dihydro-3,4- 
dihydroxy-derivatives (Young et al., 1992) have already 
been published.
Male Wistar albino rats (150-200 g) were purchased 
from the Animal Breeding Unit, University of Surrey. 
Animals were treated with single daily intraperitoneal 
injections of phenobarbitone (80 mg/kg), benzo- 
[ajpyrene (25 m g/kg), CPP-17-one (25 m g/kg) or clofi­
brate (80 m g/kg) or dexamethasone given by gastric 
gavage (100 mg/kg), for 3 days, all animals being killed 
24 h after the last administration. Another group re- 
eeived a single intraperitoneal injeetion of Aroclor 
1254 (500 m g/kg), the animals being killed on the 5th
day following administration. Finally, a group of rats 
was maintained on isoniazid (0.1%) in the drinking 
water for 10 days.
Hepatic microsomal fractions were prepared as pre­
viously described (loannides and Parke, 1975) and the 
following assays were performed: O-deethylation of 
ethoxyresorufin (Burke and Mayer, 1975), O-depenty- 
lation of pentoxyresorufin (Lubet et al., 1985), p- 
nitrophenol hydroxylase (Reinke and Moyer, 1985), 
erythromyein N-demethylase (Wrighton et al., 1985), 
lauric acid hydroxylase (Parker and Orton, 1980), total 
cytochromes P-450 (Omura and Sato, 1964) and pro­
tein (Lowry et al., 1951).
Mutagenic potential was determined in the Ames 
test (Maron and Ames, 1983) using Salmonella ty- 
phimurium strain TA  100 and 10% (v /v ) microsomal 
activation systems supplemented with glucose 6-phos­
phate dehydrogenase (1 U /p late). |
For the metabolie studies, incubation mixtures com­
prised microsomal protein (50-60 mg), NADP (4 mM), 
glucose 6-phosphate (5 mM), glucose 6-phosphate de­
hydrogenase (20 U), CPP-17-one (1 mg) and 0.1 M  
phosphate buffer, pH 7.4 to a final volume of 10 ml. 
Incubations were carried out for 30 min at 37°C in a 
shaking waterbath, and were then extracted six times 
with equal volumes of ethyl acetate and the combined 
extracts dried over magnesium sulfate. Ethyl acetate 
was evaporated to dryness under reduced pressure at 
45°C, the residue was redissolved in methanol (150 /xl) 
and aliquots (50-80 ju,l) injected into the ehromato- 
graph.
HPLC analysis was performed using a Whatman 
Partisil 10 ODS, Magnum 9 semipreparative eolumn 
(500 mm X  9 mm i.d.) and an increasing linear methanol 
gradient (30-100%).
3 . R e s u lts  I
Fig. 1 shows the structure and numbering system for 
CPP-17-one, the same as that adopted for steroids.
Crude microsomal preparations containing high 
concentrations of a spécifié cytochrome P-450 Subfam­
ily were prepared from animals pretreated with proto-
4 6
Fig. 1. The structure of 15,16-dihydrocyclopenta[a]pijenanthren-17- 
one (CPP-17-one).
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type inducing agents. To ensure that the expected 
pattern of induction occurred, mixed-function oxidase 
activities were determined using diagnostic substrates, 
and the results are shown in table 1. Treatment with 
benzo[a]pyrene, phenobarbitone, isoniazid and clofi­
brate gave rise to a marked increase in the O-deethyl­
ation of ethoxyresorufin (C YPIA ), O-depentylation of 
pentoxyresorufin (CYP2B, eytochrome P-450 family 2, 
subfamily B), hydroxylation of p-nitrophenol (CYP2E, 
cytoehrome P-450 family 2, subfamily E), N-demethyl- 
ation of erythromycin (CYP3A, cytochrome P-450 fam­
ily 3, subfamily A ) and hydroxylation of lauric acid 
(CYP4A, cytochrome P-450 family 4, subfamily A), 
respectively. Treatment of the rats with CPP-17-one 
resulted in a marked increase only in the O-deethyl­
ation of ethoxyresorufin, indicating that it is a specific 
inducer of the C YP IA  family, in agreement with our 
previous studies (Ayrton et al., 1990).
Incubation of CPP-17-one with microsomal prepara­
tions from Aroclor 1254-treated animals revealed seven 
major peaks which were absent from blank microsomal 
preparations (fig. 2). The peaks were collected and 
their U V  spectra between 200-400 nm were obtained 
and eompared to those previously published (Coombs 
and Bhatt, 1987; Coombs et al., 1979, 1980). Peak 7 
was the parent compound, peaks 5 and 6 the 15- and
16-hydroxy-derivatives respectively. Moreover, peak 6 
in reverse phase HPLC behaved similarly to authentic
16-hydroxy-CPP-17-one. The U V  spectrum of peak 4 
was identical to that associated with a 3,4-dihydrodiol. 
Furthermore, peak 4 in reverse phase HPLC behaved 
similarly to the authentic 3,4-dihydrodiol of CPP-17- 
one. Peak 3 also possessed the U V  spectral character­
istics of a 3,4-dihydroxy compound, but as it was more 
polar than peak 4 it was tentatively identified as the
3,4,15- or the 3,14,16-trihydroxy-CPP-17-one. Finally, 
peaks 1 and 2 displayed U V  spectra associated with
1,2-dih^droxy-derivatives. Since peak 2 is appreciably 
less polar than peak 1 it was considered likely that
peak 1 represents the 1,2,15-trihydroxy-CPP-17-one 
identified in previous studies (Coombs et al., 1980).
O f the microsomal preparations studied, those from 
Aroclor 1254-treated animals were by far the most 
efficient in catalysing the metabolism of CPP-17-one, 
with very little of the parent compound remaining 
intact (fig. 3). The major metabolites were oxidation 
products of the A  ring, but monohydroxy products 
resulting from the oxidation of the non-aromatic D 
ring were also present, but to a lesser extent. Control 
microsomes metabolised CPP-17-one less effectively, 
the major products being the monohydroxy derivatives 
of the D ring. Treatment of animals with phenobarbi­
tone did not enhance CPP-17-one metabolism when 
compared with controls, but shifted metabolism from
16- to the 15-hydroxy-CPP-17-one (fig. 3). Almost an 
identical metabolic profile was obtained when CPP-17- 
one was incubated with microsomes from dexametha- 
sone-treated rats. Treatment of rats with isoniazid did 
not stimulate the metabolism of CPP-17-one, the major 
metabolites being 15- and 16-hydroxy-CPP-17-one. In ­
terestingly, small amounts of a trihydroxy-product (peak 
3) were evident, indicating some limited ability to oxi­
dise the aromatic A  ring. Clofibrate-induced micro­
somes metabolised CPP-17-one only very poorly, with 
no evidence of A  ring oxidation (fig. 3). Benzo- 
[ajpyrene-induced microsomes metabolised the hydro­
carbon more effectively than the control microsomes. 
Oxidation products included the 3,4-dihydrodiol, a tri­
hydroxy metabolite as well as 15-hydroxy-CPP- 17-one 
(fig. 3X Microsomal preparations from CPP-17-one- 
treated animals appeared to metabolise CPP-17-one 
with similar efficiency as control preparations and with 
similar metabolic patterns (fig. 3).
When CPP-17-one was used as the promutagen in 
the Ames test, a positive mutagenic response, as exem­
plified by doubling of the spontaneous reversion rate, 
was observed only with the microsomal preparations 
isolated from the Aroclor 1254-pretreated rats (table
T A B L E  1
Mixed-function oxidase activities of hepatic preparations used in the metabolism and mutagenicity studies 
Results are presented as mean ( +  S .E .M .) o f three animals.
Treatment Ethoxyreso­
rufin O - 
deethylase 
(pm ol/m in  
per mg pt) “
Pentoxy­
resorufin O - 
depentylase 
(p m o l/m in  
per mg pt)
p-Nitro- 
phenol hydroxy­
lase (n m o l/  
min per mg pt)
Erythro­
mycin N-demeth- 
ylase (n m o l/ 
min per mg pt)
Lauric acid 
hydroxylase 
(nm o l/m in  
per mg pt)
Cytochrome
P-450
(n m o l/m g pt)
Microsomal 
protein 
(m g /g  liver)
Control 2 8 ±  6 1 1 + 3 1.6 ± 0 .2 23 ±  3 2.4 ± 0 .4 0.50 ±0 .04 2 9 ± 2
CPP-17-one 504 ±  49 17 ±  3 1.9 ± 0 .2 26 ±  3 2.5 ± 0 .3 0.47 ±0 .01 2 7 ± 2
Benzo[a]pyrene 4,224 ±1 ,151 38 ±  4 3.4 ± 0 .7 15 ±  1 2.7 ± 0 .3 0.44 ±0 .13 2 7 ± 6
Phenobarbitone 72 ±  33 387 ± 1 1 2.7 ± 0 .4 29 ±  2 2.4 ± 0 .3 0.74 ± 0 .06 3 1 ± 4
Isoniazid | 49 ±  14 23 ±  3 9 .2 ± 1 .7 36 ±  4 2.7 ± 0 .4 0.43 ± 0 .0 4 2 6 ± 3
Dexamethasone 168 ±  25 65 ±  9 4.2 ±1 .5 96 ± 2 4 4.3 ± 1 .3 0.36 ± 0 .1 2 2 9 ± 1
Clofibrate 1 1 9 +  1 9 ±  1 2.6 ±0 .3 30 ±  7 8.5 ± 1 .0 0 .57±0 .10 2 8 ± 1
pt =  protein.
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Fig. 2. Rat hepatic microsomal metabolism of CPP-17-one. Hepatic 
microsomes from Aroclor 1254-treated rats were incubated with 
CPP-17-one and metabolites were determined by H P L C  as described 
in the text. (1) 1,2,15-trihydroxy-CPP- 17-one; (2) 1,2-dihydroxy-CPP- 
17-one; (3) 3,4,15- or 3,4,16-trihydroxy-CPP-17-one; (4) 3,4-dihy- 
droxy-CPP-17-one; (5) 15-hydroxy-CPP-17-one; (6) 16-hydroxy-CPP-
17-one; and (7) CPP-17-one.
2). When 3,4-dihydrodihydroxy-CPP-17-one was used 
as the promutagen a very marked positive response was 
seen with the microsomal preparations derived from 
the benzo[a]pyrene- and Aroelor 1254-treated animals 
(table 3).
4. Discussion
The lack of carcinogenicity of CPP-17-one may be 
due to one or more of the following; (a) inability of the 
constitutive enzyme systems and those induced by 
CPP-17-one itself, on repeated administration, to eatal- 
yse the metabolic pathways leading to the formation of
the 3,4-dihydrodiol-l ,2-epoxide, the putative ultimate 
carcinogen; (b) poor reaetivity of this diol-epoxide with 
D N A  because of low electrophilicity; and (c) rapid 
detoxication of the diol-epoxide by conjugation with 
glutathione and/or hydrolysis to the corresponding 
tetrahydrotetraol.
Essentially planar molecules such as the polycyclic 
aromatic hydrocarbons serve as substrates of the 
C YP IA  subfamily (Lewis et al., 1986), which in un­
treated animals comprises a minor fraction of the total 
cytochrome P-450 (Luster et al., 1982). It  is not surpris­
ing, therefore, that the metabolism of CPP-17-one by 
microsomal preparations from control rats was not 
extensive. Pretreatment of rats with the potent inducer 
of C Y P IA  benzo[a]pyrene enhanced the degree of 
metabolism. However, by far the most extensive 
metabolism occurred when the metabolic system com­
prised hepatic microsomes from Aroelor 1254ftreated 
animals. Aroelor 1254 is not only a potent inducer of 
CYPl activity, but also stimulates epoxide hydrolase 
activity (Parkinson et al., 1983), which converts the 
primary epoxides to the corresponding dihydrodiols 
that undergo a second cytochrome P-450-mediated 
epoxidation to form the dihydrodiol-epoxide, the ulti­
mate carcinogen. A t the doses used CPP-17-one failed 
to enhance epoxide hydrolase activity the values for 
control and treated animals being 10.6 ±  1.1 and 9.5 ±  
1.6 nm ol/m in per mg protein respectively (n =  3). Sim­
ilarly, the C Y P IA  indueer benzo[a]pyrene, at the dose 
studied, did not enhance epoxide hydrolase activity, 
the values for control and benzo[a]pyrene-treated ani­
mals being 6.6 ±0 .6  and 6.0 ±  0.7 nmol/min per mg 
protein respectively (n =  3). Pretreatment of rats with 
phenobarbitone, a spécifié inducer of the CYP2B fam­
ily, dexamethasone a specific inducer of the CYP3A 
family and clofibrate, a specific inducer of the CYP4A 
family decreased the overall metabolism of CPP-17-one. 
Since none of these treatments signifieantly increased 
the total cytochrome P-450 levels it may be inferred 
that induction of specific cytochrome P-450 proteins by 
these agents occurred at the expense of constitutive 
forms including the C YP IA  subfamily, explaining the 
lower rates of metabolism. Treatment of the animals 
with isoniazid, a spécifié inducer of the CYP2E family, 
did not influence the microsomal metabolism of CPP-
17-one.
The metabolie profile of CPP-17-one was also de­
pendent on the source of the hepatic microsomes. The 
major metabolites generated by the control micro­
somes were the two monohydroxy products 15- and
16-hydroxy-CPP-17-one, the result of oxidation of the 
non-aromatic D ring. Only traces of the metabolites 
resulting from oxidation of the A  ring were observed. 
The C YP IA  subfamily inducer benzo[a]pytene, in ad­
dition to the 16-hydroxy-derivative of CPPjl7-one, also 
catalysed the formation of oxidation products of the A
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Fig. 3. In  vitro metabolism of CPP-17-one by hepatic microsomal preparations derived from rats pretreated with prototype inducers of 
cytochrome P -p O  proteins. Treatment of animals and incubation conditions are described in the text. Peak identification as in legend to fig. 2.
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T A B L E  2
Metabolic activation of CPP-17-pne to mutagens in the Ames test by hepatic microsomal preparations from rats treated with prototype inducers 
of cytochrome P450 proteins
The study was carried out using 10% (v /v )  activation systems supplemented with glucose 6-phosphate dehydrogenase (1 U /p la te ) , and 
Salmonella typhimurium strain T A  100. Results are presented as mean ( +  S.D.) of triplicates. The positive controls 2-aminoanthracene and 
6-aminochrysene (in the case of dexamethasone-treated animals) gave the expected positive responses.
Treatment CPP-17-one (yxg/plate)
Histidine revertants/plate
0 2 5 7 10
Control 7 9 +  5 79 ±  5 8 1 +  9 90 ± 1 2 79 ±  1
CPP-17-one 84 +  10 7 8 +  2 8 7 +  8 87 ± 1 0 79 ± 2 0
Benzo[a]pyrene 8 3 +  6 108+  4 9 2 +  6 96 ± 2 1 95 ±  6
Phenobarbitone 7 6 +  4 8 1 + 8 79 +  11 89 ± 1 2 82 ± 2 0
Isoniazid 95 +  14 8 4 +  9 7 9 +  9 86 ±  8 75 ± 1 6
Dexamethasone 82 +  16 9 9 +  8 100 +  11 82 ±  5 74 ±  8
Clofibrate 91 +  17 109 +  16 94 ± 1 5 98 ± 1 6 84 ±  2
0 0.5 1 2 5
Control 83 ± 1 3 81 ± 1 1 88 ±  4 91 ± 1 2 77 ± 1 1
Benzo[a]pyrene 89 ±  3 104 ±  9 121 ± 1 8 105 ±  5 101±  8 '
Aroclor 1254 89 ± 1 5 129 ±  8 172 ± 1 3 225 ± 3 2 173 ± 2 2
ring, such as the 3,4-dihydrodiol and 3,4-dihydrodiol of 
the 15- or 16-monohydroxy-derivatives. The dihydro­
diol is presumably formed following the hydrolysis of 
the 3,4-epoxide and is the direct precursor of the 
presumed ultimate mutagen, namely the 3,4-dihydro- 
diol-l,2-epoxide. Induction of C Y P IA  by CPP-17-one 
did not result in autoinduction of its own metabolism. 
The major metabolites were the 15- and 16-hydroxy- 
CPP-17-one. Although CPP-17-one is an inducer of the 
C Y P IA  subfamily as exemplified by an increase in the 
O-deethylation of ethoxyresorufin and by an inerease 
in the C Y P IA  apoprotein levels (Ayrton et al., 1990), 
A  ring dihydrodiols were present only in very small 
amounts. However, it must be pointed out that com­
pared with Aroclor 1254, CPP-17-one is a relatively
modest inducer of C YP IA  activity the rates of 
ethoxyresorufin O-deethylase being 5512 ±  318 and 
504 + 49 pm ol/m in per mg protein, respectively (n =
3). The most extensive metabolism of CPP-17-one was 
observed with the Aroclor 1254-induced microsomes. 
The monohydroxy metabolites at 15- and 16-positions 
were relatively minor products and the primary 
metabolites originated from A  ring oxidation, being the
l,2,15-trihydroxy-CPP-17-one, 1,2- and 3,4-dihydroxy- 
CPP-17-one and the 3,4-dihydrodiols of the 15- or
16-monohydroxy-CPP-17-ones. Only the microsomes 
from the benzo[a]pyrene- and Aroclor 1254-induced 
animals could oxidise the A  ring of CPP-17-one at the 
1,2 position. Aroclor 1254 is a mixture of planar and 
non-planar polychlorinated biphenyls that induce the
T A B L E  3
Metabolic activation of 3,4-dihydroxy-CPP-17-one to mutagens in the Ames test by hepatic microsomal preparations from rats treated with 
prototype inducers of cytochrome P-450 proteins
The study was carried out using 10% (v /v )  activation systems, supplemented with glucose 6-phosphate dehydrogenase (1 U /p la te ) , and 
Salmonella typhimurium strain T A  100. Results are presented as mean ( +  S .D .) of triplicates. The positive controls 2-aminoanthracene and 
6-aminochrysene (in the case of dexamethasone-treated rats) gave the expected positive responses.
Treatm ent 3,4-Dihydroxy-CPP-17-one (/rg /p la te )
Histidine revertants/plate
0 2 5 7 10
Control 91 ± 1 7 102 ±  9 127 ± 1 6 132 ± 1 7 144 ± 2 4
CPP-17-one 103 ± 2 1 146 ±  3 156 ± 1 9 139 ±  4 179 ± 1 7
Benzo[a]pyrene 101 ± 1 3 258 ± 1 9 445 ± 1 4 651 ± 8 7 675 ± 7 7
Phenobarbitone 107 ± 1 4 139 ±  8 135 ± 2 0 150 ± 1 2 182 ± 2 4
Isoniazid 97 ± 1 4 136 ± 2 2 132 ± 2 3 119±  8 120 ±  6
Dexamethasone 105 ±  3 11 3±1 4 129 ±  7 152 ± 2 3 153 ± 3 0
Clofibrate 78 ±  5 85 ±  6 78 ±  3 71 ±  4 78 ±  8
Control 82 ± 1 0 86 ±  2 89 ±  8 120 ± 2 4 114 ±  8
A roclor 1254 72 ±  6 207 ± 2 2 392 ± 2 3 455 ±  9 403 ± 3 4
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C YPIA  and 2B families respectively. Since the CYP2B 
family, as reflected in the phenobarbital-induced mi­
crosomes, could not metabolise CPP-17-one efficiently, 
it may be concluded that C Y P IA  is responsible for the 
increased metabolism. However, another major conse­
quence of animal treatment with Aroclor 1254 is a 
marked increase in microsomal epoxide hydrolase 
(Parkinson et al., 1983), which could explain the high 
levels of A  ring dihydrodiols.
The mutagenicity data where CPP-17-one served as 
the promutagen are in complete agreement with the 
metabolic studies. A  positive mutagenic response was 
evident only when the activation system contained mi­
crosomes from Aroclor 1254-treated rats, presumably 
because of the increased C Y P IA  and epoxide hydro­
lase activities which can catalyse the complete 
metabolism of CPP-17-one leading to the 3,4-dihydro­
diol-1,2-epoxide, the ultimate mutagen. Increase in 
C YP IA  alone, as evidenced in the benzo[a]pyrene- 
treated animals, was not sufficient to transform CPP-
17-one to mutagens. The present mutagenicity observa­
tions also indicate that the 15- and 16-hydroxy-CPP-17- 
one derivatives, the major metabolites with the other 
control and inducible microsomal preparations, are per 
se devoid of mutagenicity. They can, however, be con­
verted to mutagens if the epoxidation at 3,4-position is 
a significant pathway of metabolism (Coombs and 
Bhatt, 1987).
In the case of benzo[a]pyrene, the second oxidation, ‘ 
i.e., the conversion of the 7,8-dihydrodiol to the 7,8- 
diol-9,10-epoxide is catalysed not only by the CYPl 
family but in humans the orthologous protein to the rat 
CYP3A also catalyses this step (Shimada et al., 1989). 
The rat CYP3A protein is unable to oxidise 
benzo[a]pyrene or its dihydrodiol. In  the present study 
only the Aroclor 1254- and benzo[a]pyrene-induced 
hepatic microsomes converted the 3,4-dihydroxy-CPP-
17-one to mutagens, presumably the 3,4-dihydrodiol-
1,2-epoxide. These agents are the most potent inducers 
of the C YP IA  family among the compounds studied. 
Microsomes from rats treated with CPP-17-one, a rela­
tively weak inducer of the C Y P IA  family failed to 
convert the 3,4-dihydroxy-CPP-17-one to mutagens. 
These findings suggest that this diol is a low affinity 
substrate of the C YP IA  family. As in the case of 
benzo[a]pyrene-7,8-dihydrodiol the dexamethasone-in- 
duced (CYP3A) rat microsomes did not produce a 
positive mutagenic response, as exemplified by a dou­
bling of the spontaneous reversion rate, when 3,4-dihy- 
droxy-CPP-17-one served as the promutagen.
In  summary, the present study demonstrates that (a) 
CPP-17-one is metabolised by oxidation of the D ring 
to produce non-mutagenic monohydroxy derivatives 
and by oxidation of the A  ring to form dihydroxy-de- 
rivatives which can lead to the generation of mutagens,
(b) only tlie C YP IA  family appears to catalyse the
oxidation of the A  ring and the oxidation of the resul­
tant dihydrodiols to the dihydrodiol-epoxide, and (c) 
Aroclor 1254-induced rat hepatic microsomes are the 
most effective catalyst of the activation of CPP-17-one 
because, in addition to possessing high C YP IA  activity, 
they are also characterised by high epoxide hydrolase 
activity. The lack of carcinogenicity of CPP-17-one can, 
thus, be attributed, at least partly, to the inability of 
control and CPP-17-one-induced microsomes to effi­
ciently oxidise this A  ring and form the diol-epoxide, 
the ultimate mutagen. The possibility that the diol- 
epoxide of CPP-17-one may be readily deactivated by 
enzymic and non-enzymic conjugation with glutathione 
or conversion to the tetrahydrotetraol also merits con­
sideration.
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Putative synthetic metabolites of the hydrocarbon 16,17- 
dibydro-15H-cyclopenta[fl]pbenantbrene and its carcinogenic 
11-metbyl analogue, namely /ra/is'-3,4-dibydroxy- 3,4,16,17- 
tetrabyÂ*o-15fl-cyclopenta[fl]pbenantbrene and its 11-metbyl 
derivative, together with the four associated ^rans-3,4- 
dibydroxy-syn- and a«b‘- l ,2-epoxides, vyere assayed for 
mutagenicity in the Ames test with Salmonella typhimurium 
TAIOO with and without microsomal activation. The hydro­
carbons were weakly mutagenic and the 3,4-diols were more 
strongly so, but all required activation to express their 
mutagenic potential. A ll four diol-epoxides were much more 
potent mutagens, even in the absence of activation. This is 
in accord with the anticipated metaboUc activation sequence: 
hydrocarbons -* 3,4-diols — 3,4-diol-l,2-epoxides.
Introduction
It is well established that most polycyclic aromatic hydrocarbons 
that are carcinogenic possess at least four fused aromatic rings, 
usually three of which are non-linear as in phenanthrene (Harvey, 
1991). The latter tricyclic hydrocarbon is itself inactive (Hartnell, 
1951a), but weak carcinogenicity is induced in it by bay-region 
methyl substitution to give, e.g. 1,2,4-trimethylphenanthrene (la) 
(Butenandt and Dannenberg, 1953) and 1,2,3,4-tetramethyl- 
phenanthrene (lb) (Badger et at. , 1942) (see Figure 1). Activation 
by bay-region methyl substitution is a well known phenomenon. 
For example, both benzfa] anthracene (2a) (Roe et at. , 1963) and 
chrysene (3a) (Hartnell, 1951b) are inactive or at best very weakly 
carcinogenic, whereas this activity is considerably augmented in 
their bay-region methyl derivatives, 12-methylbenz[a]anthracene 
(2b) (Huggins et a l , 1967; Wislocki et a l , 1982) and 5-methyl- 
chrysene (3b) (Hoffmann et a l ,  1974), respectively.
Cyclopenta[a]phenanthrenes are of interest as aromatic 
analogues of steroids. They occur naturally in mineral oüs from 
petroleum-bearing shales (Mair and Martiez-Pico, 1962; Ludwig 
et a l,  1981) as well as in river and lake sediments (Wakeham 
et a l , 1980); they are also formed during the heating of edible 
OÜS which contain sterols of plant origin (Hoffelner et a l , 1964). 
By analogy with phenanthrene, 16,17-dihydro-15^-cyclopenta 
[ajphenanthrene (4a) (Figure 1) is not a carcinogen, but its 
11-methyl derivative (4b) is weakly active (Butenandt and 
Dannenberg, 1953). In this series conjugation by an additional 
double bond in the five-membered ring markedly increases this 
activi^. Thus both the hydrocarbon bearing a 16,17-double bond,
ll,17-dimethyl-15i7-cyclopenta[a]phenanthrene (5) and the
17-ketone 15,16-dihydro-1 l-methylcyclopenta[a]phenanthren-
17-one (6b) are strong carcinogens (Coombs and Croft, 1969),
©  Oxford University Press
the potency of the latter being similar on mouse skin to that of 
the classical polycyclic aromatic hydrocarbon benzo[a]pyrene 
(Coombs et a l , 1979). Extended metabolic studies (summarized 
by Coombs and Bhatt, 1987) have indicated that, similar to 
benzo[a]pyrene, the 1 l-methyl-17-ketone (6b) is biologically 
activated to its ultimate carcinogenic form by metabolic conver­
sion to its bay-region anri-diol-epoxide (7), but final proof of 
this must await the chemical synthesis of this labile metabolite 
because it has not proved possible to isolate it during metabolic 
experiments.
In considering the chemical synthesis of the anri-diolepoxide 
(7) the initial aim, which has now been realised (Young et a l , 
1992, 1993), was to synthesize the corresponding metabolites 
of the hydrocarbons (4a,b) lacking the rather reactive carbonyl 
group which considerably complicates the synthetic approach with 
the 17-ketones. The 3,4-dihydrodiols (8a,b) (Figure 2) and anti- 
diol-epoxides (9a,b) as well as the 5yn-diol-epoxides (10a,b) of 
the original hydrocarbons have therefore become available, and 
this paper describes their behaviour in the Ames mutagenicity 
test with Salmonella typhimurium TAIOO.
CHa^
CHa
1 II
k A
1
R
1
12
^ 1
4 6
4
C H a ^
a, R=H
b, R=CH3
Fig. 1. Compounds referred to in the text.
a, R=H
b, R=CH3
ho'
OH
10
Fig. 2. Synthetic metabolites investigated for mutagenic potential in the Ames test
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Table I .  Mutagenicity of synthetic metabolites and parent cyclopenta[a]phenanthrene hydrocarbons in the Ames test
Compound Concentration
(/tg/plate)
Histidine revertants/plate 
without aetivation with activation
Spontaneous reversion rate — 115 ±  8 113 ±  23
M N NG  (positive control) 2652 ± 4 4 6 —  '
2-Aminoanthracene (positive control) — 1612 ±  310
Unsubstituted hydrocarbon (4a) 5 91 ±  3 184 ±  16
10 99 ±  19 114 ±  10
25 102 ±  8 123 ±  12
50 88 ±  12 116 ± 6
Unsubstituted 3,4-diol (8a) 5 113 ± 1 1 247 ±  33
10 116 ±  8 270 ±  55
25 150 ±  9 353 ±  13
50 111 ±  15 384 ±  27
Unsubstituted anft-diol-epoxide (9a) 5 528 ±  79 767 ±  3
10 111 ±  44“ 103 ±  32“
25 95 ±  19“ 159 ±  27“
50 97 ±  23“ 189 ±  54“
Unsubstituted syn-diol-epoxide (10a) 5 561 ±  80 634 ±  89
10 919 ±  18 781 ±  238
25 220 ± 1 1 2 “ 1225 ±  189
50 101 ± 5 0 “ ND*’
11-methyl hydrocarbon (4b) 5 106 ±  5 117 ±  12
10 98 ±  5 147 ±  19
25 102 ±  12 140 ±  4
50 83 ±  9 221 ±  8
11-Methyl 3,4-diol (8b) 5 129 ±  11 206 ±  24
10 115 ± '3 286 ±  23
25 112 ±  13 ' 338 ±  36
50 94 ±  7 ND'’
11-Methyl onti-diol-epoxide (9b) 5 471 ±  49 723 ±  35
10 538 ±  51 543 ±  106
25 93 ±  22“ 190 ±  46“
50 microcolonies 205 ±  103“
11-Methyl jyn-diol-epoxide (10b) 5 510 ±  43 680 ±  73
10 494 ±  146 730 ±  130
25 87 ±  22“ 183 ±  72*
50 microcolonies ND^
Assays were carried out using S.typhimurium TAIOO, the compounds dissolved in dimethyl sulphoxide (100 pi), in the presence and absence of an activation 
system (4% v/v) derived from the livers of rats induced with Aroclor 1254. Results are presented as mean ±  SD for triplicates.
“Sparse background lawn. *’Not determined.
Materials and methods
The rra«5-3,4-dihydrodiol (8a) and its 11-methyl analogue (8b), along with the 
associated 3,4-dihydroxy-anri-l,2-epoxides (9a,b) and ayn-1,2-epoxides (10a,b), 
were synthesized and characterized by Young et al. (1992, 1993) in Chicago, 
and stored as dry solids at —20° C or lower until their mutagenicity was assayed 
at Guildford within a few weeks of their preparation. They were dissolved in 
anhydrous dimethyl sulphoxide (Aldrich, product no. 27,685-5) for assay 
immediately before use. Other cyclopenta[a]phenanthrenes employed were 
available from earlier work (Coombs, 1966, 1969). Aroclor 1254 was purchased 
from Robens Institute, University of Surrey. The S.typhimurium strain TAIOO 
was a generous gift from Professor B.N.Ames, Berkeley, CA.
Male Wistar albino rats (150 -2 0 0  g) were purchased from the Experimental 
Biology Unit, University of Surrey. Animals received a single intraperitoneal 
injection of Aroclor 1254 (500 mg/kg) and were killed 5 days later. Hepatic 
microsomal fractions were prepared as previously described (loannides and Parke, 
1975). Mutagenicity was determined in the Ames test (Maron and Ames, 1983) 
using S.typhimurium TAIOO with or without a 4% (v/v) microsomal activation 
system supplemented with glucose 6-phosphate dehydrogenase (1 unit/plate). All 
tests were repeated at least once and exhibited essentially the same results; TAIOO 
was previously established to be the most sensitive strain to cyclopenta[a]- 
phenanthrenes.
Results
Initially all the synthetic metabolites shown in Figure 2, together 
with the parent hydrocarbons (4a,b) (Figure 1), were tested over 
the dose range 2—50 /tg/plate, with and without activation; the 
results of this experiment appear in Table I. As expected from 
previous work with the Ames test with a range of cyclopenta[a]- 
phenanthrenes (Coombs et a l,  1976), both hydrocarbons (4a,b) 
were weakly mutagenic with metabolic activation, but inert in 
its absence. However, neither compound could induce a doubling 
of the spontaneous reversion rate. Both 3,4-dihydrodiols (8a,b) 
were decidedly more mutagenic, showing 2- to 3-fold increases 
in reversion rate in a concentration-related fashion, but neither 
was mutagenic in the absence of microsomal activation. This 
again is in accord with our previous observation (Coombs and 
Bhatt, 1982) that the metabolically derived 3,4-dihydrodiol of 
the carcinogenic 11-methyl-17-ketone (6b) was more mutagenic 
than the ketone itself, but only in the presence pf a microsomal 
activation system. In this case it was further demonstrated that
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Table U . Mutagenicity o f four diolepoxides in the Ames test i 
of biological activation
in the absence
Compound Concentration
(/tg/plate)
Histidine revertants/ 
plate
Spontaneous reversion rate — 141 ±  11
M N N G  (positive control) 2722 ±  175
Unsubstituted anri-diol-epoxide (9a) 0.1 168 ±  9
0.5 144 ±  16
1.0 751 ±  33
2.0 1052 ±  152
Unsubstituted syn-diol-epoxide (10a) 0.1 156 ±  6
0.5 121 ±  9
1.0 660 ±  55
2.0 739 ±  71
11-Methyl anft'-diol-epoxide (9b) 0.1 174 ±  25
0.5 428 ±  61
1.0 864 ±  28
2.0 939 ±  45
11-Methyl ayn-diol-epoxide (10b) 0.1 210 ±  13
0.5 587 ±  168
1.0 963 ±  60
2.0 1513 ±  100
Assays were carried out as deseribed in Table I, but without activation, 
this diol was also a stronger carcinogen in the mouse skin model 
than the ketone (6b). However, it was the four diol-epoxides 
which displayed the most mutagenic response. A ll were much 
more mutagenic than the hydrocarbons or their 3,4-dihydrodiols, 
giving 5- to 9-fold increases in reversion rates at low concentra­
tions in the absence of biological activation, compatible with their 
role as the ultimate mutagenic forms. At the concentration range 
tested the diol-epoxides clearly gave a toxic response; for this 
reason they were re-tested at lower concentrations of 0 .1—2 pg! 
plate in the absence of activation (Table H). For all four diol- 
epoxides the maxima (5- to 10-fold increases) occurred at a 
concentration range of 1—2 /^ g/plate giving rather similar 
reversion rates (calculated from the straight part of their dose 
responses) of; (9a) 192, (10a) 169, (9b) 266 and (10b) 292 
revertants/nmol. When the dimethyl sulphoxide solutions were 
stored at 5°C overnight and the test was repeated with them, 
little difference in mutagenic response was seen except with the 
jyw-diol-epoxide (10a), the reversion rate of which had dropped 
to less than half its original value. However, after storage under 
these conditions for 9 days, only a trace of mutagenicity was 
found with all these solutions. When these diol-epoxides [with 
the exception of the unsubstituted anh-diolepoxide (9a), the 
supply of which had been exhausted in the first tests] were stored 
at —20°C as dry solids for 6 months and then re-tested over a 
concentration range of 0.2—5 /xg/plate, they still retained 
mutagenic potential. The maxima (4—5 times background) now 
occurred in the 2 —5 j^ g/plate range with reversion rates of: (10a) 
44, (9b) 50, and (10b) 81 revertants/nmol. This gives us 
confidence that the results shown in Figure 2 are correct for the 
pure diol-epoxides, at least for the three re-tested at 6 months. 
It is notable that the 11-methyl-substituted derivatives exhibited 
higher levels of activity than the corresponding unsubstituted 
analogues, consistent with previous findings for the parent 
hydrocarbons.
Discussion
This order of mutagenic response, i.e. diol-epoxides >  diols >  
parent hydrocarbons, strongly suggests a metabolic process
similar to that described for benzofajpyrene, with the direct-acting 
diol-epoxide being the ultimate mutagen in each case. Although 
the in vitro metabolism of these hydrocarbons has not been studied 
to date, it is probable that this would follow the same course as 
that of the closely related 17-ketones which have been studied 
in detail and for which this sequence has been postulated on other 
grounds (Coombs and Bhatt, 1987). This route for the biological 
activation of these 17-ketones is therefore supported in a general 
way by the present study with the corresponding hydrocarbons 
and their synthetic metabolites.
Of course, the mutagenicity of the unsubstituted hydrocarbon
16,17-dihydro-15fl-cyclopenta[a]phenanthrene (4a) is not in line 
with its lack of carcinogenicity. This is tme also of the correspond­
ing 17-ketones, 15,16-dihydrocyclopenta[a]phenanthren- 17-one 
(6a) and its 11-methyl homologue (6b), for both are mutagenic 
in the Ames test. However, in many experiments in which they 
have been tested side by side for carcinogenicity, the unsubstituted 
ketone has uniformly failed to produce tumours where the 
11-methyl ketone has proved to be a strong carcinogen. In vitro 
metabolic studies (Hadfield et a l , 1984) with hepatic microsomes 
from rats induced with 3-methylcholanthrene have established 
that both 17-ketones give rise to fmay-3,4-dihydrodiols, although 
to a greater extent with the 11-methyl ketone; A-ring oxidation 
to the biologically inert 1,2-dihydrodiol predominates with the 
unsubstituted ketone. Whereas in the Ames test induced enzyme 
is employed under optimum conditions to elicit the biological 
response, in the intact uninduced animal this is far from the case 
and this may contribute towards the observed discrepancy 
between mutagenicity and carcinogenicity for this compound.
The present work with the cyclopenta[a]phenanthrene 
hydrocarbons (4a) and (4b) indicates that their bay-region diol- 
epoxides possess similar genotoxicity and that they are of 
comparable chemical stability. Whether biological inactivation 
by conjugating enzymes such as glutathione S-transferase is also 
similar for the two series has yet to be determined. Use of pure, 
chemically synthesised diol-epoxides will be crucial in 
establishing this.
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The in vitro metabolic activation of the 11-trifluoromethyl analogue 
of the potent carcinogen 15,16-dihydro-ll-methyl-cyciopenta[a]- 
phenanthren-17-one to mutagens
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A strongly electronegative, bay-region analogue of the potent 
carcinogen 15,16-dihydro-l l-methylcyclopenta[a] phenanth- 
ren-17-one, namely 15,16-dihydro-ll-trifluoromethylcyclo- 
penta[a]phenanthren-17-one, is mutagenic to Salmonella 
typhimurlum TAIOO. Also it is metabolized at the 1,2- and
3,4-positions in the A-ring as well as C-15 in the D-ring to 
give 3,4-dihydroxy-3,4,15,16-tetrahydro-ll-trifluoromethyl- 
cyclopenta[a]phenanthren-17-one as the only mutagenic 
metabolite. In  these respects its behaviour is closely similar 
to that of the 11-methyl compound, suggesting that the 
electronic nature of the bay-region substituent is rather less 
critical than its spatial configuration in infiuencing metabolism 
to genotoxic intermediates. It remains to be seen, however, 
whether the trifluoromethyl compound is also a carcinogen.
15.16-Dihydrocyclopenta[a]phenanthren-I7-one (1, çpp-17-one*) 
(Figure 1), the parent . 17-ketone. of . the
15.16-dihydrocyclopenta[a]phenanthrene (cpp) series, is devoid 
of intrinsic carcinogenicity (I); however, substitution of a methyl 
group at C-11 (figure 1) confers considerable carcinogenic activity 
on the molecule (2). This 11-methyl derivative (2) has been found 
to induce skin tumours in a number of mouse strains (1 —5) as 
well as a variety of other soft tissue tumours following s.c. 
injection in rats and mice (2,3,6). More recently it has been 
observed to increase the rate of myeloid leukaemia in male 
Sprague—Dawley rats; in addition the compound was found to 
act as a potent initiator of süica-induced mesothelioma (7). The 
carcinogenicity of cpps is believed to be mediated through 
metabolic activation to bay-region diolepoxides (2,8). It was 
therefore of interest to examine whether it is the steric or 
electronic effects of the 11-methyl group that influence the 
activation of the compound to reactive intermediates. It was 
decided to synthesise an analogue of 1 l-CHg-cpp-lV-one (2) 
possessing a group at C-11 which was spatially similar to methyl, 
yet electronically very different. The most appropriate candidate 
for this replacement was considered to be trifluoromethyl, due 
to the similarit]^  in size of hydrogen and fluorine (van der Waals 
radii H = 1.2 Â; F = 1.35 À), but their very different affinities 
for electrons (H = 0.8 eV; F = 3.448 eV, in the gas phase at 
OK) (9). Consequently the 11-trifluoromethyl derivative (3) was 
synthesized (10), and its in vitro metabolism has now been 
examined and the identities of the principal metabolites
* Abbreviations: cpp-17-one, 15,16-dihydrocyclopenta[a]phenanthren-17-one. 
Other derivatives of 15,16-dihydrocycIopenta(a]phenanthrcne (cpp) are similarly 
abbreviated.
determined. Moreover the compound and its metabolites have 
been tested for activity in the Ames mutagenicity assay 
The 11-trifluoro-17-ketone (3) was metabolized and the 
metabolites separated by HPLC as previously described (11), 
using hepatic microsomal preparations from rats pretreated with 
Aroclor 1254 (prepared as outlined in ref. 12). The principal in 
vitro metabolites were tentatively identified on the basis of 
retention times on HPLC coupled with UV absorption spectra. 
Previous experience (2,13) has shown that the positions of 
saturation in the aromatic rings (and hence the positions of the 
hydroxyl groups) can be unambiguously assigned from their UV 
chromophores, especially since in each case simple in situ 
reduction of the carbonyl group produces a second, highly 
characteristic chromophore. These identities were then verified
(1 )R =H
(2) R= CHj
(3) R= CF3
F]C.
FjC,
HO""'OH
O H
15-hydroxy-15.16-dihyd(0-11-CF3- 
cpp-17-one (peak 4)
3.4xkhy(ko%y .3 .4 .15,1 e-tetrahydro-l 1C F , -  
Cpp-17H3ne (pcak3)
1.2<lSiydtDxy-12.1S.16-letrahyd(0-l 1C F ,- 
qip-17.one (peak 2)
1.2,15-trihydroxy-12 .15.16-tetrahydro-11C F ,  
cpp-17K>ne (peaki)
Fig. 1. Structures o f compounds 1—3, and the major metabolites of the 
II-trifluoromethyl-17-ketone (3).
Injection
Fig. 2. HPLC profile o f the in vitro metabolites of 15,16-dihydro-l 1-tri- 
fluoromethylcyclopenta[a]phenanthren-l7-one. Metabolism was carried out as 
previously described. Trace monitored by U V  absorption at 254 nm.
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Table I .  Mass spectral data o f peaks 1 —5
Peak Predicted miz (% relative abundance) and m/z o f molecular ion o f TM S
mol. mt probable fragments(s) lost derivative
5 C fsH iiO Fj 300 (100), M; 272 (7), M-CO; 231 (11) —
M , 300 M-CF3; 203 (91), M -C0 -CF3'
4 CtgHnOzF] 316 (100), M; 298 (45), M -H jO ; 288
M , 316 (11), M-CO; 270 (47), M -H 2O-CO; 251 
(50), M -H 2O-CO-F; 247 (11), M -CF3;
229 (16), M -H 2O-CF3; 219 (18), M -CO-CF3
388
(one OH group)
3 C|gH;)0 gF3 334 (13), M ; 316 (100), M -H 2O; 288
M , 334 (80), M-H2O-CO; 287 (12), M -H 2O-CHÜ; 
259 (13), M -H 2O-CO-CHO; 219 (52), M - 
H 0 -CO-CF3
478
(two OH groups)
2 CigHi303F3 334 (19), M ; 316 (43), M -HjO; 288
M , 334 (100), M -H 2O-CO; 287 (9), M -H 2O-CHO; 478
259 (11), M -H 2O-CO-CHO; 219 (34), M - 
H2O-CO-CF3
(two OH groups)
1 C 1ÇH13O4F3 350 (16), M ; 332 (30), M -H 2O; 314 (31),
M , 350 . •  - - M -2H2O; 304 (49), M -H 2O-CO; 286 (43), 566
M -2H 2O-CO; 258 (21), M -2H2O-2CO; 
189 (1.00), M -2H 2O-2CO-CF3
(three OH groups)
by 70 eV electron impact mass spectrometry using a VG Quattro 
instrument; the metabolites were dissolved in ethyl acetate for 
direct insertion, and later derivatized by addition of trimethylsilyl 
imidazole (Aldrich, product no. 15 358—3) to the solution for 
a few minutes at room temperature before reinsertion. Mutagenic 
potential was determined in the Ames test (14) using Salmonella 
typhimurlum TAIOO as previously described (11)
Incubation of 1 l-CF^-cpp-lV-one (3) with microsomal 
preparations jfrom Aroclor 1254-treated rats revealed the presence 
of five major peaks which were absent from blank microsomal 
preparations (Figure 2). Peak 5, being the least polar compound 
present, was unchanged ll-trifluoromethyl-cpp-17-one (3) 
identified by its retention time and UV absorption spectrum 
(Xmax^T/, 300, 354, 371; after 259 nm—italics indicates 
peaks of highest intensity). Peak 4 was assigned the structure 
of a D-ring mono-ol since it was observed to be somewhat more 
polar than the parent compound (peak 5), and its UV spectmm 
was very similar (X^^ 275, 300, 357, 374; after BH4" 258 nm) 
as expected, since they possess the same chromophore. It is 
thought likely that the compound was in fact the 15-hydroxy 
derivative since 15-ols have been found as major metabolites of 
other cpp-17-ones (2). Peak 3 was found to inhabit the region 
of the chromatograph usually occupied by a diequatorial
3,4-dihydrodiol and this was confirmed by its UV absorption 
characteristics ()onax 268, 331; after BH^" 246, 323 nm). 
Peaks 1 and 2 were observed to elute at HPLC areas usually 
inhabited by the diaxial 1,2-dihydrodiols and 1,2,15-triols, and 
their structures were again established by their ultraviolet spectra 
(peak 1, Xniax 234, 272, 334; after BH^ "^  257, 265, 311 nm; 
peak 2, X^ ax 233, 265, 331; after BH4" 258, 266, 310 nm). 
Since peak 1 was rather more polar than peak 2 it was considered 
likely that peak 2 was the l ,2^ihydrodiol, while peak 1 was the
1,2,15-trihydroxy derivative found as a major metabolite of other 
cpp-17-ones (2). All these retention times were closely similar 
to those of the corresponding metabolites derived from the 
11-methyl compound, in these cases known to be trans. These 
tentative identifications were confirmed by MS (Table I) which 
showed that the metabolites’ mol. wts and major fragments were 
consistent with the proposed structures (see Figure 1). Moreover, 
after treatment with trimethylsilyl imidazole in order to convert
3,4-diol
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Fig. 3. Activation o f 1 l-CF^-cpp-17-one (3) and 3,4-dihydroxy-l l-CF^-cpp- 
17-one to mutagens by hepatic microsomal preparations from rats pretreated 
with Aroclor 1254. Spontaneous reversion rate was 81 ±  12. Figures are 
presented as m ean±SD. Neither compound was mutagenic in the absence of 
an hepatic microsomal activation system.
Peak 2 Peak 3 Peak 4
Metatwlic fraction
Fig. 4. Mutagenicity of the principal compounds separated by HPLC  
following in vitro metabolism of 1 l-CF^-cpp-l7-one. All compounds tested 
at 7 /rg/plate using a 10% (v/v) microsomal activation system prepared from 
the livers of rats pretreated with Aroclor 1254. Spontaneous reversion rate 
was 87 ± 9 . Figures are presented as mcan±SD.
Activation of the 11-trifluoromcthyI analogue of cpp-17-one
hydroxyl residues to their trimethylsilyl ethers, in each case the 
molecular ion was in accord with the expected number of OH 
groups.
The 11-trifluoro-17-ketone (3) was examined in the Ames test 
using Salmonella typhimurium TAIOO and a 10% (v/v) 
microsomal activation system utilising microsomes from rats 
pretreated with Arolcor 1254 (Figure 3). Since the compound 
was found to be mutagenic only after metabolic activation, it was 
decided to ascertain which of the in vitro metabolites were 
involved in its mutagenicity. The five principal peaks present after 
in vitro metaboUsm were collected and put into solution in DMSO 
at 100 /ig/ml. Each was tested, with metabolic activation, at 7 
/ig/plate, the most mutagenic concentration of 
ll-CF3-cpp-17-one (Figure 3). Only peak 5 [II-C F 3- 
cpp-17-one (3)] and peak 3 (the 3,4-dihydrodiol) were found to 
be mutagenic (Figure 4). To confirm the mutagenicity of the
3.4-dihydrodiol (peak 3) the assay was repeated at four concentra­
tions of the compound (Figure 3), giving a good dose—response 
relationship.
Thus the in vitro metabolism of 15,16-dihydro-l 1-trifluoro- 
methylcyclopenta[a]phenanthren l^7-one (3) by hepatic micro­
somal preparations resulted in the production of four principal 
metabolites (Figure 1) identified as 15,16-dihydro- 15-hydroxy- 
11 -trifiuoromethylcyclopenta[a]phenanthren-17-one (peak 4),
3.4-dihydroxy-3,4,15,16-tetrahydro-l 1-trifluoromethylcyclo- 
penta[a]phenanthren-17-one (peak 3), 1,2-dihydroxy-1,2,15,
16-tetrahydro-11 -trifluoromethylcyclopenta[û]phenanthren-17- 
one (peak 2) and 1,2,15,16-tetrahydro-l,2,15-trihydroxy-l 1- 
trifluoromethylcyclopenta[a]phenanthren-17-one (peak 1). Thus 
the 11-trifluoromethyl compound (3) is metabolized in a 
qualitatively similar manner to its 11-methyl analogue (2) (15) 
in that metabolism occurs at two sites on the A-ring and at one 
of two positions on the D-ring. Although the metabolism proceeds 
in a qualitatively similar manner, in terms of the major meta­
bolites produced, to that of II-C H 3-CPP-17-one, the overall 
metabolic profile of the 11-trifluoromethyl compound (3) is 
simpler (Figure 2). Metabolism of the 11-methyl compound (2) 
produces a more complex pattern of minor metabolites such as 
the I6-0I and 11-hydroxymethyl compound and their A-ring 
derivatives (2) which are largely absent in the metabolism of its 
II-C F 3 analogue.
The activation of 1 l-CF3-cpp-17-one (3) to genotoxic 
intermediates appears to proceed via the 3,4-dihydrodiol since 
this was the only metabolite found to be mutagenic (Figures 3 
and 4) and moreover was observed to be a more potent mutagen 
than the parent compound. The cpp-17-ones are considered to 
exert their observed genotoxicity through a bay-region
3.4-diol-1,2-epoxide (2) and it is known that this reactive 
intermediate is generated from the parent compound via the
3.4-düiydrodiol which is more mutagenic than the parent 
compound (2,11). Thus it appears that II-C F3-CPP-17-one (3) 
is activated to genotoxic species in an entirely analogous manner 
to its 11-methyl analogue (2). The electronic nature of the -CF3 
substituent at C-11 is radically different from that of the -CH3 
group that it mimics, yet qualitatively similar metabolism occurs 
especially in the apparent activation of the compound to 
genotoxins. Given the apparent similarity of the metabolism and 
activation of ll-CH3-cpp-17-one (2) and its II-C F 3 analogue 
(3), it would appear that the electronic nature of the substituent 
at C -11 is not vital in determining whether or not the compound 
is activated to genotoxic intermediates; consequently the more 
important effect of the substituent at C-11 would appear to be 
steric. Whether the electronic nature of the substituent at C -II
affects the carcinogenicity of the molecule is a question that cannot 
be addressed through the medium of these metabolic studies and 
must therefore await the results of longer term tumourigenicity 
experiments.
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Cytochrome P450-dependent metabolism and mutagenicity of
15,16-dihydro-ll-methylcyclopent^henanthren-17-one and their 
implications in its carcinogenicity^
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Chemistiy, University o f Surrey, Guildford, Surrey, GU2 5XH, UK and 
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Méthylation of the non-carcinogen 15,16-dihydrocycIo- 
penta[a]phenanthren-17-one (CPP-17-one) at the bay region 
to form ll-CH3-CPP-17-one confers carcinogenic potential. 
In  the present study we have investigated the in vitro 
metabolism and mutagenicity of the methylated compound 
by hepatic microsomal preparations from rats pretreated with 
various prototype inducers of cytochrome P450 proteins in 
order to provide a rationale for this marked difference in 
carcinogenic activity. The most effective metabolism of 
ll-CH3-CPP-17-one occurred in the presence of Aroclor 
1254-induced microsomes, the principal metabolites being 
oxidative products of the A- and D-rings and of the methyl 
substituent. When benzo [a] pyrene-induced microsomes 
served as the metabolising system, the major A-ring meta­
bolite was the 3,4-diol. A similar metabolic pattern was seen 
with microsomes from rats treated with ll-C H 3-CPP-one 
itself, but the overall effect of metabolism was lower than that 
observed with benzo[fl]pyrene-treated microsomes but higher 
than that of control animals. In  contrast, microsomes from 
rats treated with clofibrate, dexamethasone, isoniazid and 
phénobarbital failed to enhance the metabolism of II-C H 3- 
CPP-17-one when compared with control microsomes and the 
metabolites reflected primarily oxidation of the D-ring. When 
lI-CH3-CPP-17-one was employed as a promutagen in the 
Ames test, a mutagenic response was evident only in the 
presence of microsomes from benzofa]pyrene-induced rats, 
but induction \vith phenobarbitone, isoniazid, dexamethasone, 
clofibrate and the compound itself, failed to elicit a positive 
mutagenic response. \^ e n  3,4-dihydroxy-ll-CH3-CPP-17- 
one served as the promutagen, a mutagenic response was 
observed in the presence of benzo[a] pyrene-induced and, to 
a lesser extent, ll-CH3-CPP-17-one-induced microsomes. 
Treatment of rats with ll-CH3-CPP-17-one caused a marked 
increase in the 0 -deethylation of ethoxyresorufin and, to a 
much lesser extei^ in epoxide hydrolase activity. It is 
concluded that (i) ll-CH3CPP-17-one is an inducer of the 
CYPl family; (ii) under the present experimental conditions 
only the C YPl family can oxidise the A-ring to form the
3,4-dihydroxy-l I-C H 3-CPP-17-one the precursor of the 
ultimate carcinogen and (iii) only the CYPl family oxidises 
the diol to generate the ultimate carcinogen. Finally, the 
carcinogenic potential of the ll-methylated CPP-17-one, w hen 
compared with the inactive unsubstituted compound, may be 
attributed, at least partly, to (I) higher CYPI-catalysed 
metabolism of the ll-methylated compound to the 3,4-dihy­
drodiol and (2) more potent induction of the CYPl family
*  Abbreviation: C<^P, cyclopcntaphcna[fllphcnanthrene.
by the 11-substituted derivative, when compared to th< 
parent, unsubstituted compound.
Introduction
The cyclopentaphena[a]phenanthrenes (CPPs*) constitute a 
chemical series within the polycyclic aromatic hydrocarbon class 
of chemical carcinogens. They display mutagenicity in a number 
of short-term tests (1,2) and carcinogenicity in various animal 
models (3,4).
Similar to other polycyclic aromatic hydrocarbons (5,6) the 
CPFs manifest their mutagenicity/carcinogenicity only following 
metabolism to their ultimate carcinogenic forms, the
3,4-dihydrodiol-1,2-epoxides, the entities that interact covalently 
with DNA and possess the highest mutagenic potential (7,8). The 
initial step in CPP activation is an oxidation to form the 3,4-arene 
oxide which serves as a good substrate of the epoxide hydrolase, 
generating the 3,4-dihydrodiol; the latter undergoes a second 
oxidation to yield the 3,4-dihydrodiol-1,2-epoxide. Both oxidation 
steps in the activation of polycyclic aromatic hydrocarbons are 
catalysed by the cytochrome P450-dependent mixed-hinction 
oxidases, especially the CYPl A l protein (9). This protein is the 
best catalyst of the oxidation of the A-ring in 15,16-dihydrocy- 
clopenta[fl]phenanthren-17-one (CPP-17-one) leading to the 
production of the ultimate genotoxin and is the only protein 
capable of incorporating the second oxygen to the 3,4-dihydrodiol 
to form the diol-epoxide. Other xenobiotic-metabolising families 
of cytochrome P450 are not only poor catalysts of the metabolism 
of ÇPP-17-one, but also appear to direct oxidation towards the 
non-aromatic D-ring to generate non-genotoxic products (8).
Both the unsubstituted CPP-17-one and its bay-region 
11-methyl analogue (11-CH3-CPP-17-one) are mutagenic yet 
only the latter exhibits carcinogenicity (1,3,10,11). One or more 
of the following mechanisms may account for this marked 
difference in carcinogenic potential: (i) The 3,4-dihydrodiol-
1,2-epoxide of the 11-CH3-CPP-17-one is more readily formed 
when compared with that of the unsubstituted compound; (ii) the 
diol-epoxide of the 11-substituted derivative is more genotoxic; 
(iii) the diol-epoxide of 1 l-CH3-CPP-17-one is less efficiently 
detoxicated by enzyme systems such as the glutathione S- 
transferases and (iv) the substituted compound is a more potent 
inducer of CYPl A I and of epoxide hydrolase, responsible for 
its activation. The last mechanism may, at least partly, contribute 
to the difference in carcinogenic potential since the methylated 
derivative is a more potent inducer of the hepatic CYPl A 1 
activity in the rat when compared with the unsubstituted 
compound (12). However, recent studies have suggested that an 
increase in CYPl A 1 activity, in the absence of concomitant 
increase in epoxide hydrolase activity, cannot always be translated 
into increased activation through a rise in diol-epoxide production 
(8,13).
In the present paper we report the hepatic microsomal 
metabolism and mutagenicity of 15,16-dihydro-l l-methylcyclo- 
penta[fl]phenanthren-l7-one (11-CH3-CPP-17-one), the principal
^ y d  et al.
Fig. 1. The structure ofM  1 -m eth^ 15.16-dihvdr^yclopenta[Q] phenanthren 
17-one (ll-CHj-CPP-lT-one).
objective being to compare these with the properties of the 
unsubstituted compound (8) in order to provide a rationale for 
the difference in the carcinogenic potential of the two compounds.
The structure and numbering system for 1 l-CH^-CPP-lV-one, 
the same as that adopted for steroids, are illustrated in Figure 1.
M a te r ia ls  a n d  m eth o d s
Penioxyresorufin, ethoxyresorufin and resorufin (Molecular Probes, Eugene, OR), 
6enzo(a]pyrene-4,5-epoxlde and benzo[a]pyrene-4,5-dihydrodiol (N C I Chemical 
carcinogens reference standard respository, Kansas, MO), phenobarbitone (BDH, 
Poole, Dorset, UK), benzo[a]pyrene, dexamethasone, clofibrate and all cofactors 
(Sigma Chemical Co., Poole, Dorset, UK) were all purchased. The syntheses 
and characterisations of 1 l-CH^-CPP-lV-one (14) its 15-hydroxy- (15) and 
16-hydroxy-derivatives (16) and of the 3,4-dihydrodiol (17) have already been 
published.
Male Wistar albino rats (150—200 g) were purchased from the Animal Breeding 
Unit, University of Surrey. Animals were treated with daily i.p. injections of 
phenobarbitone (80 mg/kg), benzo[a]pyrene (25 mg/kg), clofibrate (80 mg/kg) 
or dexamethasone administered by gastric gavage (100 mg/kg), for three days, 
all animals being killed 24 h after the last administration. Similar i.p. administration 
of 1 l-CHj-CPP-17-one (25 mg/kg) led to toxicity and consequently only a single 
dose was admirtistered. Finally, another group of rats was maintained on isoniazid 
(0 . 1%) in the drinking water for 10 days.
Hepatic microsomal fractions were prepared as previously described (18) and 
the following determinations were carried out: O-deethylation of ethoxyresorufin 
(19), D-depentylation of pentoxyresorufin (20), epoxide hydrolase using 
benzo[a]pyrene-4,5-oxide as substrate (21), total cytochrome P450 content (22) 
and protein (23).
Mutagenicity was determined in the Ames test (24) employing Salmonella 
typhimurium strain TAIOO and 10% (v/v) microsomal activation systems 
supplemented with glucose-6 -phosphate dehydrogenase (1 unit/plate).
For the metabolic studies, incubation mixtures comprised microsomal protein 
(50 -6 0  mg), NADP (4 m M), glucose 6-phosphate (5 m M), glucose 6 -phosphate 
dehydrogenase (20 units) and 1 l-^^CH]-CPP-17-one (10 mCi/mmol) (1 mg in
0.23 ml DMSO) in a final vol of 10 ml. Following a 30 min incubation at 37°C  
in a shaking waterbath, mixtures were extracted six times with equal volumes 
of ethyl acetate and the combined extracts dried over magnesium sulphate. The 
solvent was evaporated to dryness under reduced pressure at 45 °C , the residue 
was redissolved in methanol (150 /d) and aliquots (50 — 80 fil) used for 
chromatography. HPLC analysis was performed using a Whatman Partisil 10 
CDS Magnum 9 semi-preparative column (500 mm x9 mm i.d.) and an increasing 
linear aqueous methanol gradient (30—100% methanol).
R esu lts
Hepatic microsomal preparations from untreated rats and from 
rats treated with cytochrome P450 inducers, when incubated with 
Il-C H 3-CPP-I7-one in the presence of NADPH-generating 
systems could metabolise the compound, but at markedly different 
rates and with different metabolic profiles. By far the most 
efficient catalyst of the metabolism of II-C H 3-CPP-17-one were 
tlie microsomes from Aroclor 1254-treated rats where some 80% 
of the substrate was metabolised (Figure 2) producing eight peaks 
(Figure 3). These peaks were collected and their UV spectra 
between 200 —400 nm were obtained and compared with those 
previously published (11,25,26). Peak 8 was the parent, 
unmetabolised 17-ketone displaying the UV spectrum 
characteristic of the intact phenanthrene ring strucmre conjugated
Injection
Fig. 2. Hepatic microsomal metabolism of 1 l-CHj-CPP-H-one. Hepatic 
microsomes from Aroclor 1254-treated rats were incubated with 
1 l-CH^-CPP-H-one and metabolic products determined by HPLC as 
described in the text. Peak 1: 1,2,15-trihydroxy-11-CH3-CPP-17-one; Peak 
2: Unidentified; Peak 3: 3,4,15/3,4,16/3,4,-11-hydroxymethyl-CPP-17-one: 
Peak 4: Uitidentified; Peak 5: 15-hydroxy-11 -hydroxymethy 1 -CPP-17-onc: 
Peak 6 : 3,4-dihydroxy-ll-CH^-CPP-H-one; Peak 7: 
15-hydroxy-ll-CH3-CPP-17-one, and Peak 8 : I I-C H 3-CPP-17-one.
to a carbonyl group at position C-17 (25). The UV spectrum of 
peak 7 was that characteristic of monohydroxy products where 
hydroxylation occurs at the non-aromatic D-ring i.e. the 15- or
16-monohydroxy derivatives. As this peak had the same retention 
time as the authentic 15- but not 16-hydroxy derivative, it was 
assigned the structure of 15-hydroxy-II-CH3-CPP-17-one 
(15,26). Peak 6 possessed a UV spectrum associated with a 
dihydrodiol of the A-ring. Following chemical reduction of the
17-carbonyl group with sodium borohydride, a 20 nm shift was 
observed characteristic of the 3,4-diol of CPP-17-ones. 
Moreover, peak 6 in reverse-phase HPLC co-eluted with 
authentic 3,4-dihydroxy-l I-CH3-CPP-17-one. The UV spectrum 
of peak 5 was very similar to that of peak 7, the 
15-hydroxy-ll-CH3-CPP-17-one; the greater polarity of peak 5, 
however, indicates further hydroxylation at a site which does not 
influence the conjugation of the system, namely, the 11-methyl 
group. Such a metabolite has already been documented (25). The 
UV spectrum displayed by peak 3 was that characteristic of a
3.4-dihydroxy derivative but since it is more polar than the
3.4-dihydroxy-l I-C H 3-CPP-17-one (peak 6), it was considered 
likely to be either the 3,4,15-, 3,4,16-trihydroxylated metabolite 
or die 3,4-dihydroxy-l 1-hydroxymethyl derivative. Peak 1 
possessed the UV absorption chacteristics of the 1,2,15-triol, a 
major metabolite of the CPP 17-ketones. Peaks 2 and 4 were 
minor metabolites, not present in sufficient quantities to generate 
good UV spectra to enable identification.
Of the microsomal preparations studied, Aroclor 1254-treated 
animals were the most effective catalysts of the metabolism of 
11-CH3-CPP- 17-one. Nearly 20% of the substrate was convened 
to products resulting from A-ring oxidation. The major 
metabolite, however, was the 15-monohydroxy derivative
Cytochrome P450 and 15,16-dihydro-l l-methylCPP-17-one
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are described in the text.
>.(Figure 3). Control animals metabolised II-CH^CPP-17-one 
almost exclusively to D-ring oxidation products, the principal 
metabolites being 15-hydroxy-CPP-17-one and its hydro xymethyl 
derivative (Figure 3). Hepatic microsomes from benzo[a]pyrene- 
7, treated rats metabolised 11-CH3-CPP-17-one more effectively 
than control animals but less effectively than the Aroclor 
. 1254-induced microsomes, the major metabolites being the
15-monohydroxy derivative and the 3,4-dihydrodiol, with traces 
of the 1,2,15-triol. Microsomes from rats treated with the 
1 1 -methyl compound itself were also better catalysts, when 
compared with control microsomes, the major metabolites being 
the 15-monohydroxy compound and its hydroxymethyl 
derivative, with small amounts of the 3,4-dihydrodiol and of the
1,2,15-triol also being generated (Figure 3). Phénobarbital-
fgoyd et al.
Table I .  Metabolic activation of I I-C H 3-CPP-17-one to mutagens in the Ames test by hepatic microsomal preparations from rats treated with prototype 
inducers of cytochrome P450 proteins
Treatment II-C H 3-CPP-17-one (/ig/plate) 
0  2 
Histidine revertants/plate
5 7 10
Control 98 db 7 99 ±  3 100 ±  10 91 ±  2 98 ±  12
ll-CH3-CPP-17-one 95 ±  10 94 ±  5 102 ±  5 114 ±  5 110 ±  6
3enzo[<3]pyrene 100 ±  13 176 ±  32 259 ±  37 291 ±  26 335 ±  13
!*henobarbitone 97 ±  6 103 ±  8 111 ±  14 128 ±  8 120 ±  8
soniazid 103 ±  13 99 ±  9 97 ±  8 102 ±  11 112 ±  18
Dexamethasone 102 ± 2 4  115 ±  2 113 ±  4 111 ±  8 110 ±  11
Clofibrate 116 ±  10 97 ±  6 102 ±  4 106 ±  6 102 ±  14
The study was earned out using 10% 9v/v) activation systems .supplemented with glucose 6 -phosphate dehydrogenase ( I  unit/plate) and S.typhimurium strain
'A  ICO. Results are presented as mean ±  SD o f triplicates.
Table I I .  Metabolic activation of 3,4-dihydroxy-l I-C H 3-CPP-17-one to mutagens in the Ames test by hepatic microsomal preparations from rats treated with
prototype inducers of cytochrome P450 proteins
Treatment 3,4-dihydroxy-lI-CH3-CPP-17-one (/tg/plate)
0  1 2 5 7
Histidine revertants/plate
Control 83 ±  8 97 ±  2 92 ±  4 116 ±  7 102 ±  8
l-CH3-CPP-17-one 81 ±  12 124 ±  3 144 ±  17 159 ±  30 170 ±  18
lenzo[<3]pyrene 82 ±  5 319 ±  11 337 ±  132 944 ±  158 715 ±  64
’henobarbitone 82 ±  10 94 ± 115 ±  23 123 ±  20 103 ±  18
soniazid 84 ±  9 89 ±  16 89 ±  15 114 ±  16 104 ±  2
)examethasone 75 ±  3 94 ±  23 101 ±  19 112 ±  22 119 ±  22
'.lofibrate 80 ±  10 91 ±  16 100 ±  14 100 p8 121 ±  2
"he study was carried out using 10% y \N ) activation systems supplemented with glucose 6 -phosphate dehydrogenase (1 unit/plate) and S.iyphimuriivn strain 
'A 100. Results are presented as mean ±  SD of triplicates.
‘able ni. Hepatic microsomal mixed function oxidases following treatment of rats with 11-C H 3-CPP-17-one
ctivity Control Treated
thoxyresorufm 0 -  
xthylase (pmol/min/mg
XJtein) 63 ±  13 496 ±  126"
entoxyresomfin O-
:pentylase
mol/min/mg protein) 13 ±  5 30 ±  7*’
poxide hydrolase
mol/min/mg protein) 6.42 ±  0.85 10.62 ±  1.29*’
jtal cytochrome P450
mol/mg protein) 0.51 ±  0.05 0.51 ±  0.03
icrosomal protein
ig/g liver) 28 ±  1 24 ±  3
>  %.001 and *>0.05
duced microsomes also formed as major metabolites the 
-monohydroxy compound and its hydroxymethyl derivative 
th traces of 3,4-dihydrodiol. A similar metabolic profile was 
'Served with dexamethasone- and isoniazid-induced 
crosomes. Finally, clofibrate-induced, microsomes were the 
orest of those studied in catalysing the metabolism of 
-CH3 -CPP-17-one, with more than 80% of the substrate 
naining unchanged (Figure 3). 15-Monohydroxy-11 -CH3 - 
’P-17-one was the major metabolite with traces of its hydroxy- 
:thyl derivative and of the 3,4-dihydrodiol.
The mutagenicity of 11 -CH3 -CPP-17-one was evaluated in the 
nes test in the presence of hepatic microsomes derived from 
s pretreated with the various cytochrome P-450 prototype
inducers. M icrosom es from  control, phenobarbital- 
dexamethasone-, isoniazid- and clofibrate-treated animals failed 
to elicit a positive mutagenic response (Table I). A positive 
mutagenic response was, however, evident when the source of 
the activation system were microsomes from the benzo[a]pyrene- 
treated animals (Table I). When the 3,4-dihydroxy-l I-CH3 - 
CPP-17-one was employed as the promutagen, a marked positive 
response was observed in the presence of benzo[a]pyrene-induced 
microsomes (Table H). A positive, but weak mutagenic response 
was also evident in the presence of microsomes from animals 
treated with the II-CH 3 -CPP-17-one itself.
Treatment of rats with 11 -CH3 -CPP-17-one gave rise to a 
marked increase in the O-deethylation of ethoxyresorufin and to
Cytochrome P450 and 15,16-dihydro-ll-methyICPP-17-one
a much lesser extent in the 0 -depentylation of pentoxyresorufin 
(Table III). Finally, epoxide hydrolase activity, using 
benzo[a]pyrene-4,5-oxide as substrate, was also induced 
significantly by the same treatment.
Discussion
The most effective catalysts of 11 -CH3 -CPP-17-one metabolism 
were the Aroclor 1254-induced microsomes, as previously 
observed in the case of the unsubstituted compound (8 ) but some 
striking differences in the metabolic profile are evident. Although 
both compounds are metabolised by oxidation of the A- and D- 
rings, the nature of the metabolites differ quantitatively. D-ring 
oxidation in the case of the unsubstituted CPP-17-one led to the 
formation of two monohydroxy derivatives,-namely, 15- and
16-hydroxy-CPP-17-one which were formed by all hepatic 
microsomal preparations irrespective of inducer treatment (8 ). 
In the case of the bay-region 11-methyl-substituted 17-ketone, 
only the 15-monohydroxy product was generated by all 
microsomal preparations. Oxidation of the A-ring in the case of 
CPP-17-one yielded metabolites resulting from oxidation at the
1.2- and 3,4-positions, the former generally predominating, and 
a similar pattern was observed in the case of II-CH 3 -CPP-
17-one. An additional metabolite of 1 l-CH3-CPP-17-one is also 
formed by oxidation of the methyl group to the alcohol. Thus, 
11-methyl substitution of CPP-17-one greatly reduces 16-hy- 
droxylation on the D-ring but, qualitatively, oxidation of the A- 
ring appears not to be significantly affected. A major quantitative 
difference, however, is that when benzo[a]pyrene-induced 
microsomes are used, oxidation at the 3,4-position clearly 
predominates in the case of 11 -CH3 -CPP-17-one, but when 
CPP-17-one is used as the substrate oxidation occurs at both the
1.2- and 3,4-positions.
Of the various cytochrome P450 families, it is the CYPl A 
family, and especially the CYPl A 1 protein that usually catalyses 
the metabolism of fairly planar molecules such as the polycyclic 
aromatic hydrocarbons (9,27). Aroclor 1254 is an inducer of at 
least two cytochrome P450 families, namely CYPl A and 
CYP2B, as well as of epoxide hydrolase (28) and thus does not 
allow the role of individual cytochrome P450 proteins to be 
assessed. Phénobarbital, a potent inducer of CYl^B, produced 
a metabolic profile veiy similar to that of control microsomes, 
the two principal metabolites being the 15-hydroxylated product 
and its hydroxymethyl derivative with only traces of the
3,4-dihydrodiol. In contrast, induction with benzo[a]pyrene, a 
specific inducer of the CYPl A family, generated as the principal 
metabolites the 3 ,4-dihydroxy and 15-hydroxy-derivatives of 
11-CH3 -CPP-17-one with traces of the l X%, 15-trihydroxy 
product. It is worth pointing out that 1 ,2 -oxidation products were 
generated only by the Aroclor 1254- and benzo[a]pyrene-induced 
microsomes, implicating CYPl A as the sole catalyst of this 
pathway. Treatment of rats with II-CH 3-CPP-17-one induced 
CYPl A, as exemplified by an increase in the (9-deethylation of 
ethoxyresorufin, a specific substrate of this family in agreement 
with our previous studies (12). The relatively smaller increase 
in the 0 -depentylation of pentoxyresorufin is compatible with 
the effect of CYPl A inducers on this activity (20). Finally, the 
same treatment significantly enhanced epoxide hydrolase activity. 
Microsomes from rats treated with 11 -CH3 -CPP-17-one gave 
rise to the 15-hydroxy metabolite and its hydroxymethyl 
derivative with lower levels of the 3,4-dihydrodiol and 
3,4,15/16-trihydroxylated-l I-CH3 -CPP-17-one and traces of
1,2 ,15-trihydroxy-11-CH3 -CPP-17-one. It is pertinent to point 
out at this stage that ben/.ofnlpyrene is a more potent inducer
of the CYPl A family when compared to 11 -CH 3 -CPP-17-one 
( 1 2 ) explaining why the latter was less effective in directing 
oxidation towards the A-ring. The metabolic profile generated 
by microsomes from isoniazid-treated (inducer of CYP2E 
proteins) and dexamethasone-treated (inducer of CYP3A proteins) 
rats were similar to that of control animals in that almost no 
oxidation o f the A-ring occurred. Finally, clofibrate-induced 
microsomes were less effective than control microsomes in 
metabolising 11 -CH 3 -CPP- 17-one, an observation also made in 
the case of CPP-17-one, indicating that the clofibrate induction 
(induction of CYP4A) occurs at the expense of proteins 
responsible for the metabolism of these two CPPs.
When the m utagenicity o f 1 1 -C H 3 -CPP-17-one was 
investigated in the Ames test, in the presence of microsomes from 
control rats and rats treated with the various inducing agents, 
a positive response was elicited only with the benzo[a]pyrene- 
induced microsomes, in accordance with the metabolic studies 
where the 3,4-dihydrodiol was a principle metabolite. In contrast, 
when the unsubstituted CPP-17-one was used as the mutagen, 
none of these activation systems produced a positive mutagenic 
response, presumably because in the latter case metabolism occurs 
mainly at other sites generating non-mutagenic intermediates. An 
additional alternative possibility is that the 3,4-dihydrodiol-1,2- 
epoxides of the two compounds have different genotoxic potential. 
The fact that none of the other activation systems which 
metabolise II-C H 3 -CPP-17-one to the 15-monohydroxy product 
and its hydroxymethyl derivative, induced a positive mutagenic 
response, indicates that these metabolites lack genotoxic potential.
When the 3,4-dihydrodiol o f 1 1 -CH 3 -CPP-17-one was 
employed as the promutagen, a positive response was observed 
with the benzo[a]pyrene-induced microsomes and a weaker 
response with the microsomes derived from the rats treated with 
the 11 -CH3 -CPP-17-one itself indicating that only the CYPIA 
family could catalyse its further oxidation. In contrast, when the
3,4-dihydrodiol of the CPP-17-one was used as the promutagen, 
no mutagenic response was evident in the presence of animals 
treated with this CPP-17-one (8 ), reflecting the much higher 
CYPIA induction potential of the 11-methyl derivative. More­
over, in the presence of benzo[a]pyrene-induced microsomes the 
mutagenic response provoked by the 3,4-dihydrodiol of 11 -CH3 - 
CPP-17-one was generally higher than that o f the unsubstituted 
compound although a direct comparison in the same assay was 
not possible because of lack of material. This is compatible with 
a higher genotoxic potential of the 3 , 4 - d i h y d r o d i o l - 1 ,2 -epoxide 
of the methyl-substituted compound when compared to that of 
the unsubstituted compound, or that the diol-epoxide is more 
readily formed. Such inference is not supported, however, by 
previous work with the corresponding CPP hydrocarbons where 
the mutagenicity of the syn-3,4-dihydrodiol-1,2-epoxide of CPP 
was similar to that of 11 -CH3 -CPP (7). Direct assessment of the 
genotoxic potential o f the dihydrodiol-epoxide of the two 
CPP-17-ones must await the chemical synthesis o f substantial 
amounts.
In summary, the present study demonstrates that: (i)
1 1 -CH3 -CPP-17-one is metabolised by oxidation of the A- and 
D-rings and of the methyl substituent. Oxidation of the D-ring 
yields largely one product, the 15-monohydroxy derivative. In 
contrast to the unsubstituted analogue, little or no 16-hydroxy- 
lation occurs; (ii) Aroclor 1254-induced microsomes are the most 
effective catalysts of the metabolism of 1 1 -CH 3 -CPP-17-one; 
(iii) the CYPIA family oxidises the A-ring more readily than 
other xenobiotic-metabolising cytochrome P450 families and (iv) 
only the C Y P I A  family oxidises I I - C H 3 - C P P - 17-one at the 1,2
foyd et al.
3,4-positions. Possible mechanisms that may account, at least 
partly, for the higher carcinogenicity conferred by II-C H 3 
lubstitution of CPP-17-one may include: (i) Higher CYPIA- 
:atalysed conversion to the 3,4-dihydrodiol, the precursor of the 
iltimate carcinogen, when compared to the unsubstituted 
:ompound and (ii) a more potent induction of the CYPIA family 
)y the 11-substituted compound (12) resulting in the more 
efficient metabolism of the 3,4-diol to the 3,4-dihydrodiol-1,2- 
ipoxide observed in the present study. The possibility however, 
hat the 3,4-dihydrodiol-1,2-epoxide of the 11-substituted 
lydrocarbon is more genotoxic, or less effectively deactivated 
)y the glutathione S-transferases may also be contributory factors 
hat cannot be ruled out at this stage.
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